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Nanoparticles improve drug efficacy by delivering drugs to sites of disease. To effectively 
deliver a drug in vivo, a nanoparticle must overcome physical and physiological hurdles that are 
not present in cell culture, yet in vitro screens are used to predict nanoparticle delivery in vivo. An 
ideal nanoparticle discovery pipeline would enable scientists to study thousands of nanoparticles 
in vivo. Here, we discuss technologies, such as DNA barcoding, to enable the efficient delivery of 
nucleic acid therapies and study the delivery of lipid-based nanoparticles. 
This work will specifically describe the improvement and development of nucleic acid 
delivery vehicles. In Chapter 2, we report new DNA barcodes designed with minimal secondary 
structure, dispersed semi-randomized sequences, and a ddPCR site can be quantified at low doses 
in vitro. We demonstrate that in vivo nanoparticle biodistribution measured with fluorescence 
underestimates the number of targeted cell types in vivo compared to ddPCR DNA barcodes. These 
study shows that rationally designed DNA barcodes can quantify delivery with higher sensitivity 
than traditional fluorescence-based assays. 
 In Chapter 3, we quantified how over 100 nanoparticles delivered siRNA to 9 cell types in 
vivo using a novel siGFP-based barcoding system and bioinformatics. We found nanomaterials 
containing conformationally constrained lipids formed stable LNPs, herein named constrained lipid 
nanoparticles (cLNPs). cLNPs delivered siRNA and sgRNA to T cells at doses as low as 0.5 mg / 
kg, and unlike previously reported LNPs, did not preferentially target hepatocytes. The data suggest 
natural lipid trafficking pathways can promote T cell delivery, offering an alternative to active 
targeting approaches. 
 In Chapter 4, we explored the relationship between inflammation and drug delivery. 
Specifically, we found that TLR4 activation could override LNP-mediated mRNA delivery. We 
determined that TLR4 activation blocked mRNA translation in several cell types, without 
significantly reducing LNP uptake Notably, the data suggest that the mechanism could be driven, 
 xiv 
in part, by TLR4-mediated reductions in endosomal escape and was likely driven by a TLR4-
mediated reduction in mRNA translation. More generally, this suggests a LNP which delivers 
mRNA to one inflammatory disease may not deliver mRNA to another. 
 In Chapter 5, we identify design rules for nebulized LNP delivery of mRNA using an in 
vivo, iterative, cluster-based experiments. We found that PEG-lipids are crucial for LNP 
formulation, low PEG molar percentages improve LNPs with neutral helper lipids, and high PEG 
molar percentages improve LNPs with cationic helper lipids. We also identified an LNP that 
delivers mRNA to the lungs at low doses and used this LNP to protect adult mice from a lethal 
H1N1 flu challenge. 
 In Chapter 6, we studied whether a single LNP trait can reduce liver delivery and increase 
non-liver delivery. Using DNA barcoding, we identified three novel LNPs with distinct in vivo 
mRNA delivery profiles at clinically relevant doses, enabling us to edit genes in the lung by co-
delivering Cas9 mRNA and sgRNA. 
 Finally, in Chapter 7, we proposed new ideas within the field of nucleic acid drug delivery. 
We discuss ways to continue improving nucleic acid drug delivery. Specifically, we emphasize the 
need for new screening approaches, ways to understand the genes involved in drug delivery, and 
the importance of studying drug delivery across larger animal models. 
 
 1 
CHAPTER 1. INTRODUCTION 
 
 
The work presented here is a modified excerpt from Lokugamage MP, Sago CD, Dahlman JE. 
“Testing thousands of nanoparticles in vivo using DNA barcodes” Current Opinion in Biomedical 
Engineering, 2018. 
 
1.1 Nucleic acid-based therapies 
1.1.1 RNA therapies are limited by inefficient delivery to target tissues 
Advances in genomics have armed scientists with lists of genes that cause diseases. This 
has brought about a significant change in the way drugs are designed and discovered. Researchers 
were previously limited to targeting broad cellular phenotypes; for example, cisplatin intercalates 
into double-stranded DNA, causing toxicity in any cell undergoing cell division. Although many 
of these drugs successfully treated disease, they also caused severe side effects driven by drug 
activity in “off-target” cells. Researchers now often use small molecules that target specific 
mutations. However, only 15% of the protein coding genome—and a much smaller percentage of 
the non-coding genome—is “druggable” using small molecules1. This has led scientists to develop 
technologies to target all genes.  
RNA therapies have emerged as a promising solution to the problem of “undruggable” 
targets2. RNAs can specifically turn any gene in the genome on or off, regardless of its eventual 
protein structure. Gene silencing can be mediated by RNA interference (RNAi), a well-
characterized mechanism where base pairing between small interfering RNA (siRNA) and target 
mRNA catalyzes RISC-mediated mRNA degradation. Gene silencing can also be mediated by 
DNA nucleases, including those derived from zinc fingers (ZFNs)3, transcription factor-like 
effectors (TALENs)4, or clustered regularly interspaced short palindromic repeats and their 
associated proteins (CRISPR-Cas) systems5,6. Similarly, mRNA-based therapies can transiently 
upregulate genes7. To date, siRNA therapies have shown the most promise in patients. In one 
 2 
example, a degenerative disease that was uniformly fatal has been halted (and in some cases, 
reversed) in Phase III clinical trials8,9. More generally, over 1,200 patients have been treated with 
siRNA, some for as long as 36 months. With a few exceptions, primarily limited to antisense 
nucleotides (which are distinct from siRNA)10, siRNA therapies have been well tolerated and 
efficacious. Advances in siRNA biochemistry11 and improved delivery vehicles12 raise the exciting 
prospect that once-yearly injections to treat genetic disease are within reach.  
Although siRNA is currently the most clinically advanced RNA therapy, DNA nucleases 
and mRNA therapies are up and coming. They have shown efficacy in mice13,14 and non-human 
primates15, and are poised to treat disease in humans16-18. The results described above have one 
limitation: most clinical trials have involved RNAs locally injected into muscle (e.g., vaccines), 
eye, or lymph nodes, administered to cells ex vivo, or systemically delivered to hepatocytes. 
Systemically delivering therapeutic RNA outside the liver remains a substantial unsolved problem19 
that limits the development of gene therapies targeting other organs. RNA therapies will require 
delivery because naked RNAs are quickly degraded by nucleases, and their large molecular weight 
and highly negative phosphodiester backbone prevent them from crossing the anionic cell 
membrane20. 
 
1.1.2 RNA therapies are clinically relevant 
RNA therapies have tremendous clinical potential but will require on-target drug delivery 
to reach the clinic. siRNA drugs in the liver are a great example; several patient populations are 
already benefiting from treatments that silence genes in hepatocytes. However, without new 
delivery vehicles, the clinical impact will be limited to local injection and to the liver19. To target 
new cell types, it is important to test as many nanoparticles as possible. Traditional screening 
methods test delivery vehicles in vitro; however, in vitro particle screens may inaccurately predict 
delivery in vivo. In conjunction with rapid nanoparticle synthesis, high-throughput in vivo 
nanoparticle screening methods will allow scientists to track more particles simultaneously than 
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ever before. Over time, this may allow scientists to better understand how nanoparticles behave in 
the body. We envision a time when enough nanoparticles have been tested in vivo that nanoparticles 
which target a given cell type can be rationally designed. We find it likely these high-throughput 
approaches will help accelerate the development of new genetic therapies. 
 
1.2 DNA barcodes allow for the testing of thousands of particles simultaneously in vivo   
1.2.1 Nanoparticles screened in vitro may not predict in vivo delivery 
 RNA delivery vehicles are designed to protect the nucleic acid and transport it to the target 
cell. Although many drug delivery vehicles have been used to deliver RNA, we will focus on 
nanoparticles, which have generated promising clinical data8. Here we define a nanoparticle as a 
structure with all three dimensions less than 1,000 nm. Scientists have made steady advances in 
nanoparticle design. Nanoparticles can be made with variable size21, ionizability22, hydrophilicity23, 
shape24, and varying degrees of active targeting ligands25. Large, chemically diverse libraries have 
been synthesized using simple synthetic routes including, but not limited to, Michael addition26, 
epoxides27, peptide28, and thiol chemistry29. Importantly, advances in nanoparticle formulation—
defined here as the process of “loading” the nucleic acid into the nanoparticle—have also been 
reported. High-throughput microfluidics has been shown to reliably make small, consistent batches 
of nanoparticles that are stable for weeks30,31. It is still difficult to cover the entire nanoparticle 
chemical space; formulating nanoparticles using available chemistries, it is feasible to formulate 
between 100 million and 200 billion chemically distinct nanoparticles (Fig. 1.1).  
After nanoparticles are formulated, they are screened in vitro. More specifically, scientists 
(a) synthesize thousands of different nanoparticles before (b) evaluating whether they deliver RNA 
in easily expandable cell lines (e.g., HeLa). Scientists have also used primary cells in place of 
immortalized cells32. Based on in vitro results, a very small number of nanoparticles are (c) tested 
in vivo. This process is only an efficient use of time and resources if in vitro nanoparticle delivery 
predicts in vivo delivery. To test this, we compared how the same 300 nanoparticles delivered 
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nucleic acids in vitro and in vivo in multiple cell types; we found no correlation33 (Fig 1.2A). The 
discrepancy between in vitro and in vivo delivery is not necessarily surprising. If a nanoparticle is 
systemically administered, it must travel through the blood stream and enter the target tissue. 
Several physical factors dictate where the nanoparticles go. For example, it is difficult for 
nanoparticles to access the brain, which is physically cordoned off by the blood–brain barrier. 
Nanoparticles can also be physically disassembled by the glomerular membrane in the kidney34. As 
a counterexample, nanoparticles often target hepatocytes since nanoparticles can exit the blood via 
nanoscale pores in sinusoidal blood vessels and basement membrane35. Physiological factors also 
influence nanoparticle delivery. For example, serum proteins can bind to nanoparticles in the 
blood36,37, changing nanoparticle interactions with the immune system and target cells38. 
Interestingly, systemic nanoparticle delivery can also change with local disease states; in one 
example, scientists found that delivery to systemic organs was affected by the presence of a primary 
tumor39. Even if the nanoparticle reaches its target cell, it must enter the cytoplasm, often by 
escaping an endosome. Endosomal escape is inefficient; an LNP that delivers siRNA to hepatocytes 
very efficiently (50% target gene silencing after a 0.01 mg/kg injection) still had >95% of its siRNA 
sequestered within endosomes40. The nanoparticle must also evade liver, kidney, and splenic 
clearance, as well as avoid initiating an immune response. The majority of these obstacles are not 
recapitulated in vitro. Some processes are required for in vitro delivery and in vivo delivery (e.g., 
endocytosis and endosomal escape). However, these processes are carefully regulated41 by gene 
expression that is likely to change with microenvironmental cues. Increasing evidence suggests that 
gene expression in cultured cells may not reliably predict gene expression in primary cells or in 
vivo42. 
 
1.2.2 Barcoding enables simultaneous analysis of  >100 nanoparticles in vivo 
The lines of evidence described above suggest that screening nanoparticles directly in vivo 
would be useful. However, the expensive nature of in vivo experiments has limited the field to 
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testing a few in vivo. This is a universal problem in nanomedicine, and it has driven groups to 
design systems that facilitate high-throughput in vivo nanoparticle screens. In all cases, these 
systems utilize “multiplexed” signals, which are signals that can be quantified without interfering 
with one another. In the simplest case, nanoparticle 1, with chemical structure 1, is “barcoded” (i.e., 
“tagged”) with signal 1; nanoparticle N, with chemical structure N, is barcoded with signal N. The 
nanoparticles are co-administered, and later, signals 1 and N are quantified simultaneously. In one 
example, scientists isotopically barcoded silver nanoparticles with different functional peptides to 
evaluate potential targeting ligands43. Another group used quantum dots to barcode polymeric 
nanoparticles; in vivo screens were performed to understand how nanoparticle surface 
modifications altered delivery through the blood–brain barrier44.  
One multiplexed signal that has been used by groups (including ours) is DNA33,45,46. DNA 
is an excellent molecule for multiplexing. The number of different barcodes scales exponentially 
faster than any other signaling molecule; 4N different barcodes can be generated with a DNA 
sequence N nucleotide long. An 8-nucleotide barcode can create 65,536 different sequences. 
Additionally, DNA sequence readouts are easy to analyze. The cost of DNA sequencing has 
decreased more rapidly than Moore’s Law; it is now possible to generate 400 million DNA reads 
for $2,000 using a machine that fits on a desktop. Because DNA sequencing has become an 
increasingly more common tool in several fields47, easy-to-use software packages are readily 
available to help analyze and interpret the data.  
Two distinct nanoparticle DNA barcoding systems have been reported to date33,45,47. In one 
example, DNA was formulated into liposomes alongside different chemotherapies46 (Fig. 1.2B). 
By varying the primers or altering the barcode length, different sequences were detected using gel 
electrophoresis or real-time PCR. The authors tested several drugs at once in vivo and concluded 
that the DNA barcodes found in dead cells corresponded to nanoparticles containing effective 
chemotherapies. This method may be used in the future to test hundreds of different cancer drugs 
in vivo. We developed a separate DNA barcoding system that utilizes next-generation sequencing. 
 6 
Our barcodes contain (i) universal primer sites, (ii) a 7 nucleotide region with fully randomized 
sequences (to monitor for biased PCR amplification), and (iii) an 8 nucleotide barcode region in 
the center45 (Fig 1.3A). Initially, we demonstrated that this system predicted siRNA delivery in vivo 
and generated DNA sequencing outputs that were linear with respect to the administered DNA45. 
Later, we demonstrated that this system, which we named Joint Rapid DNA Analysis of 
Nanoparticles (JORDAN), could simultaneously analyze over 150 nanoparticles simultaneously in 
vivo33 (Fig 1.3B). 
Although there are different ways to design DNA barcodes, specific traits help increase the 
robustness of the data. Most importantly, universal primer sites—which are primer sites that do not 
change—confer an important advantage, maximizing the chance all barcodes are amplified in an 
unbiased way. This seems counterintuitive, but the vast majority of a DNA barcode should be 
identical; the barcode region of the DNA should be small. Adding chemical modifications including 
phosphorothioates to the 5’ and 3’ termini increase barcode stability. The barcode regions should 
also be designed to work together on solid-phase next-generation sequencing (NGS) platforms like 
Illumina. Since solid-phase NGS relies on fluorophores (Fig. 1.3C), each individual barcode must 
have a “base distance” of at least 3; in other words, each barcode must be different from all other 
barcodes at three of the eight positions (Fig. 1.3D). We have designed >200 barcodes with base 
distances of 3 or more33. It is also critical to sequence the DNA “input” administered to the animals. 
This allows us to normalize the data and compare different cell types to each other within an 
experiment. Finally, like all big data systems, nanoparticle DNA barcoding experiments should 
include proper controls in each experiment. Two examples include a liposome loaded with caffeine 
(instead of a chemotherapeutic)46 and a naked barcode33; in both cases, the negative controls 
performed poorly relative to the experimental conditions, as expected.  
DNA barcodes enable nanotechnologists to track how hundreds of distinct nanoparticles 
deliver drugs in vivo for the first time; this enables nanoparticle studies that were not feasible using 
traditional methods. As an example, we compared how dozens of different nanoparticles delivered 
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DNA to eight different cell subtypes in the spleen. Using unbiased Euclidean clustering—a 
common bioinformatics technique that analyzes large datasets—we found that specific types of 
immune cells tended to be targeted by the same nanoparticles33. DNA barcodes have enabled large-
scale experiments in fields as varied as oncology, developmental biology, and viral delivery. As an 
example, by using the single-guide RNA (sgRNA) sequence as a “barcode” to denote a gene that 
was knocked out, scientists performed whole genome screens to identify genes and non-coding 
regions that regulate cellular response to cancer and immunotherapies48-51. More specifically, a 
system named Genome-Scale CRISPR-Cas9 Knockout Screening (GeCKO) helped determine 
which genes promote resistance to anti-cancer drugs50. GeCKO was used to target 18,080 in the 
same experiment; multiple sgRNAs were designed per gene. The pool of sgRNAs was administered 
to human cancer cell lines that also expressed Cas9; as a result, each cell—on average—had no 
gene knocked out, or 1 gene knocked out. After adding an anti-cancer drug, cells were allowed to 
grow; enriched sgRNA sequences in live cells corresponded to genes that increased drug resistance 
(Fig 1.4A). The same approach has been used to study metastasis in vivo. In this case, a pool of 
tumor cells was edited using GeCKO and administered in the hind limb of a mouse. After waiting 
a period of time, the authors isolated metastatic tumor cells from different organs, and thereby 
identified genes that promoted metastasis52. Similar approaches have been used to identify genes 
that suppress primary tumor growth in the liver and brain (Fig. 1.4B)53,54. Scientists also designed 
a combinatorial DNA barcode system named PolyLox that identified stem and progenitor cells that 
led to the development of the immune system55. Finally, there are reports of “capsid shuffling” and 
other combinatorial cloning strategies; these use sequences that code for amino acids as barcodes 
that denote which amino acids successfully enabled AAV vectors that facilitate cellular entry and 
DNA delivery56-58. Given that DNA is a highly efficient method to store and access information, it 





Figure 1.1 (A) Lipid nanoparticle libraries can be generated with a variety of chemical compounds. 
LNPs are formulated by combining different biomaterials with cholesterols, lipid-PEG compounds, 
and helper lipids. (B) High-throughput nanoparticle formulation allows for the rapid production of 
large, diverse libraries. (C) Nanoparticle libraries can be generated by varying the molar ratio of 
biomaterials, cholesterols, PEG, and helper lipids. (D) Between 1 x 108 and 2 × 1011 chemically 
distinct nanoparticles can be made by combining these compounds. Notably, these numbers do not 






Figure 1.2 (A) Chemically diverse LNPs are tagged with unique DNA barcodes. LNPs were pooled 
together and administered both in vitro and in vivo. For in vitro studies, delivery at condition 1 
often correlates with delivery at condition 2. However, in vitro delivery does not correlate to in vivo 
delivery. These results were consistent across many cell types, and across different experiments, 
for >300 different LNPs. (B) Liposomes carrying different chemotherapies were formulated with 
unique barcodes. After administering the liposomes in vivo, tissues were removed and cells were 
stained with propidium iodine (PI), which distinguishes dead cells from live cells. Barcodes 





Figure 1.3 (A) JORDAN barcodes contain universal primer sites, a 7 nucleotide randomized 
region, and an 8 nucleotide barcode region. This barcode design allows us to multiplex hundreds 
of different barcodes. The normalized delivery for every barcoded LNP is determined; this is 
analogous to ‘counts per million’ in RNAseq studies. (B) JORDAN uses DNA barcodes and NGS 
to analyze the biodistribution of thousands of particles in vivo. Next generation sequencing is an 
effective way to read DNA barcodes. (C) Solid phase NGS reads each nucleotide of the sequencing 
using fluorescent nucleotides. Understanding how NGS generates data is important to 
understanding barcode design; NGS is reviewed extensively in reference 47. (D) For example, each 
barcode must differ from all other barcodes at 3 of the 8 positions. If any reading errors during 





Figure 1.4 (A) In cancer cells, each gene in the genome of Cas9 expressing cells was knocked out 
individually using sgRNAs. The sgRNA served as the barcode that denoted which gene was 
silenced. After knocking every protein coding gene, an anti-cancer drug is added to the cells and 
time is allotted to facilitate drug resistance. Enriched sgRNA sequences in the live cells correspond 
to genes that affect cancer drug resistance. In this example, knocking down Gene A promotes drug 
resistance. (B) The same whole genome studies have identified genes that – when knocked down 





CHAPTER 2.  MODIFYING A COMMONLY EXPRESSED ENDOCYTIC RECEPTOR 
RETARGETS NANOPARTICLES IN VIVO 
The work presented here is an excerpt from Sago CD*, Lokugamage MP*, Lando GN, Djeddar N, 
Shah NN, Syed C, Bryksin AV, Dahlman JE. “Modifying a Commonly Expressed Endocytic 
Receptor Retargets Nanoparticles in vivo.” Nano Letters, 2018. 
 
2.1 Introduction.  
siRNAs delivered to hepatocytes have treated disease in patients8,59,60, but delivery to other 
cell types remains challenging61. The liver exhibits physiological advantages that promote 
nanoparticle accumulation62,63, and as a result, rational approaches will be required to minimize 
unwanted liver delivery. An ideal approach would involve (i) synthesizing hundreds of 
nanoparticles with diverse chemical structures, and (ii) analyzing them in vivo using an animal 
model that (iii) tests a specific biological hypothesis (e.g., gene X alters delivery) in vivo. However, 
the current gold standard is to study nanoparticles in vitro. Thousands of nanoparticles can be 
synthesized for nucleic acid delivery, but they are screened in vitro27,28,64-67, which can be a poor 
predictor of in vivo delivery68. Genes that alter nanoparticle delivery in vitro have been identified69-
72; genes that affect systemic nanoparticle delivery in vivo remain much more difficult to study. 
Exceptions to this73-76 have provided valuable insights, but have focused on soluble factors in 
serum73,74 or receptors on hepatocytes74-76. Whether a commonly expressed gene can exert cell type-
specific effects on nanoparticle delivery in vivo remains unexplored. 
Nanomedicines are often delivered using ligands that bind receptors expressed on target 
cells77. For example, the ASGPR is expressed on hepatocytes; GalNAc has targeted ASGPR78, 
leading to delivery in animals and patients. Other receptors include EGFR79, folate receptor80, 
transferrin receptor81, VCAM-151, and ICAM-182. Given that few receptors are (i) highly expressed 
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on one cell type and (ii) induce nanomedicine endocytosis upon binding, we envisioned an 
alternative approach: manipulating an endocytosis receptor expressed on many cells. An ideal 
receptor would inhibit delivery to cell type A more than cell type B, promoting delivery to cell type 
B. This approach is timely. Our understanding of cell heterogeneity is progressing; RNA-seq83 has 
revealed that gene expression varies with disease state84 and within cell populations previously 
believed to be homogeneous85,86. Large scale approaches like the Human Cell Atlas87 are likely to 
uncover endocytic genes whose importance varies with cell type. Since hundreds of genes are in 
involved in endocytosis88, and many genes are regulated by disease- and microenvironment-derived 
cues41,89, it is foreseeable that manipulating 1 gene could alter delivery in a tissue- or disease-
specific manner. To test the hypothesis that manipulating a commonly expressed receptor can affect 
nanoparticle delivery in cell type-dependent manner, we focused on Cav1, a gene involved in 
caveolin-mediated endocytosis90. Caveolin can endocytose nanoparticles in vitro91 and in vivo92. Its 
expression changes with fibrosis93-96, lung disease97, cancer98-101, neurological disease102,103, and 
other pathologies104-106, demonstrating that its expression is regulated by microenvironmental 
signals and disease. 
 
2.2 Results.  
2.2.1 QUANT barcodes are designed to provide highly sensitive readouts. 
Given that in vitro nanoparticle delivery can be a poor predictor of in vivo delivery68 and that gene 
expression can change when cells are cultured in vitro42, we tested our hypothesis in vivo, 
eventually testing 226 chemically distinct LNPs. This approach is distinct from previous studies 
for 2 reasons. First, LNP studies typically evaluate many nanoparticles in vitro before selecting a 
small number to test in vivo27,28,64-67. Second, most LNP studies focus on hepatocytes, not 
macrophages27,28,65-67.  
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We used microfluidics107 to formulate a validated ionizable LNP that has delivered siRNAs 
in vivo64,108-112. The LNP carried a single stranded DNA (ssDNA) (Fig. 2.1A) that was chemically 
modified with phosphorothioates to reduce exonuclease degradation, and fluorescently tagged with 
Alexa-647. We chose Alexa-647 since it was significantly brighter than Alexa488 (Fig. 2.1B). One 
hour after intravenously injecting WT or Cav1 deficient (Cav1-/-) mice with the clinically relevant113 
dose of 0.5 mg / kg DNA, we quantified Alexa-647 MFI in 13 cell types (Fig. 2.1C) using flow 
cytometry (Fig. 2.1D,E). In WT mice, >75% of the MFI signal was found in Kupffer cells or hepatic 
endothelial cells; we could not reliably quantify delivery in other cell types. The same was true for 
Cav1-/- mice, suggesting Cav1 did not change LNP biodistribution (Fig. 2.1F).  
Given the role of Cav1 in nanoparticle endocytosis114, the fact caveolin inhibitors affect 
this LNP in vitro64, and the fact this LNP delivers siRNA and sgRNA to pulmonary and 
cardiovascular endothelial cells in vivo64,108-112, we hypothesized that our Alexa-647 biodistribution 
data were inaccurate. Our hypothesis was recently strengthened by demonstrations that the 
fluorescent biodistribution of small molecules delivered by nanoparticles can change in ways that 
do not reflect delivery115. Since nucleic acids are degraded by nucleases that cleave phosphodiester 
bonds116 - and fluorophores are not – we reasoned the fluorescent signal may not track with the 
nucleic acid. To test this, we engineered a novel biodistribution assay named QUANT; QUANT 
utilizes ddPCR – a technique used to quantify rare genomic events117 – to quantify the 
biodistribution of the nucleic acid itself with high sensitivity, allowing us to directly compare it to 
the biodistribution of the fluorescent readout. This is important since fluorescent biodistribution 
studies are ubiquitously used throughout to measure nucleic acid biodistribution. 
Since ddPCR requires efficient DNA amplification, we rationally designed QUANT DNA 
barcodes to increase DNA polymerase access (Fig. 2.2A,B, Fig. 2.1A). We minimized DNA 
2˚ structure on the forward and reverse primer sites and minimized G-quadruplex formation by 
separating our randomized 7 nucleotide region68,118 into semi-randomized NWNH and NWH sites. 
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We flanked the primer sites with 3 additional phosphorothioate-modified nucleotides to reduce 
exonuclease degradation of the primer site. Finally, we identified universal primer binding sites 
that would not amplify mouse or human gDNA. Specifically, we designed primers with similar 
melting temperatures (within 1˚C) and added them to human and mouse gDNA without barcode 
template (Fig. 2.3A). We identified primers that did not amplify gDNA after 40 cycles (Fig. 2.3B), 
but amplified barcode templates with 20 cycles. Based on these results, we added the ‘no gDNA 
background’ primer sites to our barcodes. We then optimized the ddPCR protocol (Fig. 2.3C-G) 
by varying annealing temperatures, primer concentrations, and probe concentrations. We increased 
the signal: noise ratio 14-fold compared to current standard protocols117. As a control, we scrambled 
the ddPCR probe site; no signal was generated, demonstrating that the signal required specific 
barcode-probe interactions (Fig. 2.3H). 
Standard curve experiments revealed QUANT was highly sensitive. QUANT ddPCR 
signal was linear (with respect to the DNA added) when barcodes were diluted in Tris-EDTA buffer 
to a concentration between 750 aM and 12 fM (R2 = 1.00) and was detected at 300 aM (Fig. 
2.2C,D). As a control, we reduced the concentration to 30 aM, and did not observe readouts above 
an untreated baseline. QUANT was also highly sensitive in vitro. We fluorescently tagged QUANT 
barcodes and administered them to iMAECs119 in 96 well plates with L2K at doses between 1 pg 
and 400 ng / well. Twenty-four hours later, we quantified biodistribution using flow cytometry, and 
observed measurable (but non-linear) increases in MFI above 10 pg / well (Fig. 2.4A). Separately, 
we administered QUANT barcodes without a fluorophore at doses between 60 and 16,000 
zeptogram (zg) / well. ddPCR readouts were linear (R2 = 0.91) between 120 and 8000 zg / well 
(Fig. 2.2E), 108x lower than the minimum dose required for a fluorescent signal. We then 
formulated QUANT barcodes into validated LNPs64 using microfluidics107; LNPs carrying 
barcodes formed nanoparticles with an average hydrodynamic diameter of 53 nm. We 
intravenously administered them at 0.5 mg / kg, isolated lung endothelial cells using FACS 24 
hours later, and quantified barcode delivery using ddPCR. We compared samples immediately after 
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completing the experiment to samples analyzed after storage at -20˚C for 20 or 31 days. Readouts 
were consistent when performed by different individuals using different reagent stocks (Fig.2.2F).  
 
2.2.2 QUANT biodistribution is more sensitive than fluorescence in vivo. 
We hypothesized that fluorescent biodistribution would yield different results than 
QUANT. We formulated the same LNP64 with QUANT barcodes that were, or were not, 
fluorescently tagged with Alexa-647. One hour after intravenously administering 0.5 mg / kg, we 
isolated the same 13 cell types (Fig. 2.1C) using FACS and quantified LNP delivery using Alexa-
647 MFI or QUANT (Fig. 2.5A). 87% of the Alexa-647 signal was found in liver cells; the 
remaining 10 cell types only generated 13% of the total fluorescent signal (Fig. 2.5B-D). QUANT 
biodistribution was different; only 56% of the ddPCR signal derived from the liver (Fig. 2.5B-D). 
We compared delivery in all 13 cell types and found statistically significant differences in 7 of them 
(Fig. 2.5E). In Figure 2E, we normalized delivery to Kupffer cells, which readily clear 
nanoparticles62,63. Notably, in all cases, fluorescence overestimated liver biodistribution. To 
exclude the possibility these results were due to a specific timepoint, we performed a 
pharmacokinetics experiment in 5 cell types: liver endothelial cells, Kupffer cells, hepatocytes, 
lung endothelial cells, and lung macrophages. We intravenously injected mice with 0.5 mg / kg 
QUANT barcodes, and sacrificed mice 0.4, 0.75, 1.25, 12, 24, and 36 hours later (Fig. 2.6A). At 
the 0.4-, 0,75-, and 1.25-hour timepoints, fluorescent biodistribution was localized to liver cells; 
only 1 of 6 non-liver signals (2 cell types, 3 timepoints) were statistically significant compared to 
untreated mice. At later timepoints, fluorescent biodistribution was not significantly above PBS-
treated mice in any cell type. Out 30 potential data points (5 cell types, 6 time points), only 6 
generated a fluorescent signal that was statistically significant compared to untreated mice (Fig. 
2.6B). By contrast, QUANT-based biodistribution was observed in all 30 data points (Fig. 2.6B). 
We calculated under the curve (Fig. 2.6C) and the maximum DNA delivery (Fig. 2.6D); once 
again, the results suggested Alexa-647 fluorescence overestimated delivery to the liver. Finally, we 
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investigated how robust QUANT readouts were across experiments. We compared the absolute 
ddPCR values from all 5 cell types in the first QUANT biodistribution experiment (Fig. 2.5) and 
the pharmacokinetic experiment (Fig. 2.6) at similar timepoints (1 and 1.25 hours, respectively). 
ddPCR readouts were reproducible (R2=0.98) between experiments (Fig. 2.6E). Figures 1-3 
demonstrate that QUANT is a sensitive and repeatable method of quantifying nanoparticle 
biodistribution.  
 
2.2.3 Distribution profiles of over one hundred can be analyzed with QUANT.  
QUANT enabled us to measure LNP delivery with increased sensitivity; we took advantage 
of this to test the hypothesis Cav1 affects LNP delivery in a cell type-specific manner in vivo. To 
ensure our results were not specific to 1 LNP chemical structure, we exploited a second advantage 
of QUANT: it can be multiplexed so the distribution of >100 LNPs is analyzed at once. Multiplexed 
analysis of nanoparticle delivery has been reported by our group68,118 and others120, but critically, 
these barcoding systems can only quantify delivery of LNP-1 relative to LNP-2 within the same 
sample; it cannot quantify absolute delivery. Without the ability to quantify absolute delivery, it is 
difficult to directly compare readouts (i) between different tissues, (ii) between different mouse 
models (e.g., WT and Cav1-/-), or (iii) between ddPCR and fluorescence.  
We performed 2 high-throughput in vivo LNP screens. We formulated LNP-1, with 
chemical structure 1, so it carried QUANT barcode 1; we formulated LNP-N, with chemical 
structure N, to carry QUANT barcode N (Fig. 2.7A-C). The 8-nucleotide barcode region on the 
QUANT DNA sequence - located in the center - can generate 65,536 unique barcodes; we designed 
156 that were compatible with one another on Illumina sequencing machines. Each barcode has a 
base distance of 3 or more, which means every 8-nucleotide barcode sequence is different from all 
other 8 nucleotide barcode at 3 of the 8 positions (or more). We used microfluidics107 to formulate 
LNPs with QUANT barcodes68,118. We analyzed the hydrodynamic diameter of each LNP 
individually using dynamic light scattering and pooled LNPs together if they met 2 inclusion 
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criteria: (i) hydrodynamic diameters between 20 and 200 nm, and (ii) an autocorrelation curve with 
1 inflection point (Fig. 2.7D, Fig. 2.8A); We also included a naked DNA barcode, which served as 
a negative control. We selected these LNP criteria, and the control based on experience with a 
different barcoding system68. We studied 2 LNP libraries; as expected, the normalized delivery of 
the naked DNA barcode was lower than the normalized delivery for barcodes carried by LNPs in 
library 1 (Fig. 2.7E,F) and library 2 (Fig. 2.8B,C). Normalized delivery quantifies how well an 
LNP performs, relative to all other LNPs in a given sample (Fig. 2.7A, Fig. 2.8D). It is analogous 
to counts per million in RNA-seq83, and can describe nanoparticle biodistribution68,118.  
 
2.2.4 Cav1 influenced nanoparticle delivery in a tissue- and cell-type dependent way 
We intravenously administered the LNPs to WT and Cav1-/- mice at a total DNA dose of 
0.5 mg / kg and used FACS to isolate 10 cell types 24 hours after administering the LNPs (Fig. 
2.8E). We focused on endothelial cells and macrophages since they exist in every tissue; this 
allowed us to study cell- and tissue-level effects. In LNP library 1, we formulated 128 LNPs; 111 
met our 2 inclusion criteria and were pooled together (Fig. 2.7C,D, Fig. 2.8F,G). Multiple lines of 
evidence suggested Cav1 influenced nanoparticle delivery in a tissue- and cell-type dependent way. 
First, the ‘total experimental’ biodistribution – defined as the total ddPCR counts in the 10 tested 
cell types – was reduced in Cav1-/- mice, relative to WT mice (Fig. 2.9A). In these pie charts, the 
area corresponds to total ddPCR counts. It is important to note this pie chart is not equal to the total 
clearance for the organ, since we did not measure the clearance in every cell type, and the values 
are not weighted by the percentage of a given cell type within the organ. We chose not to weight 
the values since the percentage of each cell type within an organ, for all tested organs, was not 
available.  
The decrease in ddPCR counts was not constant across different tissues; Cav1 exerted 
tissue-specific changes on LNP delivery. For example, the biodistribution to the liver was 
predominant in WT mice but was much less so in Cav1-/- mice (Fig. 2.9A). The decrease in liver 
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delivery was substantial; the total number of ddPCR counts in the liver of (Fig. 2.9B) Cav1-/- mice 
decreased by 93%. The Cav1-/- counts in lung and kidney were reduced by 43% and 27%, 
respectively, relative to WT mice (Fig. 2.9C,D). We then analyzed this effect at the cellular level 
in all 3 organs. In the liver, most of the decrease in Cav1-/- barcode readouts were due to decreased 
Kupffer cell delivery (Fig. 2.9E). Delivery to hepatic endothelial cells also decreased, but delivery 
to hepatocytes was not impacted significantly (Fig. 2.9B,E).  
The data above describe the average change in barcode counts for all LNPs. We then 
quantified how all 111 individual LNPs were affected by Cav1 expression. We multiplied the 
ddPCR readouts by the normalized delivery, to calculate absolute delivery for each LNP. We then 
plotted absolute delivery for each LNP in WT and Cav1-/- mice for 3 cell types in the liver (Fig. 
2.9F). Delivery to Kupffer cells in Cav1-/- mice was visibly lower than delivery to Kupffer cells in 
WT mice, even when plotted on a Log10 scale (Fig. 2.9F). Delivery to Kupffer cells was affected 
more than endothelial cells and hepatocytes. Notably, the high throughput analysis of absolute 
delivery has not been reported before; it is not possible to generate these plots using previous LNP 
DNA barcoding technologies. 
We repeated this experiment using a second LNP library. We rationally designed LNP 
library 2 to be similar to LNP library 1, with an important distinction: In library 1, LNPs contained 
the 7C1 lipid, cholesterol, PEG, and the helper lipid 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC); in library 2, LNPs contained the 7C1 lipid, cholesterol, and PEG. We omitted DSPC to 
exclude the possibility that the effects we observed in macrophages were due to changes in CD36 
expression. CD36 is expressed by macrophages; it acts as a receptor for phosphocholine, which is 
present in DSPC121. Critically, CD36 expression can be modulated by Cav1122. We formulated 120 
LNPs, of which 115 were stable, pooled, and injected (Fig. 2.8H-J). Most of the observations we 
made with LNP library 1 were consistent in LNP library 2. The ‘total experimental’ biodistribution 
was – once again - reduced in Cav1-/- mice, relative to WT mice (Fig. 2.10A). There was a 
pronounced change in delivery to the liver (72% reduction) (Fig. 2.10B), and very little change in 
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the kidney (Fig. 2.10C). Unlike library 1, in library 2, delivery to the lung was also reduced (Fig. 
2.10D). When we measured the cell type-specific changes in the liver, we found that Kupffer cell 
delivery was reduced again, strongly suggesting any effects we observed did not require the 
phosphocholine group in the LNPs (Fig. 2.10B,E). Delivery to hepatic endothelial cells and 
hepatocytes were decreased significantly (Fig. 2.10E). Finally, we calculated the delivery for all 
115 individual LNPs, and were able to visually observe the differences in Kupffer cells more so 
than hepatic endothelial cells and hepatocytes (Fig. 2.10F).  
 
2.2.5 Cav1 influences distribution of LNPs to Kupffer cells. 
Given the consistent results in Kupffer cells, we investigated whether Cav1 similarly 
affected pulmonary and renal macrophages (Fig. 2.11A). The total ddPCR counts in pulmonary 
macrophages did not change with Cav1 expression; renal macrophage delivery decreased, but not 
significantly. When assessing absolute delivery in WT Kupffer cells as well as pulmonary and renal 
macrophages, we observed that average nanoparticle delivery was ~10-fold higher in Kupffer cells 
than in lung and renal macrophages (Fig. 2.11B). To exclude the possibility the Kupffer cell 
reduction was due to (i) fewer Kupffer cells or (ii) differences in Kupffer cell phenotype in Cav1-/- 
mice, we measured the (i) number of Kupffer cells / total liver immune cells, and (ii) the expression 
of CD86 and CD206, 2 markers for Kupffer cell activation in livers of WT and Cav1-/- mice after 
they were injected with a 1 mg / kg dose of the same previously validated 7C1 LNP we used in our 
QUANT studies (Fig. 2.5, Fig. 2.6). In all previous experiments, we injected 0.5 mg / kg; in this 
experiment, we injected a 1 mg / kg dose to increase the chance we would observe immune 
activation. We reasoned this was the most clinically relevant experiment, since all 226 LNPs 
included the 7C1 compound. The LNPs contained a siRNA that did not target any murine gene 
(siLuciferase) to minimize the chance gene silencing affected Kupffer cell behavior. We found no 
differences between number and phenotype of Kupffer cells in WT and Cav1-/- mice (Fig. 2.11C-
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E). Taken together, these results suggest that caveolin-mediated endocytosis of nanomedicines by 
macrophages varies with tissue type. 
We also observed that Cav1 exerted cell type-specific effects on endothelial cell delivery. 
We first quantified the ddPCR counts in different endothelial cell beds in WT mice, and found 
LNPs were delivered to liver, lung, heart, and kidney endothelial cells with differential efficiency 
(Fig. 2.12A). We then calculated the barcode delivery in Cav1-/- mice and normalized to delivery 
in WT mice (Fig. 2.12B). Cav1-/- had a statistically significant impact on barcode delivery in liver, 
lung, and heart endothelial cells. Interestingly, delivery to kidney endothelial cells was impacted 
less. We next measured the individual biodistribution of all 226 LNPs tested in both WT and Cav1-
/- and found that barcode delivery to endothelial cells was consistently impaired in Cav1-/- mice 
(Fig. 2.12C-E). 
  
2.3 Discussion.  
Here we show that Cav1 affects LNP delivery in a cell type-specific manner in vivo. 
Delivery to Kupffer cells was significantly altered, leading to changes in nanoparticle 
biodistribution. Interestingly, Kupffer cell delivery was affected more than delivery to lung or 
kidney macrophages. These results suggest that Caveolin plays a more prominent role in LNP 
clearance in Kupffer cells, relative to other macrophage populations. These results are important 
for drug delivery systems, given that macrophages clear administered LNPs. Given that LNPs are 
lipid-like nanomaterials with compositions that can be similar to HDL, LDL, and VLDL, it will be 
interesting to evaluate whether the observations we made here extend to these ‘natural’ nanoscale 
carriers76,123. If so, these results could elucidate how cholesterol is trafficked to different tissues. 
Our results suggest macrophage uptake changes with tissue type. If future studies elucidate the cell 
signaling pathways that govern these differences, this cell signaling pathways could be manipulated 
to alter nanoparticle targeting.  
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Independent of the Cav1 results, we believe the discovery of QUANT is an important 
advance. More specifically, we found that a rationally designed ddPCR-based barcode system can 
quantify delivery with very high sensitivity. Previous DNA barcode technologies designed to track 
nanoparticle biodistribution could only compare relative biodistribution within the same cell type, 
but could not be used to compare biodistribution between different cell types124. We anticipate 
future studies further improving the design of QUANT barcodes by incorporating different patterns 
of chemical modification. Moreover, given that QUANT was able to read out delivery to all tested 
cell types here, we anticipate it will help scientists identify nanoparticles that target stem cells, 
immune cells, neurons, and other hard-to-target cell types.  
We found that fluorescent biodistribution overestimated delivery to the liver, compared to 
readouts of the nucleic acid itself. Our results were consistent over several experiments, and echo 
results generated by scientists studying small molecule delivery115. Given that the known 
mechanisms of nucleic acid degradation116 are different than the mechanisms that degrade 
fluorophores, we hypothesize the degradation of the nucleic acid is different from the degradation 
of the fluorophore. Further studies will be required to confirm or disprove this hypothesis. If 
confirmed, our results will be important, since most LNPs are thought to preferentially target the 
liver – often based on fluorescent biodistribution assays. These results could have important 
implications for nanoparticle discovery pipelines. 
It is important note the limitations of our work. First, we only used 1 nucleic acid size; 
changing the size of QUANT barcodes may better model different classes of nucleic acid drugs. 
Second, toxic or unstable LNPs will not work with QUANT. Nonetheless, QUANT enables new 
types of nanoparticle studies that will help elucidate the biological factors that affect LNP targeting 





2.4 Materials and Methods 
Nanoparticle Formulation. Nanoparticles were formulated using a microfluidic device as 
previously described26. Briefly, nucleic acids (DNA barcodes) were diluted in 10mM citrate buffer 
(Teknova) while lipid-amine compounds, alkyl tailed PEG, cholesterol, and helper lipids were 
diluted in ethanol. All PEGs, cholesterol, and helper lipids were purchased from Avanti Lipids. 
Citrate and ethanol phases were combined in a microfluidic device by syringes (Hamilton 
Company) at a flow rate of 600 µL/min and 200 µL/min, respectively.  
 
DNA Barcoding. Each chemically distinct LNP was formulated to carry its own unique DNA 
barcode. For example, LNP1 carried DNA barcode 1, while the chemically distinct LNP2 carried 
DNA barcode 2. 91 nucleotide long single stranded DNA sequences were purchased as ultramers 
from IDT. Three nucleotides on the 5’ and 3’ ends were modified with phosphorothioates to reduce 
exonuclease degradation and improve DNA barcode stability. To ensure equal amplification of 
each sequence, the we included universal forward and reverse primer regions on all barcodes. Each 
barcode was distinguished using a unique 8nt sequence. An 8nt sequence can generate over 48 
(65,536) distinct barcodes. We used 156 distinct 8nt sequences designed by to prevent sequence 
bleaching on the Illumina MiniSeqTM sequencing machine. A 26nt probe was purchased from IDT 
with 5’ FAM as the fluorophore, while internal Zen and 3’ Iowa Black FQ were used as quenchers. 
Fluorescent barcode was purchased from IDT with AlexaFluor647 or AlexaFluor488 conjugated 
to the 5’ end. 
 
In Vitro L2K. IMAECS were seeded at 10,000 cells per well in a 96-well plate. 24 hours after 
seeding, QUANT barcodes or Alexa-647-barcodes were transfected using Lipofectamine 2000. 24 
hours after transfection, DNA was isolated from cells treated with QUANT barcodes and 
fluorescent barcodes were measured using a DN Accuri C6 flow cytometer. 
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Nanoparticle Characterization. LNP hydrodynamic diameter was measured using high throughput 
DLS (DynaPro Plate Reader II, Wyatt). LNPs were diluted in sterile 1X PBS to a concentration of 
~0.06 µg/mL, and analyzed. To avoid using unstable LNPs, and to enable sterile purification using 
a 0.22 μm filter, LNPs were included only if they met the criteria of monodisperse population with 
diameter between 20 and 200nm. Particles that met these criteria were dialyzed with 1X phosphate 
buffered saline (PBS, Invitrogen), and were sterile filtered with a 0.22 μm filter.  
 
Animal Experiments. All animal experiments were performed in accordance with the Georgia 
Institute of Technology IACUC. C57BL/6J (#000664) and Caveolin1-/- (#007083) mice were 
purchased from The Jackson Laboratory and used between 5-8 weeks of age. In all in vitro and in 
vivo experiments, we used N=3-5 group. Mice were injected intravenously via the lateral tail vein. 
The nanoparticle concentration was determined using NanoDrop (Thermo Scientific). For in vivo 
nanoparticle screens, mice were administered at a dose of 0.5 mg/kg.  
 
Cell Isolation & Staining. Cells were isolated 24 (for screens) or 96 (for in vivo gene editing) hours 
after injection with LNPs unless otherwise noted. Mice were perfused with 20 mL of 1X PBS 
through the right atrium. Tissues were finely cut, and then placed in a digestive enzyme solution 
with Collagenase Type I (Sigma Aldrich), Collagenase XI (Sigma Aldrich) and Hyaluronidase 
(Sigma Aldrich) at 37 ºC at 550 rpm for 45 minutes. The digestive enzyme for heart and spleen 
included Collagenase IV64,108,110. Cell suspension was filtered through 70µm mesh and red blood 
cells were lysed. Cells were stained to identify specific cell populations and sorted using the BD 
FacsFusion and BD Facs Aria IIIu cell sorters in the Georgia Institute of Technology Cellular 
Analysis Core. For in vitro flow cytometry experiments, a BD Accuri C6 was used in the Georgia 
Institute of Technology Cellular Analysis Core. The antibody clones used were: anti-CD31 (390, 
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BioLegend), anti-CD45.2 (104, BioLegend), anti-CD68 (FA-11, Biolegend), and anti-CD11b 
(M1/70, Biolegend). Representative flow gates are located in Supplementary Figure 2.1.  
 
Digital Droplet PCR. The QX200TM Droplet DigitalTM PCR System (Bio-Rad) was used to prep 
and analyze all ddPCR results. All PCR samples were prepared with 10µL ddPCR with ddPCRTM 
Supermix for Probes (Bio-Rad), 1µL of primer and probe mix (solution of 10µM of target probe 
and 20µM of Reverse/Forward Primers), 1µL of template/TE buffer, and 8µL water. 20µL of each 
reaction and 70µL of Droplet Generation Oil for Probes (Bio-Rad) were loaded into DG8TM 
Cartridges and covered with DG8TM Gaskets. Cartridges were placed in the QX200TM Droplet 
Generator to create water-oil emulsion droplets. Cycle conditions for PCR were as follows: 1 cycle 
of 95º for 10 minutes, followed by 40 cycles of 94ºC for 30 seconds, 60ºC for 1 minute, and 1 cycle 
of 95ºC for 10 minutes. Plates were stored at 4ºC until ran on the QX200TM Droplet DigitalTM PCR 
System.  For each biological rep, 3 technical repetitions were completed. In all cases, technical reps 
were averaged. Technical reps were only excluded if they saturated the detection or showed 
inconsistent positive event amplitudes. 
 
PCR Amplification for Illumina Sequencing. All samples were amplified and prepared for 
sequencing using a two-step, nested PCR protocol (Fig. 2.3C). More specifically, 2 μL of primers 
(10 uM for Base Reverse/Forward) were added to 5 μL of Kapa HiFi 2X master mix, and 3 μL 
template DNA/water. This first PCR reaction was ran for 20-30 cycles. The second PCR, to add 
Nextera XT chemistry, indices, and i5/i7 adapter regions was ran for 5-10 cycles and used the 
product from ‘PCR 1’ as template. Dual-indexed samples were ran on a 2% agarose gel to ensure 
that PCR reaction occurred before being pooled and purified using BluePippin (Sage Science). 
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Deep Sequencing. Illumina sequencing was conducted in Georgia Institute of Technology’s 
Molecular Evolution core. Runs were performed on an Illumina Miniseq. Primers were designed 
based on Nextera XT adapter sequences.  
 
Barcode Sequencing Normalization. Counts for each particle, per cell type, were normalized to the 
barcoded LNP mixture applied to cells or injected into the mouse.  
 
Data Analysis & Statistics. Sequencing results were processed using a custom R script to extract 
raw barcode counts for each tissue. These raw counts were then normalized with an R script prior 
for further analysis. Statistical analysis was done using GraphPad Prism 7; more specifically, 1-tail 
T-test, Paired 2-tail T-test, or One-way ANOVAs were used where appropriate. Data is plotted as 






Figure 2.1 (A) QUANT Barcode Design. (B) Comparison of Mean Fluorescent Intensity of 
barcodes conjugated with Alexa-488 and Alexa-647 at 200ng and 50ng per well. 
*p<0.05,***p<0.001, 2 tailed t-test. (C) Cell types in the liver, heart, lung, spleen, and kidney were 
sorted based on the following FACS Markers. (D) Representative FACS gating for lung. We 
isolated endothelial cell (CD31+CD45-) and macrophages (CD31-CD45+CD11b+). (E) 
Representative FACS gating for liver. We isolated endothelial cells (CD31+CD45-), Kupffer cells 
(CD31-CD45+CD68+), and Hepatocytes (CD31-CD45-CD68-). (f) MFI of barcodes conjugated 
with Alexa-647 in WT and Cav1 -/- mice. 
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Figure 2.2 (A) QUANT barcodes are rationally designed to provide highly sensitive readouts of 
nanoparticle delivery. QUANT barcodes contain universal primer sites, an 8 nucleotide barcode 
region, a probe binding site, and splitsemi-randomized regions. These designs reduce DNA 
secondary structure and increase DNA polymerase access. (B) Barcodes can be formulated into 
chemically distinct lipid nanoparticles using high throughput microfluidics. (C) Standard curve of 
QUANT barcodes diluted in TE buffer; (D) barcodes can be identified above background at 300aM 
concentrations. **p<0.01, 2 tailed t-test. (E) An in vitro standard curve; barcodes were quantified 
24 hours afterbeing delivered to cell using Lipofectamine 2000. (F) QUANT barcode readouts 
immediately after DNA was isolatedfrom cells following in vivo nanoparticle delivery, or after the 
samples were stored at -20˚C for 20 or 31 days. Eachexperiment was performed using different 
stock reagents, demonstrating the repeatability of the assay. (G) Comparison of fluorescence and 
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Figure 2.3. (A) A multi-step approach to optimizing the signal generated by ddPCR QUANT 
barcodes. Primer combinations were tested to avoid non-specific amplification by genomic DNA 
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(gDNA). Different primer pairs were added to mouse and human gDNA without any barcode 
template. (B) Primers that didnot amplify gDNA were selected. (C) A two-step PCR adds Illumina 
nextera chemistry regions, indices,and Illumina adapters for Illumina sequencing and (D) produces 
a clear product. € Dual indices allow formultiplexed Illumina sequencing. (F) ddPCR was 
optimized using an annealing temperature of 60°C and (G) probe concentration 2x more than the 
ddPCR standard protocol concentration. (H) A scrabbled probesite was tested to verify the 





Figure 2.4. (A) Alexa-647 fluorescence 24 hours after fluorescently labeled QUANT barcodes 
were administered in vitro to iMAECs with Lipofectamine 2000 and analyzed with flow cytometry.  
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Figure 2.5. (A) A direct comparison of fluorescent- and ddPCR-based biodistribution in vivo 
reveals differences. QUANT barcodes with (or without) a fluorophore was formulated into a LNP 
and injected intravenously. Five tissues were isolated and barcode delivery to 13 cell types isolated 
by FACS was measured by QUANT or fluorescence. (B) Cumulative biodistribution measured by 
QUANT or fluorescence in liver and non-liver cell types. **p<0.01, 2 tailed t-test. (C,D) 
Cumulative biodistribution within the 5 tissues examined by QUANT and fluorescence. 
Fluorescence readouts overestimate liver delivery. (E) Comparison of biodistribution in the 13 cell 




Figure 2.6. (A) QUANT barcodes with (or without) a fluorophore were formulated into LNPs, 
injected intravenously, and isolated at different timepoints. Nanoparticle distribution was measured 
using QUANT or fluorescence. (B) Relative nanoparticle biodistribution (normalized to maximal 
signal in any cell type) 0.4, 0.75, 1.25, 12, 24, and 36 hours after administration of a LNP carrying 
647-QUANT barcode or QUANT barcodes at a dose of 0.5 mg / kg. Asterisk denotes a signal that 
was significantly different than PBS-treated mice. (C) Comparisons of area under the curve as 
measured by QUANT or fluorescence. Delivery to the lungs was underestimated by >3 fold by 
fluorescence. (D)Peak DNA delivery (normalized to liver ECs) as measured by QUANT and 
fluorescence. No fluorescent signal was detected in lung macrophages. **p<0.01, ***p<0.001 2 
tailed t-test. (E) R2 analysis of QUANT absolutely counts from the 1 hour timepoint (Figure 2.5) 




Figure 2.7. (A) QUANT was applied to screen over 100 nanoparticles in WT and Cav1-/- mice. 
Unique QUANT barcodes can be formulated into chemically distinct nanoparticles. (B) QUANT 
ddPCR readouts can be coupled with deep sequencing to measure absolute delivery mediated by 
>100 LNPs at once in vivo. (C) LNPs libraries can be synthesized with the LNP 7C1, Cholesterol, 
DSPC, and PEG compounds at variable molar ratios;128 different LNPs were formulated for screen 
1. (D) The diameter of each LNP in screen 1 was measured individually; stable LNPs, with 
diameters between 20 and 200 nm, were included. (E) The average normalized delivery from all 
LNPs and the naked barcode (negative control) from screen 1. (F) As expected, the naked barcode–








Figure 2.8. (a) Using DLS, LNPs were includedif they met the following inclusion criteria: 
autocorrelation curves with 1 inflection point and hydrodynamicdiameters between 20 nm and 200 
nm. (B) Average normalized delivery of each LNP from library 2. (C) In all samples of library 2, 
naked barcode – the negative control – was delivered less efficiently thanbarcodes carried by LNPs, 
as expected. (D) The following example illustrates how our deep sequencingdata was normalized. 
(E) Cells were sorted on the indicated FACS markers. (F) LNPs libraries for screens1 and 2 were 
synthesized with the LNP 7C1, Cholesterol, DSPC, and variable PEG compounds atvariable molar 
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ratios. (G) The formulation ratios and diameter of each LNP for screen 1. (H) 
Nanoparticleformulation ratios for screen 2; in this screen, we formulated 120 different LNPs. (I) 
Stable LNPs withdiameters between 20 and 200 nm were included. (J) The formulation ratios and 




Figure 2.9. High throughput QUANT studies reveal Caveolin1 affects delivery in atissue- and cell-
type dependent manner in vivo. (A) The total ddPCR counts in alltested cell types – which are equal 
to the area of the circle - were used to determinethe ‘total experimental’ biodistribution in WT and 
Cav1-/- mice. (B) The total ddPCRcounts were determined in different cell-types from the liver, 
(C) lung and (D) kidney.Compared to cells isolated from WT mice, ddPCR counts from Cav1-/-
decreased, with the most dramatic effect in the liver. (E) Within the liver cell-types,normalized 
library 1 nanoparticle biodistribution demonstrates that Kupffer cells inCav1-/- uptake less nucleic 
acids when compared to Kupffer cells from WT mice.****p<0.0001 2-way ANOVA. (F) 
Combined sequencing data and ddPCR resultsshows the absolute delivery of 111 nanoparticles for 
each LNP in the liver in WT(blue) and Cav1-/- (red) mice, from library 1, in Kupffer cells, liver 





Figure 2.10. (A) Total ddPCR barcode counts for library 2 – equal to the area of the circle - were 
used to determine the overall biodistribution from the LNP screens previously described across 
multiple organs from WT and Cav1-/- mice. (B) The total ddPCR counts were determined in 
different cell-types from the liver, (C) lung and (D) kidney. (E) Within the liver cell-types, 
normalized nanoparticle biodistribution demonstrates that Kupffer cells in Cav1-/- uptake less 
nucleic acids when compared to Kupffer cells from WT mice. *p<0.05 2-way ANOVA. (F) 
Combined sequencing data and ddPCR results shows the absolute delivery of 115 nanoparticles for 
each LNP in the liver in WT (blue) and Cav1-/- (red) mice, from library 1, in Kupffer cells, liver 





Figure 2.11. QUANT studies show Caveolin1 significantly affects delivery in Kupffer cells in 
vivo. (A) Nanoparticlebiodistribution in macrophages were isolated from multiple tissues from WT 
and Cav1-/- mice. Lungand kidney macrophages were less impacted by the loss of caveolin. 
**p<0.01 1-tailed t-test. (B) Absolutenanoparticle delivery to WT and Cav1-/- macrophages in the 
liver, lung, and kidney. Kupffer cells werestatistically significant compared to other macrophage 
beds. ****p<0.0001 One-way ANOVA. (C) The percentageof Kupffer cells (CD68+ CD45+) 
within the immune cell population (CD45+) in WT and Cav1-/-mice were similar. Phenotype 
variations in WT and Cav1-/- Kupffer (CD68+ CD45+) cells populationswere determined by MFI 




Figure 2.12. (A) Normalized nanoparticle biodistribution across two screens (226 LNPs) in liver, 
lung, heart, and kidney endothelial cells. (B) QUANT demonstrates that endothelial cells in Cav1-
/- uptake less QUANT barcodes than endothelial cells in WT mice. *p<0.05, ***p<0.001 1 tailed 
t-test. (C) Combined sequencing data and ddPCR results for each LNP in lung endothelial cells in 




CHAPTER 3.  CONSTRAINED NANOPARTICLES DELIVER SIRNA AND SGRNA TO 
T-CELLS IN VIVO WITHOUT TARGETING LIGANDS 
 
The work presented here is an excerpt from Lokugamage MP*, Sago CD*, Islam FZ, Gan Z, 
Krupzak BR, Dahlman JE, “Constrained nanoparticles deliver siRNA and sgRNA to T cells in vivo 
without targeting ligands.” Advanced Materials, 2019. 
 
3.1 Introduction 
T lymphocytes help regulate immune responses, which makes them important drug targets. 
For example, antibodies that block T cell CTLA-4 or PD-1 signaling can drive anti-tumor 
responses125. However, antibodies target druggable proteins, which constitute approximately 15% 
of total proteins. By contrast, siRNA can inhibit the translation of any gene; many ‘undruggable’ 
proteins were recently implicated in T cell-mediated immunity126.  
Clinically relevant RNA delivery to cells other than hepatocytes9 remains challenging19. 
However, there have been advances in T cell siRNA delivery. For example, siRNA was delivered 
to T cells using a single chain antibody linked to a cationic peptide; this led to gene silencing at 5 
mg / kg127. In a second example, nanoparticles were coated with anti-CD4 antibodies, leading to 
20% target gene silencing at 1 mg / kg doses128. More recently, LNPs that target hepatocytes were 
re-targeted to T cells by coating them with CD4 antibodies, leading to 50% in vivo T cell gene 
silencing at 6 mg / kg doses25. These papers (and others)129 achieve T cell delivery using peptide-, 
protein-, or aptamer-based targeting ligands, and more generally, ligand-based targeting is used 
throughout nanomedicine. However, ligands can make reproducible manufacturing at human scales 
more challenging130.  
One alternative to active targeting is to exploit endogenous lipid trafficking; notably, the 
only FDA approved RNA nanoparticle therapy9 utilizes LNPs without ligands that are trafficked to 
hepatocytes via endogenous cholesterol transport36. Natural trafficking has not been exploited to 
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promote nanoparticle delivery to T cells, yet these cells can interact with viruses and lipoprotein 
particles, which can have diameters similar to LNPs76,131. We therefore hypothesized that LNPs 
could interact with T cells without targeting ligands. To test this hypothesis, we quantified how 
well 168 LNPs delivered siRNA to 9 cell types in vivo. Using traditional 1-by-1 in vivo approaches, 
this would require FACS analysis of hundreds of mice. Thus, to generate large scale in vivo data, 
we developed a siGFP / DNA barcode-based screening system. This system quantifies how over 
100 nanoparticles deliver siGFP to any desired combination of on- and off-target cell types in vivo. 
This in vivo approach contrasts with previous LNP research, which utilizes in vitro screening to 
select a small number of nanoparticles for in vivo evaluation132. The approach is supported by 
evidence that in vitro nanoparticle delivery can be a poor predictor of in vivo nanoparticle 
delivery33. By combining high throughput in vivo analyses and bioinformatics, we found that a new 
class of materials, named conformationally constrained lipids, can form stable LNPs. We also 
found these ‘constrained LNPs’ (cLNPs) can deliver siRNA to T cells in vivo. These data 
demonstrate that the conformational state of lipids can alter LNP tropism and provide intriguing 
preliminary evidence that natural trafficking can promote T cell delivery, offering a potential 
alternative to active targeting.  
 
3.2 Results 
3.2.1 Lipid nanoparticles containing a constrained lipid can form stable LNPs 
We synthesized 13 chemically diverse lipids containing amines or boronic acid. The library 
was constructed to investigate whether the structure of the (i) head groups and (ii) lipid tail affected 
delivery. We purified a ‘scaffold’ containing the unsaturated lipid linoleate and two ester bonds 
(Fig. 3.1A, Fig. 3.2A). This scaffold did not have any ionizable components; we attached head 
group variants to the reactive sites, in order to create chemical diversity. At reactive site 1, we 
added 11 head groups (labeled 1-11) via esterification, resulting in head groups linked by ester or 
carbonate linkages, respectively (Fig. 3.1B). At reactive site 2, we added 3 lipid tails (labeled A-
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C) with diverse structures (Fig. 3.1C) via esterification. Tail A contained adamantane, a constrained 
lipid with a defined ‘armchair’ structure. Tail B contained 2 lipid tails, bringing the total number 
of tails to 3. The control tail, C, was linoleate; this created a construct with two identical lipid tails. 
After synthesis, we confirmed the chemical structure of all 13 lipids using high resolution mass 
spectroscopy or 1H-NMR (Fig. 3.2B-D). We named each lipid with the nomenclature ‘head group 
number – tail letter’ (e.g. 11-A). 
We then investigated whether the 13 ionizable lipids formed stable LNPs. We measured 
the hydrodynamic diameter of LNPs carrying a siRNA targeting GFP76 (siGFP) as well as a DNA 
barcode133; the LNPs were formulated using microfluidics107. The siGFP was chemically modified 
to reduce immunostimulation and enhance on-target silencing via preferential antisense RISC 
loading (Fig. 3.3A). To minimize the chance our results were affected by other constituents added 
to the LNP, we added previously validated constituents: C14PEG2000, unmodified cholesterol, 
and either DSPC or DOPE (Fig. 3.1D). As a control to ensure our results were not affected by the 
molar ratio of the 4 components, we formulated each of the 13 lipids with 2 phospholipids and 4 
molar ratios, producing a total of 104 chemically distinct LNPs (Fig. 3.1D). Encouragingly, 100 of 
the 104 LNPs formed small, monodisperse populations, as evidenced by hydrodynamic diameter 
and polydispersity index; these 100 LNPs were pooled together. The diameter for individual LNPs 
varied between 30 and 170 nm. As a control, we also measured the diameter and polydispersity of 
the pooled LNPs. We found them to be 76 nm (Fig. 3.1E) and 0.23 (Fig. 3.1F), respectively, which 
was within the range of the individuals comprising the pool. We then analyzed the hydrodynamic 
diameter as a function of ionizable lipid (Fig. 3.3B), molar ratio of the four constituents (Fig. 3.3C), 
and the type of phospholipid (DSPC / DOPE) added to the formulation (Fig. 3.3D). In all cases, 
the average diameter varied between 50 and 100 nm. These data led us to conclude these lipids 




3.2.2 A high-throughput siRNA screen reveals LNPs with constrained lipids have biological activity 
in T cells 
We evaluated how each LNP delivered siRNA to target cells (in this case, T lymphocytes) 
as well as 8 off-target cell types in vivo (Fig. 3.4). Our approach utilizes DNA barcodes and siGFP, 
to evaluate how many distinct LNPs functionally delivered siGFP, in any combination of target 
cells, in a single mouse. We formulated LNP-1, with chemical structure 1, to carry siGFP and DNA 
barcode 1; we separately formulated LNP-N, with chemical structure N, to carry siGFP and DNA 
barcode N (Fig. 3.5A). We included naked barcodes as a negative control133, since DNA does not 
readily enter cells. We pooled the LNPs together, and intravenously injected them into mice that 
constitutively express GFP under a CAG promoter (Fig. 3.5B). The GFP acted as the functional 
delivery readout; LNPs which functionally delivered siGFP into the cytoplasm would have lower 
GFP protein expression. Thus, 3 days after injecting mice, we isolated GFPLow cells using FACS, 
and deep sequenced the DNA barcodes in GFPLow cells. In this way, we isolated barcodes co-
localized with cells in which GFP protein silencing occurred. After sequencing the barcodes, we 
calculated normalized delivery, i.e., the number of barcodes for each individual barcode, divided 
by the total number of barcodes within that sample. Normalized delivery is analogous to counts per 
million in RNAseq experiments124. Since GFP is expressed in all cell types, this assay allows us to 
(i) compare GFP knockdown in any combination of on- / off-target cells and (ii) identify LNPs that 
co-localized in GFPLow cells.  
Three days after injecting a total dose of 1.5 mg / kg into mice (100 distinct LNPs, 0.015 
mg / kg / particle on average), we quantified GFP silencing in 9 cell types. Compared to PBS treated 
mice, there was an increased number of GFPLow splenic B cells and splenic T cells (Fig. 3.5C). 
The average GFP protein silencing, quantified by mean fluorescent intensity, was greatest in splenic 
T cells, followed by liver immune cells, splenic B cells, and lung endothelial cells (Fig. 3.5D). 
Surprisingly, we found no evidence of silencing in hepatocytes (Fig. 3.5C,D), which are 
preferentially targeted by many LNPs127. We then monitored the controls included in our data; we 
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sequenced the GFPLow splenic T cells as well as lung endothelial cells, splenic B cells, and liver 
immune cells. In all 4 cell types, the normalized delivery of both negative controls (naked barcodes) 
was lower than barcodes delivered by LNPs, as expected (Fig. 3.5E).  
We then performed a large in vivo structure-function analysis, using the DNA sequencing 
data to evaluate whether any nanoparticle material properties promoted delivery to splenic T cells. 
First, we calculated the enrichment for different nanoparticle properties (Fig. 3.6). Briefly, we 
calculated the odds a nanoparticle with a particular property would show up by chance in particles 
that (i) performed in the top 10%, and separately, (ii) particles that performed in the bottom 10%. 
Nanoparticles formulated with DSPC were enriched in effective particles (i.e., particles with high 
normalized delivery), whereas nanoparticles formulated with DOPE were enriched in particles that 
performed poorly (Fig. 3.5F). To validate these results, we then compared the normalized delivery 
for all LNPs formulated with DSPC and DOPE, respectively, and found that DSPC-containing 
LNPs outperformed DOPE-containing LNPs (Fig. 3.7A). As an additional validation, we 
calculated the normalized delivery of ‘paired’ LNPs, i.e., LNPs that had the same molar ratios and 
ionizable lipids (but different phospholipids). We found that DSPC LNPs outperformed their paired 
DOPE containing LNP (Fig. 3.7B). Based on these data, we concluded that the phospholipid 
contained within the LNP affected splenic T cell delivery. We therefore limited future chemical 
analysis to DSPC containing formulations. 
We then analyzed enrichment for the 13 ionizable lipids, in order to evaluate the effect of 
the lipid tail and head group and found 3 ionizable lipids were enriched (Fig. 3.5G). As a control, 
we plotted enrichment of each headgroup versus headgroup molecular weight, hydrophobicity 
(LogP), and polar surface area (Fig. 3.8A-D); we did not observe correlations between these traits 
and enrichment. The lipid that was most enriched, 11-A, contained a conformationally constrained 
adamantane tail. Notably, the enrichment (Fig. 3.5G) and normalized DNA delivery (Fig. 3.5H) of 
11-A was higher than 11-B and 11-C, the two compounds with identical head groups, but 
unconstrained lipid tails. We then performed a paired analysis using compounds with the same 
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molar ratio and found that adamantane containing tails outperformed other tail structures (Fig. 
3.8E). Finally, as a control, we analyzed how LNP size affected delivery. We plotted normalized 
T cell delivery against LNP size and found no relationship (Fig. 3.8F). Taken together, these data 
provided initial evidence that adamantane-containing LNPs could deliver nucleic acids to T cells 
in vivo, without the use of a targeting ligand.  
 
3.2.3 A second high-throughput siRNA screen suggests that adamantanes can deliver siRNA to T 
cells 
To further investigate the relationship between adamantane and siRNA delivery, we 
performed a second in vivo screen with adamantane-containing LNPs. The second library was 
designed based on the results of the first screen. To do this, we first synthesized new ionizable 
lipids, using the most enriched components from the first screen, head group 1 (Fig. 3.1B) and 
adamantane tail (tail A, Fig. 3.1C). More specifically, at reactive site 3, we added 15 lipids tails 
(labeled D-S) with diverse structures (Fig. 3.9A,B) via esterification. We also included the top-
ranked LNP from our first screen (Fig. 3.9C). Thus, we synthesized 16 ionizable lipids in total. We 
named each lipid in the following manner: ‘head group number (R1) – tail letter (R2) – tail letter 
(R3)’ (e.g. 11-A-M). We formulated each LNP with C14PEG2000, cholesterol, and DSPC. Once 
again, to control against effects driven by the molar ratio of the components, we formulated all 16 
ionizable lipids at 4 molar ratios, for a total of 64 LNPs (Fig. 3.9D). Each LNP carried siGFP and 
a unique barcode. 55 of the LNPs formed small, monodisperse populations, based on the 
hydrodynamic diameter and polydispersity index, and were therefore pooled together. The diameter 
for individual LNPs varied between 20 and 200 nm, with an average of 92 nm (Fig. 3.9E) and an 
average PDI of 0.20 (Fig. 3.9F). We plotted hydrodynamic diameter for each ionizable lipid (Fig. 
3.11A) and each molar ratio (Fig. 3.11B), and found that all the compositions formed LNPs within 
the 20-200 nm range.  
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We then administered all 55 LNPs intravenously to mice at a total dose of 1.5 mg / kg. 
Three days later, we quantified GFP silencing in 9 cell types. Once again, we (i) found GFPLow 
splenic T cells (Fig. 3.9G), (ii) measured GFP protein silencing in splenic T cells (Figure 3H), (iii) 
found no evidence of silencing in hepatocytes (Fig. 3.9G,H), and (iv) found no relationship 
between nanoparticle size and delivery (Fig. 3.11C). As a control, we quantified the normalized 
delivery of both negative controls (naked barcodes), and found they were lower than barcodes 
delivered by LNPs (Fig. 3.9I). We then evaluated whether the molecule added to reactive site 3 
(Fig. 3.9B) altered delivery when adamantane was present. Using enrichment (Fig. 3.10J), we 
found reactive group D, I, and M were enriched. We were unable to identify why these variants 
performed well. However, compared to the top performing cLNP from screen 1, we found delivery 
was not greatly improved with any alteration to the reactive site 3 molecule (Fig. 3.9K). It is 
interesting to note that the top performing cLNP from screen 1 (11-A-M) was enriched more than 
any other cLNP (Fig. 3.9J). These data provided additional evidence to support the hypothesis that 
LNPs can deliver siRNA to T cells without targeting ligands. 
 
3.2.4 cLNPs deliver small RNAs that change gene expression in CD8+ T cells 
Like all high throughput screening systems, the value of this siGFP / DNA barcode assay 
is related to its ability to make predictions. We therefore evaluated whether the top-ranked LNPs 
from our first (11-A-M) and second (1-A-N) screens delivered siRNA in vivo (Fig. 3.10A). We 
formulated each LNP with siGFP and analyzed physical traits; each LNP had similar hydrodynamic 
diameter, polydispersity and pKa (Fig. 3.10B). We then intravenously injected mice with 1.5 mg / 
kg; 3 days later, we isolated cells and measured GFP protein expression. When compared to mice 
treated with a non-targeting, chemically modified siRNA (siLuc), we found 11-A-M silenced GFP 
more than 1-A-N (Fig. 3.10C). To validate the activity of 1-A-N, we formulated it with siCD45, 
and quantified CD45 silencing three days after injecting mice with 1.5 mg / kg; we found 
statistically significant silencing in T cells (Fig. 3.11D,E). Based on these head-to-head data, we 
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focused on compound 11-A-M. We performed a siRNA gene silencing dose response in vivo, and 
found that 11-A-M silenced GFP as doses as low as 0.5 mg / kg (Fig. 3.10D). We quantified 
silencing in subsets of T cells, focusing on CD4+ and CD8+ cells, respectively, and observed more 
potent protein silencing in CD8+ T cells (Fig. 3.10E). During this experiment, we also evaluated 
whether 11-A-M delivered siGFP to other common ‘off-target’ cell types by quantifying GFP 
silencing. Recapitulating observations made in both screens, we observed no significant silencing 
at doses as high as 1.5 mg / kg in other cell types, including hepatic T cells, bone marrow T cells, 
and splenic macrophages (Fig. 3.12). We then quantified on- and off-target biodistribution using 
QUANT, a highly sensitive ddPCR-based method we recently reported133. We formulated 11-A-M 
to carry the chemically modified QUANT barcode and injected 1.0 mg / kg intravenously. 24 hours 
later, we isolated cell types using FACS, and measured biodistribution in 8 cell types. We found 
that 11-A-M distribution was highest in splenic CD8+ T cells, CD4+ T cells, and B cells. 
Distribution was lower in splenic macrophages as well as endothelial cells, Kupffer cells, 
hepatocytes, and T cells isolated from the liver (Fig. 3.13A,B). We also quantified biodistribution 
mediated by 1-A-N in all 8 cell types, and found that splenic macrophages acted as the primary 
‘sink’ for this LNP (Fig. 3.13C,D). These data suggest that the 11-A-M cLNP may preferentially 
silence genes in splenic CD8+ T cells.  
Finally, we utilized 11-A-M to facilitate in vivo gene editing in T cells. We formulated it 
to carry a chemically modified sgRNA targeting GFP (Fig. 3.14) into mice112 constitutively 
expressing Cas9 and GFP. Five days after administration, we quantified GFP expression in CD3+ 
T cells as well as in CD4+ and CD8+ T Cells. We observed a similar tropism; GFP protein was 
silenced more robustly in CD8+ than in CD4+ T cells (Fig. 310F). We did not observe changes in 
GFP expression when a control sgRNA targeting the gene ICAM-2 was administered to the mice 
(Fig. 310F). Notably, cLNPs did not lead to weight loss 24 hours after administration in any 
experiment (Fig. 3.15A). Taken together, these data led us to conclude that cLNPs without targeting 
ligands can deliver siRNA and sgRNA to splenic T cells. Finally, we analyzed additional traits of 
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11-A-M cLNPs formulated with siGFP using transmission electron microscopy. We found that the 
cLNPs formed small, monodisperse spherical structures (Fig. 310G). 
 
3.3 Discussion 
Nanoparticles that deliver RNA systemically to non-hepatocytes are difficult to design19, 
in large part because (i) there is no high throughput method to study nanoparticle siRNA delivery 
in vivo and (ii) natural trafficking mechanisms to non-liver cells remain elusive. This universal 
problem in nanomedicine slows the development of all RNA therapies; currently, scientists perform 
high throughput nanoparticle assays in vitro, even though cell culture does not33 recapitulate all the 
factors that affect delivery in vivo. Notably, the results from our first siGFP screen predicted that 
preferential T cell delivery would occur; these data were confirmed by the second siGFP screen, 
and by several in vivo experiments with cLNPs selected from the library. These data suggest that 
high throughput in vivo siRNA screens can identify nanoparticles with novel tropism. The 
screening data (Fig. 3.5C,D, Fig. 3.9G,H) suggested that other immune cell subsets may be 
targeted with LNPs. Although our current data do not allow us to predict how endosomal escape 
varies between T cells and other immune cells, we believe future studies utilizing traditional cell 
signaling techniques may elucidate genes and pathways that govern (and differentiate) endosomal 
escape in subsets of immune cells. Notably, evidence suggests a given immune cell ‘type’ actually 
encompasses a spectrum of transcriptionally and phenotypically distinct cells134. We therefore 
hypothesize that the relationship between uptake and cytoplasmic delivery will vary along this 
spectrum.  
It is important to acknowledge the limitations of our work. First, the siGFP system will not 
work with unstable nanoparticles. It is critical to (i) analyze the size and polydispersity of each 
individual nanoparticle before pooling, (ii) include the naked DNA barcode control, (iii) use 
untreated GFP mice to gate during FACS, and (iv) individually confirm any lead candidates 
identified by the screen. Second, although we observed protein silencing in T cells at 0.5 mg / kg 
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doses, we will need to reduce this dose more than 30-fold before it matches the potency of a FDA-
approved siRNA delivery vehicle in mice22. We anticipate iterative in vivo approaches we recently 
reported135 may further improve T cell LNP potency. Lastly, we did not identify the natural 
trafficking pathways that promoted delivery to T cells. However, we believe that identifying the 
genes or pathways that promote LNP delivery to T cells without ligands constitutes an exciting 
scientific opportunity. In this way, we hope future work on cLNPs will lead to more effective, 
scalable RNA immunotherapies136, as well as fundamental advances in our understanding of T cell 
lipid trafficking. More generally, these data may inspire other efforts to identify natural 
mechanisms to target cells which – to date – have only been targeted with active ligands. 
 
3.4 Materials and Methods 
Nanoparticle Formulation. Nanoparticles were formulated using a microfluidic device30 as 
previously described. Briefly, nucleic acids (siRNA, sgRNA and DNA barcodes) were diluted in 
citrate buffer while lipid-amine compounds, alkyl tailed PEG, cholesterol, and DSPC were diluted 
in 100% ethanol. PEG, cholesterol, and DSPC was purchased from Avanti Lipids. Citrate and 
ethanol phases were combined in a microfluidic device by syringe pumps at a relative flow rate of 
3:1. 
 
DNA Barcoding. Each chemically distinct LNP was formulated to carry its own unique DNA 
barcode and siRNA. For example, LNP1 carried DNA barcode 1 and siGFP, while the chemically 
distinct LNP2 carried DNA barcode 2 and siGFP. Single stranded DNA sequences were purchased 
from IDT. To ensure equal amplification of each sequence, we included universal forward and 
reverse primer regions. Each barcode was distinguished using a unique 8 nucleotide sequence. We 




Nanoparticle Characterization. LNP hydrodynamic diameter was measured using a plate reader 
formatted dynamic light scattering machine (Wyatt). LNPs were diluted in sterile 1X PBS to a 
concentration of ~0.06 µg/mL and analyzed. LNPs were only included if they formed monodisperse 
populations with diameter between 20 and 200nm. Particles that met these criteria were dialyzed 
with 1X phosphate buffered saline (PBS, Invitrogen), and were sterile filtered with a 0.22 μm filter.  
 
Animal Experiments. All animal experiments were performed in accordance with the Georgia 
Institute of Technology’s IACUC. C57BL/6J (#000664), GFP (#003291), and constitutive SpCas9 
(#026179) mice were purchased from The Jackson Laboratory and used between 5-12 weeks of 
age. In all experiments, we used N=3-5 mice/group. Mice were injected intravenously via the lateral 
tail vein. The nanoparticle concentration was determined using NanoDrop (Thermo Scientific). 
 
Cell Isolation & Staining. Cells were isolated 72 hours (for screens and siRNA silencing) or 120 
hours (for in vivo Cas9 gene editing) hours after LNP injection unless otherwise noted. Mice were 
perfused with 20 mL of 1X PBS through the right atrium. As we previously described64,68, tissues 
were cut and placed in a digestive enzyme solution with Collagenase Type I (Sigma Aldrich), 
Collagenase XI (Sigma Aldrich) and Hyaluronidase (Sigma Aldrich) at 37 ºC for 45 minutes. Cell 
suspension was filtered through 70µm mesh and red blood cells were lysed. Cells were stained to 
identify populations and sorted using the BD FacsFusion in the Georgia Institute of Technology 
Cellular Analysis Core for in vivo experiments. The antibody clones used were: anti-CD31 (390, 
BioLegend), anti-CD45.2 (104, BioLegend), anti-CD68 (FA-11, BioLegend), anti-CD19 (6D5, 
Biolegend), anti-CD3 (17A2, Biolegend), anti-CD8a (53-6.7, Biolegend), and anti-CD4 (GK1.5, 
Biolegend). Representative FACS plots are found in Supporting Information Figure 3.4. 
 
 56 
PCR Amplification for Illumina Sequencing. All samples were amplified and prepared for 
sequencing using nested PCR. 2 μL of primers were added to 5 μL of Kapa HiFi 2X master mix, 
and 3 μL template DNA/water. The second PCR added Nextera XT chemistry, indices, and i5/i7 
adapter regions. Dual-indexed samples were run on a 2% agarose gel to ensure that PCR reaction 
occurred before being pooled and gel purified. 
 
Deep Sequencing. Illumina sequencing was conducted in Georgia Institute of Technology’s 
Molecular Evolution core. Runs were performed on an Illumina Miniseq. Primers were designed 
based on Nextera XT adapter sequences.  
 
Barcode Sequencing Normalization. Counts for each particle, per cell type, were normalized to the 
barcoded LNP mixture applied to cells or injected into the mouse.  
 
TNS Assay. The pKa of 11-A-M and 1-A-N was measured as previously described64. Briefly, a 
stock solution of 10mM HEPES (Sigma), 10mM MES (Sigma), 10mM sodium acetate (Sigma), 
and 140nM sodium chloride (Sigma) was prepared and pH adjusted with hydrogen chloride and 
sodium hydroxide to a range of pH between 4 and 10. Using 4 replicates for each nanoparticle at 
each pH, 140 µL pH-adjusted buffer was added to a 96-well plate, followed by the addition 5 µL 
of 2-(p-toluidino)-6-napthalene sulfonic acid (60 µg / mL). 5uL of each nanoparticle was added to 
each well. After 5 minutes of incubation under gentle shaking, fluorescence absorbance was 
measured using excitation wavelengths of 325 nm and emission wavelength of 435nm. 
 
RNA interference. siRNAs were chemically modified at the 2’ position to increase stability and 
negate immunostimulation. Seventy-two hours after injection, tissues were isolated and protein 
expression was determined via flow cytometry. GFP mean fluorescent intensity in PBS-treated 
mice was made 100%, and GFP expression in treated mice was normalized to that value. 
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In vivo Cas9 Editing. Mice constitutively expressing SpCas9 were injected with cLNP carrying 2 
mg / kg of sgGFP. 5 days after injection, cells were isolated via FACS. 
 
Data Analysis & Statistics. Sequencing results were processed using a custom R script to extract 
raw barcode counts for each tissue. These raw counts were then normalized with an R script prior 
for further analysis. Statistical analysis was done using GraphPad Prism 7; more specifically Paired 
2-tail T-test or One-way ANOVAs were used where appropriate. Data is plotted as mean ± standard 






Figure 3.1. (A) Ionizable lipid scaffold to which (B) tail variants and (C) head group variants were 
added. (D) Using 4 molar rations, each of the 13 ionizable lipids were formulated with cholesterol, 
lipid-PEG, and either DSPC or DOPE, to create 104 distinct LNPs. (E) Hydrodynamic diameter 














Fig. 3.2. (A) General synthesis for lipid 11A. (B) Mass and NMR data for key ionizable 
lipids. (C) 1H NMR spectra for Lipid 11A. (D) 13C NMR spectra for Lipid 11A. 
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Fig. 3.3. (A) Sequence and chemical modifications of siGFP. Hydrodynamic diameter of 
LNPs plotted as a function of (B) ionizable lipid type, (C) molar percent of ionizable lipid, 


















































































siGFP sense: 5’ - AcAuGAAGcAGcACGACuU dT sdT - 3’
siGFP antisense: 5’ - AAGUCGUGCUGCUUCAUGU dT sdT -3’
A, G, U, C: RNA nucleotide
dT: deoxy-T






Figure 3.4. (A) Representative FACs plots showing gating strategy for splenic CD3+ T cells. (B) 




Figure 3.5. (A) Nanoparticles were formulated to carry a distinct DNA barcode and siGFP. (B) Of 
the 104 LNPs formulated, we pooled 100 stable LNPs together, and administered them to mice 
expressing GFP. After 3 days, we isolated GFPLow cells and sequenced the DNA barcodes within 
that population. (C) Percent GFPLow cells in 9 cell types. Two-way ANOVA, **P<0.01, 
****P<0.0001. (D) Normalized decrease in GFP MFI in 9 cell types. Two-way ANOVA, *P<0.05. 
(E) Normalized DNA delivery in lung endothelial cells, splenic B and T cells, as well as liver 
immune cells. (F) Enrichment of DSPC-containing LNPs in splenic T cells. (G) Enrichment for 
each of the 13 ionizable lipids. (H) Normalized DNA delivery of LNPs formulated with head group 
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Figure 3.7. (A) Normalized DNA delivery of LNPs plotted as a function of phospholipid. 2-way T 
test, **P<0.01. (B) Paired analysis of normalized DNA delivery of LNPs containing DSPC or 





Figure 3.8. (A) Physical and chemical analysis of headgroups. (B) Correlation of headgroup 
molecular weight and enrichment. (C) Correlation of headgroup LogP and enrichment. (D) 
Correlation of headgroup polar surface area and enrichment. (E) Normalized delivery of LNPs 
formulated with different ionizable lipids sharing headgroup 11, but with different tail structures. 




Figure 3.9. (A) 15 cLNPs can be formed with the top performing head group and (B) 15 tail 
variations. (C) The top performing constrained lipid from screen 1 was included. (D) Using 4 molar 
rations, each of the 16 ionizable lipids were formulated with cholesterol, lipid-PEG, and DSPC to 
create 64 distinct LNPs. (E) Hydrodynamic diameter and (F) polydispersity index of all formulated 
LNPs, measured individually. (G) Percent GFPLow cells in 9 cell types. Two-way ANOVA, 
*P<0.05. (I) Normalized decrease in GFP MFI in 9 cell types. (J) Normalized DNA delivery in 
lung endothelial cells, splenic B and T cells, as well as liver Kupffer cells. (J) Enrichment for each 




Figure 3.10. (A) Structure of ionizable lipid 11-A-M, top performing cLNP from screen 1 and 
structure of ionizable lipid 1-A-N, top performing cLNP from screen 2. (B) Molar composition and 
characteristics of 11-A-M and 1-A-N. (C) Normalized GFP expression in splenic CD3+ T cells 72 
hours after treatment of 2 cLNP carrying siLuc at a dose of 1.5 mg / kg or siGFP at doses of 1.5 
mg / kg. (D) Normalized GFP MFI in splenic CD3+ T cells 72 hours after treatment of cLNP 
carrying either siLuc or siGFP at various doses. One-way ANOVA, *P<0.05. (E) Normalized GFP 
MFI in splenic CD8+ and CD4+ T cells 72 hours after treatment of cLNP carrying siGFP at a dose 
of 2.0 mg / kg. unpaired 2-tail t-test, **P<0.01. (F) Normalized GFP MFI in splenic CD3+ T cells 
as well as CD8+ and CD4+ T cells after treatment of cLNPs carrying sgRNA at a dose of 2.0 mg / 
kg. Two-way ANOVA, *P<0.05, **P<0.01. (G) Transmission electron microscopy image of 11-




Figure 3.11. (A) Hydrodynamic diameter of LNPs plotted as a function of ionizable lipid 
type, and (B) molar percent of ionizable lipid. (C) Normalized delivery of in T Cells plotted 






Figure 3.12. Normalized GFP MFI of mice treated with either PBS, cLNP carrying 1.5 mg / kg 
siLuc, or cLNP carrying siGFP at a dose of 0.5 or 1.5 mg / kg in (A) hepatocytes, (B) liver immune 
cells, (C) liver kupffer cells, (D) liver endothelial cells, (E) splenic monocytes, (F) splenic B cells 
and (G) bone marrow T cells, and (H) liver T cells. (I) Percent of T cells found in the bone marrow 
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Figure 3.13. (A) Biodistribution of 11-A-M across 4 different cells types in the spleen and B) liver 
using ddPCR barcodes. C) Biodistribution of 1-A-N across 4 different cells types in the spleen and 











Figure 3.15 (A) Mouse weights 24hrs after administration of PBS or cLNP at various doses of 
siRNA. (B) Mouse weights 24hrs after administration of PBS or cLNP carrying siGFP. (C) Mouse 
weights 24hrs after administration of PBS or cLNP carrying sgGFP.  
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CHAPTER 4.  MILD INNATE IMMUNE ACTIVATION OVERRIDES EFFICIENT 
NANOPARTICLE-MEDIATED RNA DELIVERY 
 
The work presented here is an excerpt from Lokugamage MP, Gan Z, Zurla, C, Levin J, Islam FZ, 
Kalathoor S, Sato M, Sago CD, Santangelo PJ, Dahlman JE, “Mild innate immune activation 
overrides efficient nanoparticle-mediated RNA delivery.” Advanced Materials, 2019. 
 
4.1 Introduction 
Nanoparticles interact with biomolecules that alter nanoparticle efficacy and safety137. 
Insights into biological pathways that affect how nanoparticles (i) interact with the surface of target 
cells and (ii) are endocytosed are valuable. In an example of (i), the ApoE-mediated mechanism by 
which LNPs can be delivered to hepatocytes helped lead to a FDA approved siRNA drug60. 
Interactions between LNPs and serum ApoE was necessary for LNPs to bind hepatocytes, and 
LDLR, a cell surface receptor for ApoE, increased nanoparticle uptake36. Reports have also shown 
that the nanoparticle corona affects delivery76 by changing how nanoparticles interact with on- and 
off-target cells. In representative examples of (ii), authors used small molecules, RNAi, CRISPR, 
and knockout mice to reveal how nanoparticle uptake changes after endocytic genes are 
inhibited70,133. These studies and others138 identified that clathrin, caveolin, and another now-
canonical pathways impact nanoparticle uptake. 
We reasoned that another step in the drug delivery process seemed understudied. 
Specifically, we hypothesized that (iii) inflammation could alter the efficacy of a mRNA drug after 
the nanoparticle reaches the target cell by changing how the drug was translated. We tested this 
hypothesis by focusing on the gene toll-like receptor 4 (TLR4). We chose TLR4 for two reasons. 
First, understanding how TLR4 alters drug delivery is relevant to near-future mRNA therapies. 
LNP-mediated mRNA delivery139 is proposed for myocardial infarction140, colitis141, and Fabry 
disease142, as well as vaccines targeting influenza16, Zika143, and others144. TLR4 signaling plays a 
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role in these diseases145. In addition, adjuvants have been used in concert with mRNA vaccines, in 
order to improve their immunogenicity146; many adjuvants activate TLRs147. For example, authors 
found that delivering a TLR4 agonist in concert with mRNA encoding a vaccine did not improve 
vaccine efficacy in non-human primates, relative to the mRNA only148; we hypothesized this result 
could be explained by TLR4-driven reduction in mRNA delivery. The second reason we focused 
on TLR4 is its critical role dictating how pathogens are endocytosed and processed. This has been 
reviewed149; here we highlight three examples. In one example, scientists found cells exposed to 
lipopolysaccharide (LPS), which is an agonist for TLR4, led to TLR4 colocalization on endosomes. 
Imaging and biochemical assays led the authors to conclude that inflammation and endosomal 
trafficking were linked via TLR4. In another example, by labeling TLR4, authors found it was 
present at the plasma membrane as well as intracellular vesicles that contained the endosome 
marker Rab5; the authors concluded TLR4 played a central role in endocytosis150. In a third 
example, scientists found that pathogens evolved to evade recognition by the human immune 
system by preventing TLR4 recognition151.  This suggested reducing TLR4 activation could 
improve the survival of a foreign material in a human system.  
To test the hypothesis that TLR4 activation could override LNP-mediated mRNA delivery, 
we quantified functional mRNA delivery (more specifically, gene editing mediated by a protein 
encoded by mRNA) in hepatocytes, liver endothelial cells, and Kupffer cells in the presence of 
LPS, which activated TLR4. TLR4 is expressed on hepatocytes, Kupffer cells and dendritic cells152. 
In our follow-up mechanistic studies, we focused on Kupffer cells, which we selected for two 
reasons. First, upon TLR4 activation, macrophage gene expression changes153. For example, TLR4 
activation induces phosphorylation of PKR154, which reduces mRNA translation155. We therefore 
reasoned TLR4 could reduce mRNA translation, even after mRNA was delivered into the 
cytoplasm. Second, Kupffer cells play a central role in nanoparticle clearance by removing 




4.2.1 LPS impacts cKK-E12-mediated delivery of mRNA 
Initially, we performed experiments with LNPs formulated with the peptide-lipid cKK-
E12. cKK-E12 LNPs have delivered RNA28,157 to hepatocytes at clinical doses in mice and non-
human primates28; they are being considered for clinical development. After synthesizing cKK-
E1228, it was mixed with a PEG-lipid, cholesterol, and DOPE (Fig. 4.1A) with chemically modified 
mRNA encoding GFP in a microfluidic device[30], in order to formulate LNPs. The LNPs were 
small, had a low polydispersity, and a pKa of 6.2 (Fig. 4.1B). We investigated whether GFP mRNA 
delivery changed when cells were exposed to LPS. First, we added LPS or PBS to murine 
macrophages (RAWS) in a 24 well plate. Six hours later, we added LNPs carrying GFP mRNA at 
a dose of 1 µg. Twelve hours later, we quantified GFP MFI using flow cytometry. Compared to 
cells pre-treated with PBS, LPS pre-treated cells exhibited a robust reduction in MFI. Notably, 1 
ng of LPS was sufficient to reduce GFP expression by over 75% (Fig. 4.1C). We reasoned reduced 
GFP MFI could be driven by overt cell death. We therefore determined the percent of live / dead 
cells in our flow cytometry analyses by assessing the size and granularity of the cell populations. 
We observed no significant decrease in populations after exposure to LPS, suggesting the effect 
was not caused by overt cell death (Fig. 4.2A).  
We analyzed the effect of LPS on mRNA delivery in vivo. We formulated cKK-E12 LNPs 
to carry Cre mRNA, and intravenously injected them into Ai14 mice at the clinical60 dose of 0.3 
mg / kg mRNA. Ai14 mice have a Lox-Stop-Lox-tdTomato construct driven by a CAG promoter. 
If Cre mRNA is delivered into the cytoplasm and translated into functional Cre protein, the stop 
site is edited out of the genome, leading to tdTomato+ cells (Fig. 4.1D). The percentage of 
tdTomato+ cells is a validated way to quantify mRNA delivery in vivo158-160. Six hours before 
injecting LNPs, we administered 0.1 mg / kg LPS via an intraperitoneal injection; this dose is 
considered low161. Three days after injecting the LNPs, we quantified the percentage of Kupffer 
cells (CD68+CD45+CD31-), liver endothelial cells (CD45-CD31+) and hepatocytes (CD31-CD45-
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) that were tdTomato+ using flow cytometry. Compared to mice that were not treated with LPS, 
the percentage of tdTomato+ cells isolated from mice treated with LPS decreased to nearly 0% 
(Fig. 4.1E). We reasoned the effects could be driven by overt cell death. However, four lines of 
evidence suggested otherwise. First, a 0.1 mg / kg LPS dose is considered low161. Second, control- 
and LPS-treated mice experienced no significant weight loss during the experiment (Fig. 4.3A). 
Third, the data we plotted were the percentage of live hepatocyte, endothelial, or Kupffer cells that 
were also tdTomato+. Fourth, the size and granularity in cell populations cells isolated from the 
liver remained unchanged in LPS and control mice (Fig. 4.3B). 
To ensure the data were not specific to one LNP, we repeated the in vivo experiment using 
a second clinically relevant LNP named MC3. MC3 has delivered RNA in mice, non-human 
primates, and led to an FDA-approved siRNA drug60. The MC3 results recapitulated the cKK-E12 
experiments. Specifically, (i) the percentage of tdTomato+ hepatocytes, endothelial cells, and 
Kupffer cells decreased in mice treated with LPS compared to mice treated with PBS (Fig. 4.3C), 
and (ii) we did not observe any signs of cell death isolated from mice (Fig. 4.3D,E). 
 
4.2.2 In vivo barcoding identifies an LNP that preferentially delivers mRNA to Kupffer cells in vivo. 
We then investigated whether a novel LNP selected for Kupffer cell targeting could 
overcome the LPS-mediated reduction in mRNA delivery. To identify a novel LNP that 
preferentially delivers RNA to Kupffer cells (instead of hepatocytes) at a clinical dose, we 
performed a high throughput functional in vivo DNA barcoding screen (Fig. 4.4A,B). Briefly, we 
formulated LNP-1, with chemical structure 1, to carry Cre mRNA and DNA barcode 1, and LNP-
96, with chemical structure 96, carried Cre mRNA and DNA barcode 96. The formulation details 
for all 96 LNPs are detailed (Fig. 4.4C). We evaluated the diameter and polydispersity index of 
each individual LNP, and pooled together LNPs that were stable, monodisperse, and had a diameter 
less than 200 nm33. Of the 96 LNPs, 82 met these quality control criteria (Fig. 4.5A). These 82 
LNPs were injected a total mRNA dose of 1.0 mg / kg (0.012 mg / kg / particle, on average). Three 
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days after administering the LNPs to Ai14 mice, we isolated twelve tdTomato+ cell types in order 
to evaluate the on-target delivery (Kupffer cells) as well as off-target delivery (eleven cell types, 
Fig. 4.5B, Fig. 4.4D). We sequenced the tdTomato+ cells, thereby identifying barcodes colocalized 
with cells that were functionally transfected by Cre mRNA. We did not observe changes in mouse 
weight (Fig. 4.4E). We then analyzed previously described76,160 controls. We characterized the size 
and polydispersity of the 82 pooled LNPs, and found the pool was similar to the LNPs making up 
the pool (Fig. 4.5C,D). Second, we included a ‘naked’ DNA barcode as a negative control. Since 
DNA does not readily enter cells on its own, this DNA barcode was delivered into cells less 
efficiently than barcodes delivered by LNPs (Fig. 4.5E). Third, we found the nanoparticle 
sequencing data was consistent across mouse replicates (Fig. 4.4F).  
These controls led us to believe that it was appropriate to analyze the in vivo screening 
results. We quantified the percentage of live cells that were tdTomato+, using 12 cell types. We 
found that the LNP pool preferentially delivered Cre mRNA to Kupffer cells (~80% tdTomato+), 
followed by liver endothelial cells (~30% tdTomato+) and hepatocytes (~15% tdTomato+). We 
then sequenced all 82 barcodes and evaluated whether LNP size or chemical composition affected 
in vivo delivery. LNP delivery varied with the chemical composition more than the physical 
structure of the LNP. Specifically, LNPs formulated with epoxide-terminated fully saturated lipid 
tails consisting of 15 carbons were enriched in tdTomato+ cells, relative to LNPs made with other 
lipid tails (Fig. 4.5F). Enrichment analysis is detailed (Fig. 4.4G). LNP diameter did not affect 
delivery within the tested range of 20 – 200 nm (Fig. 4.4H-J), nor did lipid molar ratios (Fig. 4.4K). 
An important control for any high throughput screen is whether individual compounds 
perform as predicted. We quantified Cre mRNA delivery mediated by the best LNP from the screen, 
which we named LNP3 for simplicity (Fig. 4.5G,H). Three days after mice were systemically 
injected with 0.3, 0.1, or 0.03 mg / kg Cre mRNA formulated into LNP3, we observed mRNA 
delivery quantified by tdTomato+ cell percentage. LNP3 recapitulated the screening results: As the 
screen predicted, Kupffer cells were preferentially targeted, followed by liver endothelial cells and 
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hepatocytes (Fig. 4.5I). We did not observe delivery after a 0.03 mg / kg dose. Having identified a 
novel LNP that preferentially targeted Kupffer cells, we tested our hypothesis that LNP3 would 
overcome the LPS-dependent reduction in mRNA delivery. The data did not support this 
hypothesis; pre-treating mice with 0.1 mg / kg LPS reduced mRNA delivery in all 3 cell types (Fig. 
4.5J). To confirm the effect was consistent across LPS batches, we purchased two additional 
batches from the same company and tested them. Mice were pretreated with LPS six hours prior to 
LNP administration; three days later, we quantified by tdTomato+ cell percentage. There was a 
statistically significant reduction of mRNA delivery in all cell types in the liver (Fig. 4.4L).  
 
4.2.3 LPS-mediated innate immune activation did not significantly decrease LNP uptake. 
Having observed that mRNA delivery mediated by cKK-E12, MC3, and LNP3 was 
reduced by mild doses of LPS, we studied the biological mechanism, in vitro and in vivo. In order 
to deliver a mRNA drug that is translated inside the cell, an LNP must (i) reach the target cell and 
(ii) help the mRNA enter the cytoplasm. Then, the mRNA must be (iii) translated into protein (Fig. 
4.6A). Based on our data, we first hypothesized that (i) LPS reduced LNP uptake. We analyzed the 
biodistribution of LNP3 with QUANT, a sensitive system utilizing ddPCR to quantify LNP 
biodistribution133. We formulated LNP3 to carry a DNA barcode and injected mice at a dose of 0.3 
mg / kg DNA. Six hours before injecting LNPs, we administered 0.1 mg / kg LPS; control mice 
were pre-treated with PBS. Twenty-four hours after injecting the LNPs, we isolated Kupffer cells, 
liver endothelial cells, and hepatocytes using FACS. When compared to mice pre-treated with PBS, 
we observed increased Kupffer cell uptake in mice pre-treated with LPS. We did not see significant 
changes in the other two cells types (Fig. 4.6B). These data did not support the hypothesis that LPS 





4.2.4 LPS-mediated innate immune activation did not significantly decrease endosomal escape. 
We then tested whether (ii) LPS reduced endosome escape. We formulated LNP3 with a 
fluorescently tagged and chemically modified mRNA encoding Cre. We administered these LNPs 
to RAWS in a 24 well plate at a dose of 1 µg mRNA / well; six hours beforehand, we treated RAWS 
with 500 ng of LPS (or did not). Three, six or twenty-four hours after administering the LNPs, we 
fixed cells for imaging. Cells were stained for the endosomal markers CD63, EEA1, and Rab11, 
which co-localize with late, early, and recycled endosomes, respectively (Fig. 4.6C,D, Fig. 4.7A). 
We quantified the percentage of mRNA trapped in endosomal compartments using Mander’s 
overlap coefficient in >30 cells per condition as we previously described162 (Fig. 4.6E-G). At three 
and twenty-four hours, the Mander’s overlap coefficient was similar in PBS- and LPS-treated cells. 
At six hours, the Mander’s overlap coefficient was statistically lower in LPS-treated cells, but the 
difference was not sufficient to explain the complete reduction in protein production. Based on 
these data, we concluded that LPS-mediated decrease in protein expression was not driven 
predominantly by reduced endosomal escape. 
 
4.2.5 mRNA translation is altered by LPS through TLR4-mediated PKR activation 
We reasoned that LPS caused a difference in cell signaling that affected (iii) mRNA 
translation after the LNP reached the target cell; we therefore studied the cell signaling that drove 
this effect. We treated RAW cells with 100 ng of LPS six hours before administering LNPs carrying 
fluorescently tagged mRNA. Cell were fixed for imaging at one and three hours after LNPs were 
administered and stained for TLR4 as well as the endosomal markers CD63, EEA1, and Rab11. 
We observed vesicular localization of TLR4, and colocalization of TLR4 and LNP delivered 
mRNA. (Fig. 4.8A).  We reasoned that TLR4 inhibition could rescue mRNA delivery. We pre-
treated RAWS in a 24 well plate with 100 nM of TAK-242, a TLR4 inhibitor. One hour later, we 
administered 100 ng of LPS to cells; six hours later, we delivered 1 µg GFP mRNA using LNP3. 
Twenty-four hours after GFP mRNA was delivered, we quantified GFP MFI, and found that 
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delivery was rescued with TAK-242 (Fig. 4.9A). TLR4 can activate the downstream effector PKR, 
which can reduce protein translation154. We therefore treated cells with varying doses of C16 (Fig. 
4.9B), 2AP (Fig. 4.9C), and ISRIB (Fig. 4.9D), three PKR inhibitors. C16 and 2AP PKR inhibitors 
improved GFP delivery, while the results from ISRIB were inconclusive. Finally, we evaluated 
whether it was possible to overcome TLR4-mediated inhibition of mRNA delivery by increasing 
the LNP dose. We injected LPS pre-treated mice with 0.3 or 2.0 mg / kg Cre mRNA. Increasing 
the dose led to a non-significant increase in tdTomato+ cells (Fig. 4.9E). These data led us to 
conclude that TLR4 was an especially potent inhibitor of mRNA delivery (Fig. 4.9F).  
We then evaluated whether other inflammatory signaling affected delivery in a similarly 
potent way. We treated RAWS in a 24 well plate with 0.1, 1, or 5 µg of CpG or poly(I:C). CpG and 
poly(I:C) activate TLR3 and TLR9, respectively. Six hours later, we delivered 1 µg GFP mRNA 
using LNP3. Twenty-four hours later, we quantified GFP MFI. CpG and poly(I:C) activation 
reduced mRNA delivery, but neither reduced delivery as potently as 1 ng of LPS (Fig. 4.9G,H). 
Finally, to evaluate whether low-grade chronic inflammation reduced mRNA delivery, we injected 
mice subcutaneously with B16-F10 murine melanoma cells; this model is often used to evaluate 
immunotherapies163. Ten days later, we intravenously injected LNP3 carrying Cre mRNA at a dose 
of 0.3 mg / kg; as a control, we injected LNP3 into mice without tumors. Three days later, we 
digested the liver and quantified the percentage of tdTomato+ Kupffer cells, liver endothelial cells, 
and hepatocytes. When compared to mice that did not have tumors, there was no significant 
decrease in percentage of tdTomato+ cells (Fig. 4.9I). These data suggest that tumor-driven 
inflammation was not sufficient to reduce delivery to other organs in vivo. These data led us to 
conclude that although yet-to-be discovered inflammation pathways may also reduce mRNA 
delivery, TLR4 signaling is particularly potent. At the same time, TLR4 is expressed on the cell 
membrane while TLR3 and TLR9 are primarily expressed intracellularly; thus, we cannot exclude 
the possibility that the relative potency of TLR4 signaling was driven by the physical availability 
of the receptor. 
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4.3 Discussion 
The summation of these data led us to conclude that mild doses of the TLR4 agonist LPS 
reduce mRNA delivery in vitro and in vivo. Notably, reduced delivery was not caused by reduced 
cell uptake. Instead, the data suggest that the mechanism could be driven - in part - by TLR4-
mediated reductions in endosomal escape and was likely driven by a TLR4-mediated reduction in 
mRNA translation. Independent of the relative importance of endosomal escape and mRNA 
translation, the data support the hypothesis that TLR4 activation can block effective mRNA 
delivery after the LNP reaches the target cell. We believe these results have important implications 
for mRNA drugs delivered by LNPs. Specifically, they suggest that if an LNP delivers therapeutic 
mRNA to a given cell type in one disease state, it is not guaranteed to deliver mRNA to the same 
cell type in another disease. Thus, the on- and off-target delivery profiles of a given LNP could 
vary with disease state, not just with the LNP. These data demonstrate the need to understand how 
cell state impacts the safety and efficacy of a given nanoparticle. Historically, cell state has been 
difficult to study; however, recent advances in single cell RNA-sequencing87 make near-future 
experiments relating cell state to delivery feasible. We believe our data provide an impetus for these 
studies. We also found that a lead compound, LNP3, identified by a high throughput in vivo DNA 
barcoding screen performed as the screen predicted. Specifically, we generated and analyzed nearly 
4,000 in vivo data points. We analyzed these in vivo data points to study the relationship between 
LNP chemical structure and in vivo delivery. Interesting, LNP3 efficiently delivered mRNA in vivo 
at clinically relevant doses. This LNP was small, uniform, and potent, and unlike most previously 
reported LNPs, did not preferentially target hepatocytes in vivo. If these results are recapitulated 
by others, we believe this will be important for the nanomedicine field, given that historically, in 
vivo nanoparticle behavior has been difficult to predict using in vitro assays33. 
It is important to acknowledge the limitations of this work. First, our studies were limited 
to mice. It is possible that the results are not replicated in non-human primates. Second, it is likely 
that other genes could work in concert with TLR4 to mediate this effect. There are several proteins 
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involved in LPS-mediated signaling; we hope to detail the genetic networks driving this phenotype 
in future work using technologies such as RNA-seq to understand global gene expression. Third, 
our studies were limited to lipid-based nanoparticles. It is possible the results are not recapitulated 
in other mRNA carriers. Fourth, the high throughput in vivo barcoding system will not work for all 
nanoparticles; it is critical to include the controls described herein when performing the barcoding 
studies. Despite these limitations, we believe these data provide compelling evidence that 
inflammatory signaling can alter LNP delivery, and that high throughput in vivo barcoding can 
identify nanoparticles that deliver drugs in vivo. 
 
4.4 Materials and Methods 
Preparation of LNP3. TLC was performed on precoated silica Gel GF plates and visualized using 
KMnO4 stains. Column chromatography was performed using silica gel (300-400 mesh) eluting 
with DCM/MeOH. 1H-NMR spectra were recorded at 400 MHz or 500 MHz (Varian) using CDCl3 
with TMS or residual solvent as standard. High-resolution mass spectra (HRMS) were recorded on 
LC/MS (Agilent Technologies 1260 Infinity II/6120 Quadrupole) or a time-of-flight mass 
spectrometer by ESI or matrix assisted laser desorption/ionization (MALDI). All other chemicals 
were obtained from commercial sources and were used as received. 
 
 The compound 1 and LNP3 were prepared by reported procedure. Compound 1 (20 g, 41.9 mmol) 
was charged in a 100 ml flask and trifluoroacetic acid (42 mL) was added slowly at 0 ºC and then 
stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure and 
then the crude product dissolved in DMF (5 mL) was added dropwise to pyridine (300 mL) at 0 ºC. 
The reaction mixture was stirred at room temperature overnight. The solvents were evaporated 
under reduced pressure to afford a white solid and washed with ethyl acetate to give pure compound 
2 (8.4 g, 13.04 mmol, 31% yield).  
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To a solution of compound 2 in acetic acid/CH2Cl2 (150/150 mL) was added Pd/C (10 wt. %, 3.0 
g). The black suspension was degassed for 5 min with hydrogen and stirred at room temperature 
under hydrogen atmosphere overnight. The reaction mixture was filtered by celite and washed with 
MeOH. The combined filtrates were concentrated to obtain a crude yellow viscous oil. The oil was 
solidified by adding ethyl acetate and washed with ethyl acetate to yield compound 3 (4.8 g, 12.76 
mmol, 98% yield). 1H NMR (400 MHz, D2O) δ 1.42-1.57 (m, 4H, CH2), 1.70-1.77 (m, 4H, CH2), 
1.87-1.92 (m, 4H, CH2), 3.03 (t, J = 7.6 Hz, 4H, NCH2), 4.14 (t, J = 5.2 Hz, 2H, COCH); 13C 
NMR (100 MHz, D2O) δ 21.0, 26.3, , 32.8, 39.0, 54.1, 170.1; HRMS (ESI, m/z) calcd for 
C12H25N4O2 [M + H]+: 257.1972, found 257.1968. 
 
To a solution of compound 3 (84 mg, 0.22 mmol) and tridecyloxirane (302 mg, 1.34 mmol) in 
EtOH (2 mL) was added triethylamine (0.12 mL, 0.88 mmol). The reaction mixture was then 
irradiated in the microwave reactor at 150 ºC for 5 h. Purification of the crude residue via flash 
column chromatography (gradient eluent: 1-2.0 % of MeOH /DCM then 2.0-4.0 % MeOH /DCM 
containing 0.5 % NH4OH) afforded LNP3 (200 mg, 78%) as a light yellow oil. 1H NMR (500 
MHz, CDCl3) δ 0.87 (t, J = 6.5 Hz, 12 H, CH3), 1.22-1.32 (m, 88 H, CH2), 1.36-1.56 (m, 16 H, 
CH2), 1.73-1.99 (m, 4 H, CH2), 2.17-2.68 (br, 12 H, NCH2), 3.62 (m, 4 H, CHOH), 3.98 (m, 2 H, 
COCH).; HRMS (ESI, m/z) calcd for C72H145N4O6 [M + H]+: 1162.1159, found 1162.1153 (Fig. 
4.10). 
 
Nanoparticle Formulation. Nanoparticles were formulated with a microfluidic device as previously 
described26. Briefly, nucleic acids (DNA barcodes, mRNA, and sgRNA) were diluted in 10mM 
citrate buffer (Teknova). Lipid-amine compounds, alkyl-tailed PEG, cholesterol, and helper lipids 
were diluted in 100% ethanol. For nanoparticle screens, Cre mRNA and DNA barcodes were mixed 
at a 10:1 mass ratio. Citrate and ethanol phases were combined in a microfluidic device by syringes 
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(Hamilton Company) at a flow rate of 3:1. All PEGs, cholesterol, and helper lipids were purchased 
from Avanti Lipids.  
 
Cell Culture. In vitro experiments were performed using murine macrophages (RAW 264.7, 
ATCC) and iMAECs, provided by Hanjoong Jo at Emory). RAW cells were maintained with the 
following culture conditions: 1% penicillin-streptomycin (500 U/mL penicillin G, 0.5 mg/mL 
streptomycin) (PenStrep, VWR) and 10% (v/v) FBS (VWR) in DMEM F-12 50/50 (Corning). 
iMAEC cells were maintained with the following culture conditions: 1% penicillin-streptomycin 
(500 U/mL penicillin G, 0.5 mg/mL streptomycin) (PenStrep, VWR), 10% (v/v) FBS (VWR), 1% 
(v/v) MEM non-essential amino acid solution (MEMNEAA, Sigma Aldrich), 25 μg/mL ECGS 
(Emd Millipore) in DMEM with 1 g/L glucose, L-glutamine, and sodium pyruvate (Corning). 
Unless specified otherwise, cells were seeded in a 24-well plate at a density of 40k cells/well. In 
each case, LNPs were added 24 hours later. 12 hours after transfection, protein expression was 
analyzed with flow cytometry (BD Accuri C6 and BD FacsFusion). In all experiments, we used 
N=3-4 wells/group. 
 
Lipopolysaccharides from Escherichia coli O55:B5 was purchased from Sigma Aldrich and 
solubilized in 1X PBS. Poly(I:C) was purchased from InvivoGen and solubilized in 1X PBS. CpG 
(T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*G*T*T) was purchased from IDT and 
solubilized in water. TLR4 Inhibitor, TAK-242, was purchased from Sigma Aldrich and solubilized 
in DMSO. 
 
DNA Barcoding. Each LNP was formulated to carry its own unique DNA barcode. LNP1 carried 
DNA barcode 1, while the chemically distinct LNP2 carried DNA barcode 2. DNA barcodes were 
designed rationally with several characteristics, as we previously described. Ninety-one nt long 
single stranded DNA sequences were purchased from IDT. Additional nucleotides on the 5’ and 3’ 
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ends of the of the ssDNA were modified with phosphorothioates to reduce exonuclease 
degradation. Universal forward and reverse primer regions were included on all barcodes to ensure 
equal amplification of each sequence. To monitor for PCR bias, each barcode was also designed 
with 7 random nucleotides. Each barcode was distinguished using a unique 8 nucleotide sequence. 
An 8-nucleotide sequence can generate over 48 (65,536) distinct barcodes. We used distinct 8 
nucleotide sequences designed by to prevent sequence bleaching and reading errors on the Illumina 
MiniSeqTM sequencing machine.  
 
Nanoparticle Characterization. LNP hydrodynamic diameter was measured using high throughput 
DLS (DynaPro Plate Reader II, Wyatt). LNPs were diluted in sterile 1X PBS and analyzed. To 
avoid using unstable LNPs, and to enable sterile purification using a 0.22 μm filter, LNPs were 
included only if they met 3 criteria: diameter >20 nm, diameter <200 nm, and correlation function 
with 1 inflection point. Particles that met these criteria were dialyzed with 1X PBS.  
 
TNS Assay. The pKa of the cKK-E12 LNP and LNP3 were measured as previously described. A 
stock solution of 10 mM HEPES (Sigma Aldrich), 10 mM MES (Sigma Aldrich), 10 mM sodium 
acetate (Sigma), and 140 nM sodium chloride (Sigma Aldrich) was prepared and pH adjusted with 
hydrogen chloride and sodium hydroxide to a range of pH between 4 and 10. Using 4 replicates for 
each pH, 140 μL pH-adjusted buffer was added to a 96-well plate, followed by the addition 5 μL 
of 2-(p-toluidino)-6-napthalene sulfonic acid (60 μg/ mL). 5uL of either cKK-E12 or LNP3 were 
added to each well. After 5 min of incubation under gentle shaking, fluorescence absorbance was 
measured using excitation wavelengths of 325 nm and emission wavelength of 435 nm using a 
plate reader (BioTek Synergy H4 Hybrid). 
Animal Experiments. All animal experiments were performed in accordance with the Georgia 
Institute of Technology’s IACUC. All animals were bread in the Georgia Institute of Technology 
Animal Facility. C57BL/6J (#000664) were purchased from The Jackson Laboratory. LSL-
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Tomato/Ai14 (#007914) were purchased from The Jackson Laboratory for breeding proposes. In 
all experiments, we used N=6-10 mice/group. Mice were injected intravenously via the lateral tail 
vein or intraperitoneal into the abdomen. The nanoparticle concentration was determined using 
NanoDrop (Thermo Scientific).  
 
Tumor Studies. Tumor experiments were performed using murine melanoma cell line (B16-F10, 
CRL-6475) purchased from ATCC. B16-F10 cells were maintained with the following culture 
conditions: 1% penicillin-streptomycin (500 U/mL penicillin G, 0.5 mg/mL streptomycin) 
(PenStrep, VWR) and 10% (v/v) FBS (VWR) in DMEM F-12 50/50 (Corning). Prior to injections, 
B16-F10 cells were resuspended in DMEM media without phenol red. C57BL/6J mice, under 
isoflurane anesthesia, were injected with 2.5 x 105 cells per hind leg. 
 
Cell Isolation & Staining. Cells were isolated 24 or 72 hours after injection with LNPs unless 
otherwise noted. Mice were perfused with 20 mL of 1X PBS through the right atrium. Tissues were 
finely cut, and then placed in a digestive enzyme solution with Collagenase Type I (Sigma Aldrich), 
Collagenase XI (Sigma Aldrich) and Hyaluronidase (Sigma Aldrich) at 37 ºC at 550 rpm for 45 
minutes. The digestive enzyme for heart and spleen included Collagenase IV [3, 4]. Cell suspension 
was filtered through 70 m mesh and red blood cells were lysed. Cells were stained to identify 
specific cell populations and sorted using the BD FacsFusion and BD Facs Aria IIIu cell sorters in 
the Georgia Institute of Technology Cellular Analysis Core. The antibody clones used were: anti-
CD31 (390, BioLegend), anti-CD45.2 (104, BioLegend), anti-CD68 (FA11, Biolengend), and PE 
anti-mCD47 (miap301, BioLegend). Representative flow gates are located in Fig. 4.11. PBS-
injected Ai14 mice were used to gate tdTomato populations for intravenous administration.  
 
ddPCR. The QX200 Droplet Digital PCR System (Bio- Rad) was used to analyze all ddPCR results.  
ddPCR samples were prepared with 10 μL of ddPCR with ddPCR Supermix for Probes (Bio-Rad), 
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1 μL of primer and probe mix (solution of 10 μM target probe and 20 μM reverse/forward primers), 
1 μL of template/TE buffer, and 8 μL of water. Once prepared, 20 μL of each reaction and 70 μL 
of Droplet Generation Oil for Probes (Bio-Rad) were loaded into DG8 Cartridges and covered with 
DG8 Gaskets. Using the QX200 Droplet Generator, water−oil emulsion droplets were created. 
Cycle conditions for PCR were as follows: 1 cycle of 95 °C for 10 min followed by 40 cycles of 
94 °C for 30 s, 60 °C for 1 min, and 1 cycle of 95 °C for 10 min. For each biological rep, three 
technical repetitions were completed. Unless stated otherwise, technical reps were averaged. 
Technical reps were only excluded if saturated was detected or there were inconsistent positive 
event amplitudes.  
 
PCR Amplification. All samples were amplified and prepared for sequencing using a one-step PCR 
protocol as previously described[2]. More specifically, 1 μL of primers (5 uM for Final 
Reverse/Forward, 0.5 uM for Base Forward) were added to 5 μL of Kapa HiFi 2X master mix, and 
4 μL template DNA/water. When the PCR reaction did not produce clear bands, the primer 
concentrations, DNA template input, PCR temperature, and number of cycles were optimized for 
individual samples. 
 
Deep Sequencing. Illumina deep sequencing was conducted in Georgia Tech’s Molecular Evolution 
core. Runs were performed on an Illumina MiniseqTM. Primers were designed based on Nextera 
XT adapter sequences.  
 
Data Normalization. Counts for each particle, per tissue, were normalized to the barcoded LNP 
mixture we injected into the mouse. This ‘input’ DNA provided the DNA counts, and was used to 
normalize DNA counts from the cells and tissues.  
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Data Analysis & Statistics. Sequencing results were processed using a custom python-based tool 
to extract raw barcode counts for each tissue. These raw counts were then normalized with an R 
script prior for further analysis. Statistical analysis was done using GraphPad Prism 8. Data is 
plotted as mean +/- standard error mean unless otherwise stated. 
 
Microscopy. mRNA was fluorescently labeled four 2’O-methyl RNA-DNA chimeric 
oligonucleotides, complementary to 4 adjacent sequences across the 3’ UTR region, with the 








MeOU-T(C6-Amino)-MeOC (Biosearch Technologies). The oligos were fluorescently labeled by 
conjugating Cy3B NHS ester (GE Healthcare) to the amino-modified thymidines following 
manufacturer’s instructions, followed by purification with 10kDa filters (Amicon, Fisher 
Scientific) to remove unbound dyes. IVT mRNA was buffer exchanged into 1X PBS and combined 
with linear oligos in a 1:0.7 molar ratio. mRNA labeling with fluorescently labeled probes was 
performed in a thermal cycler by heating the sample at 70ºC and gradually decreasing the 
temperature at RT in 1ºC/min steps. Labeled mRNA was formulated into LNPs (as previously 
described) and delivered to RAW 264.7 cells as described. 
 
Cells were seeded in glass-bottom 24-well plates at a density of 50k cells / well. 24 hours later, 
LNPs were administered. Cells were fixed with 4% paraformaldehyde (Electron Microscopy 
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Sciences) for 10 min at room temperature. Then, cells were permeabilized with 0.2% Triton X-100 
(Sigma-Aldrich) for 5 min at room temperature and blocked with 5% BSA. Cells were stained with 
CD63 (rabbit polyclonal sc-153633 Santa Cruz Biotechnology), EEA1 (rabbit polyclonal, PA5-
29013, Invitrogen) and Rab11 (rabbit polyclonal sc-9020 Santa Cruz Biotechnology), and donkey 
anti-rabbit secondary antibody, (pre-conjugated to Alexa Fluor 488) (Life Technologies). The 
samples used for the 1h and 3h time-points were additionally stained with an APC labeled anti-
mouse TLR4 antibody (Biolegend SA15-21). All antibodies were used at a 1:250 dilution in 1X 
PBS. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies).   
 
Images were aquired with a Hamamatsu Flash 4.0 v2 sCMOS camera on a PerkinElmer UltraView 
spinning disk confocal microscope mounted to a Zeiss Axiovert 200M body with a 63x NA 1.4 
plan-apochromat objective. Images were acquired with Volocity (PerkinElmer) with Z-stacks taken 
in 0.2 µm increments. Image acquisition and analysis was performed using the Volocity software 
(PerkinElmer). Thirty or more cells were analyzed per experimental condition; assays were 







Figure 4.1 (A) cKK-E12 was formulated by combining the ionizable material cKK-E12, 
C14PEG2000, unmodified cholesterol, and DOPE. (B) Characteristics of cKK-E12. (C) GFP mean 
fluorescent intensity twelve hours after cKK-E12 LNPs carrying GFP mRNA were administered. 
Data are normalized to GFP MFI of control cells that were not treated with LPS. ****p < 0.0001, 
One-way ANOVA. (D) To quantify mRNA delivery in vivo, we formulated cKK-E12 LNPs with 
Cre mRNA and injected them into Ai14 mice. If Cre mRNA is functionally translated into Cre 
protein, cells become tdTomato+. (E) The percentage of tdTomato+ cells in mice pre-treated with 
PBS or 0.1 mg / kg LPS, then injected with 0.3 mg / kg Cre mRNA. Data are normalized to mice 








Figure 4.3. (A)  Mouse weights, with and without LPS, 24 and 72 hours after injection of cKK-
E12. (B) Percent of live Kupffer cells, Endothelial cells, and hepatocytes with and without LPS. 
(C) Ai14 mice were injected with 0.1 mg / kg of LPS. Six hours later, MC3 carrying Cre mRNA 
was administered intravenously at 0.3 mg / kg. Functional Cre mRNA delivery was quantified as 
%tdTomato+ cells, in three cell types from the liver with and without LPS. **P < 0.006, *P < 0.05, 
one-tail t test. (D) Mouse weights, with and without LPS, 24 and 72 hours after injection of MC3. 
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Figure 4.4. (A) Barcoded nanoparticles are formulated with various chemical components, single 
stranded DNA barcodes, and Cre mRNA. Material 1 is formulated with DNA barcode 1 and cre 
mRNA; Material N is formulated with DNA barcode N and cre mRNA. (B) All stable LNPs are 
pooled and intravenously administered to Ai14 mice. If Cre mRNA is functionally delivered to the 
cytoplasm, it is translated into Cre protein, which edits the genome by excising the stop. As a result, 
the cells become tdTomato+ and are isolated using FACS. Barcodes are sequenced to identify 
which LNPs deliver mRNA in vivo. (C) Six cKK-E12 based lipids can be formed by varying the 
tail length with six groups. 96 LNPs were formulated with 16 different molar ratios of lipids, 
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C14PEG2000, cholesterol and DOPE. (D) Twelve cell types were isolated from 6 different tissues 
with FACS. E) Average mouse weights 24 hours after injection with LNP pool. (F) Average 
standard deviation across all mouse replicates from the screen were analyzed to quantify 
consistency between replicates. (G) Example enrichment analysis. (H) No correlation between size 
and delivery was found in Kupffer cells, (I) endothelial cells, or (J) hepatocytes. (K) We found no 
relationship between delivery and lipid molar ratio. (L) Two new batches of LPS (indicated in 
purple and grey) were used to pretreat mice at 0.1 mg / kg six hours prior to treatment with LNP. 
tdTomato+ cell percentages were quantified with flow cytometry. **P < 0.002, ***P < 0.0002, 





Figure 4.5. (A) Ninety-six chemically distinct LNPs were formulated with Cre mRNA and DNA 
barcodes. After quality control, 82 LNPs were injected into Ai14 mice. FACS was used to measure 
mRNA delivery and isolate tdTomato+ cells. (B) Twelve different cell types were isolated; the pool 
preferentially delivered to Kupffer cells. ****p < 0.0001, **p < 0.01, two-way ANOVA. (C) 
Hydrodynamic diameter and (D) polydispersity index of all administered LNPs. (E) Normalized 
delivery of all LNPs across all cell types. The naked barcode control performed poorly as expected. 
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(F) Enrichment of lipid variants in the top 10% compared to total formulated. cKK-E15 was the 
most enriched in Kupffer cells, Endothelial cells, and hepatocytes. (G) LNP3 was formulated with 
ionizable material cKK-E15, C14PEG2000, unmodified cholesterol, and DOPE. (H) Molar ratio, 
characteristics, and transmission electron microscopy image of cKK-E15. (I) The percentage of 
cells that are tdTomato+ after injections of 0.03, 0.1, or 0.3 mg / kg Cre mRNA. ****p< 0.0005, 
***p< 0.001, two-way ANOVA. J) LNP3 delivery of Cre mRNA at 0.3 mg / kg in mice pre-treated 





Figure 4.6. (A) To functionally deliver a mRNA drug, a LNP must be taken up by a cell, enter the 
cytoplasm, and be translated into protein. (B) To compare cellular uptake of LNP3 with and without 
LPS, LNP3 was formulated with QUANT DNA barcodes at 0.3 mg / kg and intravenously injected 
into mice. Twenty-four hours later, biodistribution was assessed. Biodistribution, shown as barcode 
counts (AU), for LNP3 with and without LPS. Nucleic acid uptake increased significantly in 
Kupffer cells when treated with LPS. ****P < 0.0001, two-way ANOVA. (C) Colocalization of 
fluorescently tagged mRNA formulated with LNP3 and endosomal markers in RAWS after 
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treatment of LPS. Cy3B labeled IVT mRNA (red) formulated with LNP3 was delivered to RAWS 
untreated or treated with LPS. Six and (D) 24 hours later, cells were stained for CD64, EEA1 and 
Rab11 (green) for early, intermediate and late endosomes, respectively. Scale bar represents 10 μm. 
Cropped regions are magnifications of white boxes in whole cell images with intensity profiles 
along the direction of the white arrow. (E) Percent of free mRNA was determined at 3, (F) 6 and 




Figure 4.7. (A) Colocalization of IVT mRNA formulated with LNP3 and endosomal markers in 
RAWS after treatment of LPS. Cy3B labeled IVT mRNA (red) formulated with LNP3 was 
delivered to RAWS untreated or treated with LPS. 3 hours later, cells were stained for CD64, EEA1 
and Rab11 (green) for early, intermediate and late endosomes, respectively. Scale bar represents 
10 μm. Cropped regions are magnifications of white boxes in whole cell images with intensity 




Figure 4.8. (A) Colocalization of IVT mRNA formulated with LNP3, endosomal markers, and 
TLR4 in RAWS after treatment of LPS. Cy3B labeled IVT mRNA (red) formulated with LNP3 
was delivered to RAWS untreated or treated with LPS. 1 and (B) 3 hours later, cells were stained 
for CD64, EEA1 and Rab11 (green) for early, intermediate and late endosomes, respectively, and 
TLR4 (blue). Scale bar represents 10 μm. Cropped regions are magnifications of white boxes in 





Figure 4.9. (A) When treated with TLR4 inhibitor and LPS, TAK-242, mRNA expression mediated 
by LNP3 delivery was rescued, when compared to cells treated with 100 ng LPS. GFP expression 
was non-significant when compared to the control group and the LPS. **P < 0.005, two-tail t test. 
(B) RAWS were treated with C16, (C) 2AP, or (D) ISRIB 1 hours prior to LPS. Six hours later, 
cells were treated with LNP3 carrying GFP mRNA and GFP expression was measured.  ****P < 
0.0001 (E) LNP3 carrying Cre mRNA was administered to Ai14 mice at 0.3 or 2 mg / kg. When 
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comparing 2 mg / kg to 0.3 mg / kg, tdTomato+ cells showed no significant increase. (F) TLR4-
mediated activation of PKR can lead to inhibition of mRNA translation. Inhibition of TLR4 or PKR 
can recover translation after LNP delivery. (G) RAWS were treated with CpG or (H) Poly (I:C) 
before being treated with LNP3 carrying GFP mRNA, and GFP expression was measured. No 
significant differences were found between treated and untreated groups. (I) LNP3 carrying Cre 
mRNA was administered to Ai14 mice with and without tumor xenografts. Delivery was evaluated 
by the percent of tdTomato+ cells in Kupffer cells, Endothelial cells, and hepatocytes. Delivery 





Figure 4.10. (A) Preparation of cKK-E15. Compound 1 was dissolved in DMF. The reaction 
mixture was stirred at room temperature overnight. The solvents were evaporated under reduced 
pressure and washed with ethyl acetate to give pure compound 2. Pd/C was added to Compound 2 
in acetic acid/CH2Cl2. The oil was solidified by adding ethyl acetate and washed with ethyl acetate 
to yield compound 3. Triethylamine was added to a solution of compound 3 and tridecyloxirane in 
EtOH. The reaction mixture was then irradiated in the microwave reactor at 150 ºC for 5 h. 
Purification of the crude residue via flash column chromatography to become cKK-E15. (B) NMR 




























































CHAPTER 5.  CLUSTERED IN VIVO SCREENS REVEAL DESIGN RULES FOR LIPID 




Once delivered into the cytoplasm, exogenously administered mRNA can express 
therapeutic nucleases, antigens, antibodies, or other proteins7. However, these drugs are limited by 
the need to deliver mRNA into the cytosol without eliciting an immune response139. Laboratories 
have improved mRNA delivery in mice, rats, pigs, and NHPs using LNPs2,16,124,142,143,148,159,160,164-
169. Independent of their chemical structure, LNPs are often discovered using a common workflow. 
First, dozens to hundreds of nanoparticles are made with diverse chemical compositions. Second, 
drug delivery mediated by these nanoparticles are quantified in vitro one by one. Third, in vitro 
data are used to select a small number of nanoparticles for in vivo studies. This approach is similar 
to a precedent set by the siRNA delivery field. In three representative examples26,66,132, to identify 
LNPs that deliver siRNA systemically, 4,736 LNPs were tested in vitro, whereas only 14 were 
tested in vivo.  
These and other studies revealed two key lessons we applied to nebulized mRNA delivery 
vehicles. First, all four components often used to create LNPs - ionizable lipid26, PEG-lipid170, 
cholesterol76,171, and other lipids (e.g., phospholipids)165,172  - influence delivery. The resulting four-
dimensional chemical space may therefore encompass 1010 or more distinct LNP formulations124, 
even without considering active targeting ligands. Second, in vitro nanoparticle delivery can poorly 
predict in vivo nanoparticle delivery33,160,173. These lessons highlight the need for an easily adopted 
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in vivo alternative to LNP discovery capable of efficiently and iteratively scanning diverse 
chemical space.  
Such an alternative to LNP discovery would be useful if applied to nebulization mediated 
LNP delivery to the lung. Nebulized nanoparticles have been considered as potential therapies for 
genetic disease174 as well as infectious disease, since these drugs could encode nucleases, vaccines, 
or antibodies targeting SARS-CoV-2 or its entry into human cells175. Given that LNPs can be 
manufactured at human scales, have been FDA approved176, and have demonstrated acceptable 
safety in early COVID-19 vaccine clinical trials177,178, they constitute an alternative to large 
polymeric179 and polymer-peptide-based180 nanoparticles that have delivered mRNA to the lung 
following nebulization. For example, although large (e.g., 25 kDa) polymers were shown to enable 
nebulized DNA delivery up to twenty years ago181,182, nebulized gene therapies using these 
polymers have not been FDA approved. In a recent example, a polymer for nebulized delivery 
required a polymer: mRNA mass ratio of 50:1181, a ratio five-fold higher than LNPs that have 
progressed into clinical trials.  
Demonstrating that an LNP can deliver mRNA to the lungs at low doses would open up a 
new and potentially clinically relevant chemical space for lung delivery. Yet this task remains 
difficult since LNPs that deliver mRNA after systemic administration may be dissimilar from LNPs 
that deliver mRNA to the lungs via nebulization. For example, although state-of-the-art nebulizers 
are designed to gently aerosolize the therapeutic, nanoparticles still experience shearing forces that 
can disrupt the structure of the vehicle-drug formulation. A second reason nebulized mRNA differs 
from systemic delivery is the biology of the airway. When nanoparticles are administered via 
nebulization, the cells, proteins, biomolecules, and physical barriers with which they interact183,184 
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are distinct from those with which they interact in the bloodstream38. Cells in the airways are also 
heterogenous185, which may alter delivery. 
Driven by the need for lung mRNA delivery vehicles, the lack of established LNP design 
principles, and the absence of a workflow to identify design principles, we report an in vivo cluster-
based iterative screening approach to identify LNP chemical traits that promote lung delivery. We 
found that (i) PEG is required for LNP formulation and (ii) that the combination of PEG molarity 
and helper lipid structure and charge influence delivery; this second fact underscores the need to 
understand multivariate LNP design space. Here, we identify a nanoparticle named Nebulized Lung 
Delivery 1 (NLD1). The structure of NLD1 is distinct from previously reported nanoparticles for 
nebulized delivery. Specifically, NLD1 is designed with a high amount of PEG-lipid and cationic 
helper lipid. While LNP-mediated nucleic acid delivery is often studied with low PEG-lipid molar 
ratios, we found a greater amount of PEG within an LNP can improve mRNA delivery to the lungs 
via nebulization. We also found that NLD1 is more effective than clinically relevant LNPs 
previously optimized for systemic delivery. Finally, we demonstrate that NLD1 can successfully 
be used to deliver mRNA encoding a broadly neutralizing antibody protecting mice from a lethal 
dose of H1N1 influenza. 
 
5.2 Results 
5.2.1 An in vivo workflow to evaluate how chemically diverse LNPs deliver mRNA to the lung after 
nebulization 
Based on the large LNP chemical space and the poor relationship between in vitro and in 
vivo delivery, we designed a cluster-based workflow to meet three key criteria. We reasoned the 
workflow must (i) be easily set up with equipment commonly used in nanoparticle labs, (ii) quantify 
functional mRNA delivery (i.e., mRNA translated into functional protein) in vivo, and (iii) be 
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capable of scanning a diverse LNP chemical space iteratively. We previously reported functional 
in vivo LNP screening systems utilizing DNA barcodes135,159,160,186,187; our cluster-based approach 
is distinct in two ways. First, it does not require next-generation sequencing; this may aid 
nanoparticle laboratories that do not regularly sequence DNA. Second, it uses a multi-step LNP 
design process to select LNP formulations detailed below. Inspired by Statistical Design of 
Experiment (DOE) methodologies188,189, our cluster-based approach allows us to manipulate 
several inputs (LNP traits) to determine their effect on in vivo RNA delivery. 
In this cluster-based approach (Fig. 5.1), we first identify several (in this schematic, three) 
hypotheses relating a specific LNP chemical trait to in vivo delivery. Second, we treat each 
hypothesis as an axis in a N-dimensional chemical space. Third, we formulate eight to 12 LNPs at 
a given extreme of each axis; we term these ‘extreme groups’. Fourth, we apply a three-tiered 
selection to each extreme group: do LNPs within the extreme group form small (<200 nm  
hydrodynamic diameter), stable (low dispersity, single peak on DLS nanoparticles?; if yes, does 
the extreme group remain stable after the LNPs are pooled together?; if yes, does the pooled LNPs 
from the extreme group functionally deliver mRNA into the lungs following nebulization (Fig. 
5.1A)? Fifth, we ‘expand and combine’ promising extreme groups by formulating LNPs near the 
intersection of these groups. Sixth, we individually test all these newly formulated LNPs, assaying 
whether they form small, stable LNPs, and whether they deliver mRNA in the lung following 
nebulization (Fig. 5.1B). Seventh, we use all these data, including data from groups that failed, to 
design subsequent nanoparticles. By generating distinct hypotheses, using extreme groups to test 
these hypotheses, then focusing on promising chemical spaces, we scan a diverse multi-
dimensional chemical space in vivo, offering an alternative to traditional in vitro-based screens. 
 
5.2.2 Surveying how four LNP chemical traits influence nebulized lung mRNA delivery in vivo 
In this case, data60,165,171,172,190,191 led us to hypothesize that four variables influenced 
nebulized LNP delivery: (i) the amount of PEG added to the LNP; (ii) the structure of the lipid-
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PEG; (iii) the charge of the phospholipid; and (iv) the presence or absence of cholesterol. We 
designed six extreme groups, varying molar ratios, components, and charge (Fig. 5.2A,D). In all 
six, we formulated eight to 12 LNPs with the compound 7C1, an oligomer-lipid conjugate18, 
thereby generating 56 distinct LNPs (Fig. 5.2B, Fig. 5.3A,B). 7C1-based LNPs have delivered 
siRNA in non-human primates192 and therefore may be viable for potential clinical development.  
Using microfluidics30, we formulated LNPs with mRNA encoding an GPI-anchored nano-
luciferase (AncNanoLuc) mRNA at an LNP component: mRNA mass ratio equal to 10:1. 
AncNanoLuc encoding mRNA was used in place of traditional luciferase since its GPI-anchor 
allows for the expressed protein to accumulate on the cell surface, acting as a depot for 
accumulating protein, which increases the sensitivity of the assay. We then analyzed all the LNPs 
with DLS. Extreme groups A, B, and C failed our control criteria (Fig. 5.2C), whereas extreme 
groups D, E, and F met the criteria (Fig. 5.2D). Specifically, many LNPs from extreme group A, 
B, and C were unstable and had hydrodynamic diameters greater than 200 nm (Fig. 5.2E, Fig. 
5.3A,B). Group A had very low percentages of PEG-lipid and groups B and C did not have PEG-
lipid. We therefore identified our first design rule: PEG-lipid is critical to form stable 7C1-based 
LNPs. As an additional control for LNP stability, we pooled the LNPs in extreme group D together, 
measured the hydrodynamic diameter of the pool, and found it to be within the range of diameters 
making up the pool; the same control was analyzed for extreme groups E and F (Fig. 5.2E). Once 
pooled, the clusters were nebulized and administered at 43 µg of mRNA / mouse (i.e., 6 µg / mouse 
/ particle on average, for N = 7 particles / mouse). Forty-eight hours later, we extracted the lungs, 
submerged the organs in furimazine, quantified luminescence using an IVIS in vivo imaging 
system, and calculated the fold change in lung luminescence flux, relative to background. 
Luminescence was significantly higher in lungs transfected with extreme group E, followed by D 
and then F (Fig. 5.2F,G). These results indicate that cholesterol and helper lipids are not crucial for 
initial LNP formulation, but they may improve functional LNP delivery.   
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5.2.3 A screen of LNPs containing cationic lipids from an expanded chemical space 
We then expanded a combination of extreme groups D and E. Clusters D contained cationic 
helper lipids, whereas cluster E contained a neutral lipid and a higher percentage of PEG-lipid. We 
therefore created 27 LNPs using three charged helper lipids (DOTAP, DOTMA, and 18:0 DDAB), 
C14PEG2000, cholesterol, 7C1, and 9 different molar ratios of PEG (Fig. 5.4A, Fig. 5.5A,B). 
Molar ratios of PEG varied from low (2.5, 6.5, and 15%) to high (25, 30, 35, 45, 55, 60%). LNPs 
were once again formulated with microfluidics to carry mRNA encoding AncNanoLuc at an LNP 
component: mRNA mass ratio equal to 10:1. Sixteen of the 27 LNPs formed stable, monodisperse 
LNPs with hydrodynamic diameters less than 200nm (Fig. 5.4B). We then analyzed whether the 
average hydrodynamic diameter and PDI of LNPs varied with the cationic lipid (Fig. 5.4C, Fig. 
5.5C) or the lipid-PEG molar ratio (Fig. 5.4D, Fig. 5.5D). LNPs formulated with less PEG-lipid 
were larger, which may be a useful way to roughly tune LNP size. We then nebulized and 
administered the 16 stable LNPs at the low dose of 15 µg mRNA / mouse. Forty-eight hours later, 
we isolated lungs and quantified luciferase luminescence. We observed a non-significant increase 
in luminescence when LNPs were formulated with 18:0 DDAB, when compared to DOTAP or 
DOTMA (Fig. 5.4E). Interestingly, when we plotted luminescence as a function of the PEG-lipid 
mole percentage, we observed LNPs formulated with higher amounts of PEG tended to increase 
luminescence (Fig. 5.4F,G). Additionally, we examine the PEG-lipid mole percentage in the top 
and bottom five performing LNPs. We found that the top five LNPs contained high molar 
percentages of PEG, whereas the bottom five LNPs typically were comprised of low molar 
percentages of PEG (Fig. 5.4H,I). The data suggests that the amount of PEG is important for 
formulations and that it affects delivery efficiency. Taken together, these data led us to a second 
design rule: a combination of cationic helper lipids and high molar percentages of PEG can lead to 
increased mRNA delivery after nebulization (Fig. 5.4H,J).  
 
5.2.4 A screen of LNPs containing neutral lipids from an expanded chemical space 
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We surmised LNP interactions in the lungs can be driven by several forces including PEG-
based hydrophilic interactions as well as charge193. We therefore formulated 26 additional LNPs 
using two phospholipids (DOPE and DSPC), two PEG-lipids with varied tail lengths, 
(C14PEG2000 and C18PEG2000), cholesterol, and 7C1 (Fig. 5.6A, Fig. 5.7A). Since LNPs with 
high PEG molar ratios were smaller than LNPs with lower PEG molar ratio, this experimental setup 
also allowed us to evaluate whether LNP size, as opposed to LNP chemistry, caused differences in 
LNP delivery. Once again, LNPs were formulated with AncNanoLuc mRNA at a mass ratio of 10:1 
and LNPs were only nebulized if they were monodispersed with a hydrodynamic diameter less than 
200nm (Fig. 5.6B). We plotted the average hydrodynamic diameter and PDI as a function of neutral 
lipid (Fig. 5.6C, Fig. 5.7B), PEG amount (Fig. 5.6D, Fig. 5.7C), and PEG tail length (Fig. 5.6E, 
Fig. 5.7D); notably, we observed a similar trend with LNP size; LNPs formulated with low PEG-
lipid molar ratios tended to be larger than LNPs with high PEG-lipid molar ratios (Fig. 5.6D). We 
also observed a trend with PDI and DSPC or low amounts of PEG-lipid (Fig. 5.7B,C). 
LNPs that passed the quality control assay were nebulized at a dose of 13.5µg of mRNA / 
mouse. We used 13.5 µg instead of 15 µg to identify LNPs that deliver at progressively lower doses. 
Forty-eight hours later, we isolated lungs and quantified luminescence. Consistent with our 
previous results (Fig. 5.6E), we did not observe substantial differences when delivery was plotted 
as a function of these helper lipids (Fig. 5.6F). In addition, we once again observed that delivery 
changed with PEG; specifically, LNPs formulated with a C18 tail had greater mRNA expression 
than LNPs formulated with a C14 tail (Fig. 5.6G). Moreover, LNPs formulated with lower molar 
percentages of amounts of PEG, specifically LNPs containing a 15% PEG molar amount, exhibited 
the higher luciferase expression (Fig. 5.6H,I). We then analyzed the top and bottom five 
performing LNPs, ranked by luminescence. We found that the top five LNPs contained lower 
amounts of PEG, while the bottom five LNPs contained higher amounts of PEG (Fig. 5.6J,K). 
Additionally, more of the top five LNPs contained PEG with a C18 tail while all five bottom LNP 
contained PEG with a C14 tail (Fig. 5.7E). We again found that molar percent of the components 
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influences the efficiency of an LNP (Fig. 5.6L). These data led us to the preliminary conclusion 
that LNP chemistry played a more important role in nebulized delivery than LNP size within the 
ranges we tested. Future work will be needed to understand if LNP size influences delivery across 
larger ranges. Together, these data suggested a strong correlation between PEG-lipid ratio and 
helper lipid choice, and therefore, led us to a third design rule: LNPs formulated with a neutral 
phospholipid lipid require less PEG than LNPs formulated with a cationic helper lipid. 
 
5.2.5 Design rules and optimized LNPs for therapeutic nebulized mRNA delivery 
Using our three design rules (Fig. 5.8A), we selected an LNP named NLD1 for further 
analysis (Fig. 5.8B). NLD1 formed small LNPs that were stable for four days when stored at 4˚C 
in 1X PBS (Fig. 5.8C). We formulated NLD1 to carry AncNanoLuc mRNA, nebulized it, and 
administered it to mice at a dose of 20 µg / mouse. We compared mRNA delivery to three controls: 
(i) 7C3, a previously reported LNP that also uses the 7C1 lipid, (ii) cKK-E12, which delivers RNA 
to the liver in  
s extremely low doses28, and (iii) MC3, which has been used in a FDA-approved drug194 
(Fig. 5.9A). These LNPs have all been licensed for clinical development after optimization for 
systemic RNA delivery. They therefore provide an opportunity to evaluate whether design rules for 
systemic mRNA delivery can be applied to nebulized delivery. Forty-eight hours after 
administering the LNPs, we quantified luminescence and found it to be significantly higher in lungs 
treated with NLD1 than all three controls (Fig. 5.8D, Fig. 5.9B,C). As an additional control, we 
evaluated whether MC3- and cKK-E12-based LNPs outperformed NLD1 when formulated with 
the NLD1 molar ratio. The control LNPs did not form stable nanoparticles, demonstrating that 
NLD1 delivers mRNA to the lungs more efficiently. We evaluated delivery to off-target organs, 
and observed no luminescence in other tissues after NLD1 treatment (Fig. 5.9D,E).  
We then evaluated the importance of LNP biophysical stability during the nebulization 
process. Specifically, we hypothesized that LNPs that survive nebulization ‘least damaged’ may 
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deliver mRNA more effectively. We therefore measured the stability of NLD1, 7C3, cKK-E12, and 
MC3 before and after nebulization. By comparing the relative size of different DLS peaks, we 
found NLD1 was more stable after nebulization than 7C3, cKK-E12, and MC3 (Fig. 5.10A-D). We 
compared LNP morphology before and after nebulization using TEM and found results consistent 
with our DLS analysis (Fig. 5.10E). These data suggest that systemic delivery LNP design rules 
may not select LNPs that are sufficiently stable for nebulization. Taken together, the fact that NLD1 
outperformed clinically relevant LNPs optimized for systemic delivery and the fact that NLD1 
stability through nebulization may be important for delivery underscore the value of designing a 
system to quickly uncover design rules specific for nebulization. 
To understand the biodistribution profile of NLD1 in the lungs, we performed fluorescence 
in situ hybridization (FISH) to visualize the delivered mRNA. We nebulized mice with 100 µg of 
NLD1 carrying AncNanoLuc mRNA. After four hours, animals were sacrificed, lungs were 
isolated, and tissues were prepared for imaging. We observed broad delivery of mRNA throughout 
lung sections with a uniform punctate pattern (Fig. 5.11A). The probes displayed high specificity 
for AncNanoLuc mRNA with minimal background staining (Fig. 5.11B). Treated lungs displayed 
increased mRNA density at the periphery of the lung sections in the more terminal alveolar spaces. 
In contrast, we observed decreased mRNA density toward the center of the sections nearer to larger 
air spaces. 
Next, analyzed mRNA uptake in four of the major epithelial cell types in the lung4. We 
included probes against AncNanoLuc and two markers for bronchial epithelial cells (Fig. 5.11C). 
We used probes against Foxj1and Scgb1a1 mRNA to mark ciliated and club bronchial epithelial 
cells, respectively2. We observed mRNA delivery to these cell types. In separate staining panels, 
we included probes against Pdpn and Sftpc mRNA to mark alveolar type I and II cells, respectively 
(Fig. 5.11D,E). We detected uptake of AncNanoLuc mRNA in these cell types throughout the lung 
as well. While we only included probes against epithelial cells, there is likely delivery to other cell 
types, such as alveolar macrophages. Future studies will be required to fully characterize the mRNA 
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uptake across more diverse cell types. However, taken with the biodistribution data, we believe 
these images demonstrate that NLD1 delivers mRNA broadly throughout the lung and results in 
uptake by the four major epithelial cell subtypes. Both of these properties are critical to achieving 
a strong therapeutic effect in the lung and represent opportunities for further optimization. 
We performed a comprehensive analysis of NLD1 in vivo tolerability by measuring how 
the expression of 547 inflammatory genes changed after exposure to NLD1. Mice were treated with 
50 µg mRNA via nebulization; four hours later, lungs were isolated and gene expression was 
measured. We chose this timepoint because RNA therapies elicit strong early immune responses 
that typically resolve by later timepoints such as 24 hours. Thus, we were more likely to observe 
an immune response at an early timepoint. Relative to untreated mice, only six of 547 genes 
significantly (p<0.05) increased by more than two-fold (Fig. 5.8E), demonstrating the NLD1 was 
well tolerated, even at early timepoints. As control, we separately administered mild dose LPS, and 
found that 86 genes significantly increased by two-fold (Fig. 5.8F). Additionally, no significant 
weight loss was observed in mice 24 hours after exposure to NLD1 (Fig. 5.12A). 
We then evaluated whether NLD1 efficiently delivered mRNA encoding for a therapeutic 
antibody. We chose mRNA encoding membrane anchored FI6 (aFI6), an antibody that binds 
hemagglutinin, neutralizing 16 subtypes of influenza A viruses195. To optimize our dosing regimen, 
we evaluated the kinetics of membrane anchored protein expression following NLD1 nebulization. 
After formulating AncNanoLuc into NLD1, we measured luminescence at timepoints between six 
hours and ten days. We observed high luminescence two days after nebulization as well as lower 
luminescence up to seven days after nebulization (Fig. 5.8G,H). We then investigated whether 
NLD1 could be re-administered and found that luminescence increased with the number of 
administrations (Fig. 5.12B). Based on these data, we designed a treatment regimen for influenza 
A virus subtype H1N1 (Fig. 5.8I). Specifically, we nebulized mRNA encoding aFI6, and 
administered it three days and two days before inoculating mice with influenza A/Puerto 
Rico/8/1934 at 1.5x LD50. We then monitored disease progression over time by measuring mouse 
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weights over time. Significant weight loss post treatment with influenza is considered a marker to 
predict eventual death and trigger euthanasia196. As expected with the administered viral dose, five 
of the six control mice died after progressively losing weight (Fig. 5.8J,K). By contrast, all six 
animals treated with NLD1 survived. These results demonstrate the rapid, therapeutic translation 
of this cluster-based screening system to treat a dangerous infectious disease. 
 
5.3 Discussion 
Nebulized mRNA delivery is well positioned to treat diverse lung diseases197. However, 
nebulized RNA therapies will require clinically relevant delivery. The need for delivery is 
supported by a recent nebulized gene therapy clinical trial, that unfortunately, did not result in 
sufficient efficacy174; notably, the authors highlighted the need for improved delivery.  
Concurrent with these advances in lung biology have been improvements in LNP design 
for systemic RNA delivery, which led to an FDA approved RNA drug176. Unlike early LNPs, which 
had poor therapeutic windows and required high doses for effective delivery, LNPs reported as 
early as 201022 are scalable to human doses and have clinically relevant therapeutic windows60. Yet 
most LNPs have been optimized for systemic delivery. This led to two key questions: First, can 
LNPs be redesigned for nebulized lung mRNA delivery? Second, how similar or dissimilar will 
design rules for systemic LNPs be to design rules for nebulized LNPs? By testing our NLD1 against 
LNPs previously optimized for systemic delivery, our initial data suggest LNP design rules for 
nebulized delivery can be distinct from design rules for systemic delivery. It is too early to 
understand whether this conclusion is consistent across all LNP chemistries, however these data 
support a more important general concept: answering these two key questions requires new LNP 
discovery workflows. Specifically, based on data demonstrating that many LNP chemical traits 
influence delivery and that in vitro delivery assays do not predict in vivo delivery, we reasoned an 
ideal way to discovery new LNPs for nebulized delivery must be easy to set up, enable chemically 
diverse LNPs to be tested quickly, and be performed directly in vivo. This new screening approach 
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is important, as it will help scientists test their own nanoparticles of choice. This in vivo screening 
approach identified of a novel nebulized LNP that produced therapeutically efficacious level of 
protein. However, future studies should be completed to understand whether NLD-1 based 
therapies can treat viral challenges that occur on different timescales relative to the NLD-1 
treatment. Although we did not test other nanoparticle classes (e.g., peptides, or inorganics), we 
believe this workflow may be used to study them as well.  
By testing a series of chemically distinct structures at low doses in vivo, we identified 
several design rules for nebulized LNPs. Thousands of additional LNPs will need to be tested 
before we understand whether these specific rules are applicable to all LNPs. Yet the data do 
provide compelling evidence that PEG molarity and structure is a critical when designing LNPs. 
For example, using the same 7C1 lipid, we found a 28-fold difference in delivery between the best- 
and worst-performing LNPs simply by changing the formulation ratio. Additionally, PEG density 
can alter PEG configuration198,199. Thus, PEG-lipid conformation may affect the efficiency of 
mRNA delivery to the lungs; future studies should explore the relationship between PEG 
conformation and nebulized delivery. We also found that the inclusion of a cationic lipids might be 
important for lung delivery. This hypothesis is consistent with recent work by Cheng et. al. Using 
their method known as selective organ targeting (SORT), they demonstrate that the inclusion of 
charged phospholipids could shift LNP delivery away from hepatocytes and facilitate lung 
delivery165. 
One additional unanswered question we hope to address is the mechanism by which 
changing the PEG alters nebulized lung delivery. The relationship between PEG density and 
systemic delivery of nanoparticles has been studied. Many clinically relevant LNP formulations 
contain PEG-lipids22,28,176,200 to shield them from opsonization or increase circulation 
time137,190,198,201,202. In addition, nanoparticles developed for lung delivery have been formulated 
with PEG-lipids to stabilize the particles and reduce clearance190,203. However, there remains an 
important opportunity to understand how PEG density influences nebulized lung delivery. Our first 
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hypothesis is that the harsh conditions of nebulization predominate; specifically, all LNP 
formulations are damaged during nebulization, and thus the LNPs that survive this process least 
damaged deliver mRNA effectively. This hypothesis was consistent with our results that NLD1 
was more stable than several control LNPs, which it outperformed in nebulization experiments. 
This hypothesis also aligned with our results demonstrating that LNPs with high PEG molarity and 
cationic lipids delivered mRNA in vivo more than LNPs with low PEG molarity; we reasoned that 
LNPs damaged during nebulization could aggregate, and therefore the combination of steric (PEG) 
and electrostatic (cationic) interactions, which promote self-assembly, decreased this aggregation. 
However, our data demonstrating that neutral LNPs deliver more mRNA with low PEG molar 
amounts do not support this hypothesis. A second hypothesis is that lung biology predominates; 
more specifically, stable LNP formulations survive nebulization, but are differentially affected by 
mucus and other physiological barriers within the lung. The most likely hypothesis is that both 
nebulization and lung biology alter delivery, and the extent to which one predominates over the 
other varies with the LNP. This is difficult to deconvolute in vivo; we are currently attempting to 
design experiments to test these hypotheses.  
Finally, it is important to acknowledge several additional limitations of this study. First, 
our results focused on 7C1-containing LNPs, two PEG-lipids, and several helper lipids. In future 
iterations, we will include more diverse ionizable lipids, PEG-lipids, and helper lipids, at additional 
molar ratios. Further work should be done to understand other relationships between LNP 
composition and nebulized delivery. Second, it is possible that the protein expression kinetics we 
observed may vary with the mRNA payload. Additionally, one unexplored question in the field is 
whether protein expression kinetics can be altered by immune response. More extensive studies 
will need to be done to understand the relationship between payload and delivery. Third, these 
studies were limited to mice. The anatomy of a mouse lung may not be an optimal model for 
nanoparticle delivery in a human lung. It is possible these results are not replicated in larger animals 
such as NHPs. Fourth, our data do not exclude the possibility that LNP size may play a critical role 
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in delivery for larger nanoparticles. Similarly, it may be possible that zeta potential influences LNP 
delivery. Fifth, several other factors are involved in the pulmonary RNA delivery in diseased states. 
Specifically, cystic fibrosis (CF) causes severe mucus barriers within the lungs204. The mucus 
penetration of an LNP formulation will be important for the treatment of CF205. Finally, while we 
demonstrated that nebulized NLD-1 could efficiently deliver therapies prior to an infection, future 
studies will assess whether this vehicle and construct can be used after an infection. Even given 
these limitations, we believe these data provide evidence that LNP design parameters depend on 
the route of administration, that a cluster-based approach can efficiently identify nanoparticles that 
deliver drugs in vivo, and that a mRNA encoding an antibody can protect against an otherwise 
lethal H1N1 flu challenge. 
 
5.4 Materials and Methods 
Anchored Nano-Luciferase encoding mRNA Synthesis. mRNA was synthesized as described 
previously64. Briefly, the anchored nano-luciferase sequence was ordered as a DNA gBlock from 
IDT containing a 5’ UTR with Kozak sequence, a 3’ UTR derived from the mouse alpha globin 
sequence, and extensions to allow for Gibson assembly. The sequence was human codon optimized 
using the IDT website. The sequences of the GPI anchor and nano-luciferase has been previously 
stated206. The gBlock was then cloned into a PCR amplified pMA7 vector through Gibson assembly 
using NEB Builder with 3 molar excess of insert. All reaction transcripts were 0.8% agarose gel 
purified prior to assembly reaction. Subsequent plasmids from each colony were Sanger sequenced 
to ensure desired sequence fidelity. Plasmids were linearized with NotI-HF (New England 
BioLabs) overnight at 37 °C. Linearized templates were purified by ammonium acetate (Thermo 
Fisher Scientific) precipitation before being rehydrated with nuclease free water. IVT was 
performed overnight at 37 °C using the HiScribe T7 kit (NEB) following the manufacturer’s 
instructions (N1-methyl-pseudouridine modified). RNA product was treated with DNase I 
(Aldevron) for 30 min to remove template and purified using lithium chloride precipitation 
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(Thermo Fisher Scientific). RNA was heat denatured at 65 °C for 10 min before being capped with 
a Cap1 structure using guanylyl transferase (Aldevron) and 2’-O-methyltransferase (Aldevron). 
Transcripts were then polyadenylated enzymatically (Aldevron). mRNA was then purified by 
lithium chloride precipitation, treated with alkaline phosphatase (NEB), and purified again. 
Concentrations were measured using a Nanodrop. mRNA stock concentrations were 3–5 mg/mL. 
Purified RNA products were analyzed by gel electrophoresis to ensure purity. 
 
Nanoparticle synthesis. 7C1 and cKK-E12 were synthesized as previously described18,49. 
Detailed synthesis procedures are in the Fig. 5.13. D-Lin-MC3-DMA (MC3) was purchased from 
MedKoo Biosciences. 
 
Nanoparticle Formulation. Nanoparticles were formulated using a microfluidic device as 
previously described18. Luciferase mRNA were diluted in 10mM citrate buffer (Teknova). 7C1, 
PEG-lipids (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000] and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000]), cholesterols, and helper lipids (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-3-
trimethylammonium-propane, 1,2-di-O-octadecenyl-3-trimethylammonium propane, and 
Dimethyldioctadecylammonium) were diluted in 100% ethanol. All PEGs, cholesterols, and helper 
lipids were purchased from Avanti Lipids. Citrate and ethanol phases were combined in a 
microfluidic device by syringes (Hamilton Company) at a flow rate of 3:1.  
 
Nanoparticle Characterization. The diameter and dispersity of the LNPs were measured using DLS 
(DynaPro Plate Reader II, Wyatt). LNPs were diluted in sterile 1X PBS and analyzed. To avoid 
using unstable LNPs, and to enable sterile purification using a 0.22 μm filter, LNPs were included 
only if they met 3 criteria: diameter >20 nm, diameter <200 nm, and correlation function with 1 
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inflection point. For screens, particles that met these criteria were pooled into respective groups. 
Particles were dialyzed in a 20 kD dialysis cassettes (Thermo Scientific). The nanoparticle 
concentration was determined using NanoDrop (Thermo Scientific).  
 
Animal Experiments. All animal experiments were performed in accordance with the Georgia 
Institute of Technology’s IACUC. All animals were housed in the Georgia Institute of Technology 
Animal Facility. BALBc (BALB/cJ, 000651) were used in all experiments. They were purchased 
from Jackson Laboratories. In all experiments, we used N = 2-6 mice / group.  
 
Nebulization. Mice were loaded into a custom-built nose-only exposure system constructed of a 
clear PVC tee and animal restraints (CODA Small Mouse Holder, Kent Scientific). These were 
connected using a custom 3D-printed nosecone (3D Printing Tech) made of a flexible TPU 
material. The nebulizer (Aeroneb, Kent Scientific) was then placed on the upward facing port of 
the tee. Doses were added dropwise to the nebulizer at a rate of 50 µL / mouse / droplet. After each 
individual droplet was nebulized, the clear tee was inspected until the vaporized dose had cleared 
(approximately 15-45 seconds per drop). Droplets were added until the desired dose per animal was 
achieved. After the vapor had cleared following the last droplet, the mice were removed from the 
restraints. 
 
Whole Organ Imaging. Tissues were isolated 48 hours after administration of LNPs, unless 
otherwise noted. To measure luminescence, mice were sacrificed, and organs were collected; 
organs were submerged in Nano-Glo Luciferase Assay Substrate (Promega) for 5 minutes before 
being placed on solid black paper for imaging. Luminescence was measured using an IVIS imaging 
system (PerkinElmer, Waltham, MA) and quantified using LivingImage software (PerkinElmer). 
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Transmission Electron Microscope (TEM). The nanoparticles were loaded onto the formvar coated 
nickel grids (Electron Microscopy Sciences, Hatfield, PA), followed by negative staining using a 
2% phosphotungstic acid solution (Sigma). The morphology of the nanoparticles was imaged using 
HT7700 TEM (Hitachi, Tokyo, Japan) at 120 kV coupled with the Digital Micrograph camera and 
software suite (Gatan Inc., Pleasanton, CA). 
 
Toxicity Study. Mice were treated with 50 µg of mRNA encapsulated in NLD1 or 5 µg of LPS. 
Four hours later, tissues were isolated, and flash frozen on dry ice. RNA was extracted and gene 
expression was examined using the nanoString nCounter FLEX. Gene expression profiles were 
analyzed with nanoString nSolver software. Tissues were handled and analyzed through the Emory 
Integrated Genomics Core (EIGC) at Emory University.  
 
Tissue Immunostaining. Mice were treated with 100 µg of AnNanoLuc encapsulated in NLD1 or 
1X PBS via nose cone nebulization. Four hours later, tissues were isolated and fixed in 1mL of 4% 
PFA for 24 hours. Tissues were paraffin embedded and sectioned through the Emory Winship 
Cancer Institute Cancer Tissue and Pathology Facility. 
 
mRNA FISH Analysis. Delivered AncNanoLuc mRNA and endogenous mRNA were visualized in 
tissues using RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics 
323136) according to manufacturer’s instructions. A custom probe set was designed against the 
AncNanoLuc mRNA sequence (ACD 879571). Foxj1 was used as a marker for ciliated bronchial 
epithelial cells (ACD 317091-C2). Scgb1a1 was used as a marker for club cells (ACD 420351-C3). 
Pdpn was used as a marker for alveolar type I cells (ACD 437771-C2). Sftpc was used as a marker 
for alveolar type II cells (ACD 314101-C2). Images for cell type staining were acquired using a 
Zeiss Plan-Apo 40x 1.3 NA oil objective on an UltraVIEW Spinning Disk Confocal Microscope 
equipped with a Hamamatsu Flash 4.0v2 CMOS camera. Images for biodistribution analysis were 
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acquired using a Zeiss Plan-Apo 20x 0.8 NA air objective. Images were captured and processed 
using Volocity software (PerkinElmer). 
 
H1N1 Flu Study. mRNA encoding for aFI6 was encapsulated in NLD1. Mice were dosed with 50 
µg of nebulized aFI6 mRNA per dose at 3 and 2 days prior to infection. Control mice were mock 
dosed with an equal volume of PBS. Mice were anesthetized with isoflurane and infected with 1.5x 
LD50 of influenza H1N1 A/Puerto Rico/8/1934, diluted in DMEM. For survival curves, mice 







Figure 5.1. (A) An individual chemical trait is treated as an axis. Multiple chemical traits, three in 
this example, are evaluated simultaneously. Small groups of LNPs at the ‘extremes’ of this multi-
dimensional chemical space are characterized by DLS and luciferase mRNA delivery following 
nebulization. (B) Any promising extreme group is then locally expanded; all the LNPs within this 
expanded space are characterized individually. The data from this process are used to inform 





Figure 5.2. (A) We varied the structure and amount of PEG-lipid, the phospholipid charge, and 
cholesterol within the LNP, while (B) the 7C1 compound was kept constant. In this way, we created 
(C,D) six extreme groups, of which three consistently led to stable LNPs (E) as measured by 
hydrodynamic diameter of all LNPs for all six groups. In groups D-F, we found the diameter of the 
pooled LNPs was within the range of the individual LNPs making up the groups, further suggesting 
their stability. (F,G) Luciferase luminescence in lungs 48 hours after the three groups were 
nebulized and administered to mice. Unless specified otherwise, *P < 0.01, One-way ANOVA, 








Figure 5.3. (A) Detailed outline of nanoparticles included from groups that failed the quality 
control analysis (A, B, and C). (B) Detailed outline of nanoparticles included from groups that 




Figure 5.4. (A) LNPs were formulated with one of three cationic lipids, a PEG-lipid, cholesterol, 
and the compound 7C1. (B) LNPs with hydrodynamic diameter less than 200 nm as measured by 
DLS were tested individually in mice. (C,D) LNP diameter as a function of helper lipid and PEG 
molarity, respectively. *P < 0.005, two-tailed, t-test. (E-G) Luminescence of lungs isolated from 
mice, relative to an untreated control, 48 hours after administration plotted as a function of (E) 
charged lipid and (F,G) PEG molarity, respectively. LNPs with cationic lipids, coupled with high 
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PEG molarity, delivered mRNA to lungs more than LNPs with low PEG molarity. (H-J) PEG 
molarity used in this study as well as found in the best and worst performing LNPs ranked by lung 
luminescence. Unless specified otherwise, ****P < 0.0001, ***P < 0.0005, **P < 0.004, *P < 0.05, 







Figure 5.5. (A) Molar ratios of individual LNPs nebulized. (B) The first iterations of individually 
tested LNPs were made of 7C1, cholesterol, C14PEG2000, and positive helper lipids at 9 different 






Figure 5.6. (A) LNPs were formulated with one of two neutral lipids lipids, one of two distinct 
PEG-lipids, cholesterol, and the compound 7C1. (B) LNPs with hydrodynamic diameter less than 
200 nm as measured by DLS were tested individually in mice. (C-E) LNP diameter as a function 
of helper lipid, PEG molarity,and PEG-lipid tail length respectively. (F-I) Luminescence of lungs 
isolated from mice, relative to an untreated control, 48 hours after administration plotted as a 
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function of (F) neutral helper lipid, (G) PEG-lipid tail length, and (H,I) PEG molarity, respectively. 
LNPs with neutral lipids, coupled with low PEG molarity, delivered mRNA to lungs more than 
LNPs with high PEG molarity. (J-L) PEG molarity used in this study as well as found in the best 
and worst performing LNPs ranked by lung luminescence. Unless specified otherwise, ****P < 









Figure 5.7. (A) The second iterations of individually tested LNPs were comprised of 7C1, 
cholesterol, C14PEG2000, C18PEG2000, and neutral helper lipids at 9 different molar ratios. (B-D) LNP 
PDI as a function of helper lipid, PEG amount, and PEG type, respectively. **P < 0.008, *P < 0.03, 








Figure 5.8. (A) LNP delivery to the lung can be improved by carefully selecting the type and molar 
amount of PEG-lipid. (C) NLD1 was designed with a cationic lipid and high amount of PEG-lipid. 
(C) NLD1 forms small, stable LNPs overtime. (D) NLD1 delivers mRNA to lungs at low doses in 
vivo more than leading LNPs previously optimized for systemic mRNA delivery. ***P < 0.0007, 
One-way ANOVA, average +/- SEM, n=5 mice/group. (E,F) 547 inflammatory genes were 
examine after exposure to NLD1. Compared to an LPS control, NLD1 is well tolerated in vivo. 
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Dotted vertical lines indicate>2x fold change in gene expression. The dotted horizontal line 
indicates a p-value of 0.05. (G,H) NLD1 carrying AncNanoLuc was administered at a dose of 20 
µg / mouse. Protein expression was analyzed over several days. ****P < 0.0001, *P < 0.03, One-
way ANOVA, average +/- SEM, n=3 mice/group. (I) NLD1 therapeutic treatment regimen for 
H1N1 study. Mice were treated with two NLD1 treatments (a total dose of 100 µg / mouse) prior 
to XYZ dose of PR8 virus. (J,K) Mouse weights were taken daily for up to 14 days post infection. 
All mice treated with NLD1 recovered based on weights. Significantly, 5 out of 6 mice treated with 







Figure 5.9. (A) 7C3, cKK-E12, and MC3 were formulated by combining the ionizable material 
7C3, cKK-E12, or MC3, C14PEG2000, cholesterol, and a neutral phospholipid. LNPs were 
administered via nebulization to lungs and (B,C) luciferase luminescence was measured. (D,E) 48 
hours post nebulization with NLD1, luciferase luminescence was measured in kidney, liver, spleen, 
heart, and lungs; we only found measurable luminescence in the lungs. ****P < 0.0001, One-way 








Figure 5.10. (A) LNP diameter pre- and post-nebulization of NLD1, (B) 7C3, (C) MC3, and (D) 
















Figure 5.11. (A) Biodistribution of AncNanoLuc mRNA throughout the lung of a mouse 4 hrs post 
nebulization with 100 μg mRNA. Small inset shows a lung section stained for Scgb1a1 mRNA to 
mark the bronchial airways (green), AncNanoLuc mRNA (white), and DAPI (blue). The expanded 
image shows only AncNanoLuc mRNA(white) with an outline of the lung section. The 





























against AncNa-noLuc mRNA (white) show strong staining in treated tissues. Probes against 
Foxj1 mRNA marking ciliated bronchial epithelial cells (magenta) and Scgb1a1 mRNA 
marking bronchial club cells (green) were used to visualize the bronchiolar space. Uptake of 
AncNanoLuc mRNA was observed in these bronchial eptihelial cells. (b,c) Probes against 
Pdpn mRNA and Sftpc mRNA were used to mark alveolar type I and II epithelial cells, 
respectively (ma-genta). Uptake of AncNanoLuc mRNA can be seen in both of these cell 
types as indicated by the yellow arrows. 

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the lung. (B) Negative control lung section treated with AncNanoLuc probes 4 hours post 
nebulization with 1x PBS. Small inset shows a lung section stained for Scgb1a1 mRNA to mark 
the bronchial airways (green), AncNanoLuc mRNA (white), and DAPI (Blue). The expanded 
image shows only AncNanoLuc mRNA (white) with an outline of the lung section. No major 
background of the AncNanoLuc mRNA probes was observed in the PBS section. (C) FISH analysis 
for AncNanoLuc mRNA uptake in epithelial cell subtypes. Tissues were obtained 4 hours post 
nebulization with either 100 μg of AncNanoLuc mRNA in NLD-1or 1x PBS and processed for 
FISH analysis. Probes against AncNanoLuc mRNA (white)show strong staining in treated tissues. 
Probes against Foxj1 mRNA marking ciliated bronchial epithelial cells (magenta) and Scgb1a1 
mRNA marking bronchial club cells (green) were used to visualize the bronchiolar space. Uptake 
of AncNanoLuc mRNA was observed in these bronchial epithelial cells. (D,E) Probes against Pdpn 
mRNA and Sftpc mRNA were used to mark alveolar type I and II epithelial cells, respectively 
(magenta). Uptake of AncNanoLuc mRNA can be seen in both of these cell types as indicated by 






Figure 5.12. (A) Mice showed no significant weight loss after exposure to 50 µg of NLD1 to carry 
AncNanoLuc mRNA via nebulization. (B) NLD1 was readministered at a dose of 20 µg / mouse. 











CHAPTER 6. HIGH THROUGHPUT IN VIVO LNP HELPER LIPID OPTIMIZATION 
ENABLES SYSTEMIC LUNG GENE EDITING 
 
6.1 Introduction 
 mRNA-based drugs can treat disease by transiently expressing therapeutic proteins7. To 
achieve a therapeutic effect, mRNA must be internalized into target cells and translated into protein 
without undergoing RNase-mediated degradation or eliciting an undesirable immune response139. 
One class of delivery vehicles is LNPs, which have delivered mRNA to target cells in several 
clinical trials. Specifically, LNPs have delivered mRNA-based COVID vaccines into muscle after 
local administration178,207, delivered mRNA encoding Cas9 nucleases into the liver after systemic 
administration, and delivered siRNA to the liver following systemic administration60. These data 
support efforts to design LNPs that deliver mRNA to additional tissues after systemic 
administration.  
Scientists have taken two approaches to promote mRNA delivery to non-liver tissues. In 
the first, targeting ligands including antibodies or aptamers are added to LNPs. In one example, 
mRNA loaded LNPs were targeted to Ly6c+ leukocytes utilizing anchored secondary scFv 
enabling targeting (ASSET), which integrates monoclonal antibodies into the LNPs membrane in 
order to achieve targeting141. In another example, plasmalemma vesicle- associated protein 
targeting LNPs covalently conjugated with targeting antibodies increased lung protein expression 
40-fold compared to the control LNP without the ligands208. The second approach scientists use is 
to alter cellular tropism by changing the chemical composition of the lipids making up the LNP. 
LNPs without targeting ligands are typically composed of four components: an ionizable or cationic 
lipid; a PEG-lipid; a cholesterol; and a “helper” lipid. In one example, an LNP was made to 
selectively deliver mRNA to lung endothelial cells by changing the LNP composition158. In another 
example, RNA-lipoplexes comprised of DOTMA, DOTAP, DOPE, and cholesterol were targeted 
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to lymphoid-resident dendritic cells by titrating negative charge167. In another, the composition of 
the ionizable lipid in the LNP increased protein expression within spleen B lymphocytes following 
intravenous administration209.  Finally, by adding a fifth molecule to the LNP, authors designed 
LNPs with improved tropism to the spleen and lung following intravenous injection165.  
These studies led us to hypothesize that the LNP helper lipid could be optimized to reduce 
delivery to the liver and increase delivery to non-liver cell types. To test this hypothesis, we used 
a DNA-barcoding based functional in vivo mRNA screening system159,160,186 to evaluate how 18 
helper lipids affected LNP diameter, polydispersity, cell type-specific targeting to 19 cell types, 
using 129 LNPs, all in vivo. These DNA barcoding data identified how helper lipid structure affects 
LNP delivery in vivo; they also revealed three new LNP compositions that deliver mRNA to 
distinct cell types at clinically relevant doses.  
 
6.2 Results 
6.2.1 Characterizing of helper lipid composition on LNP formation 
To test the hypothesis that helper lipid structure could shift mRNA delivery to non-liver 
cell types, we formulated 144 chemically distinct LNPs with microfluidic mixing16. Specifically, 
we mixed the canonical nanoparticle components with nucleic acids at a nanoparticle component: 
nucleic acid mass ratio of 10: 1 (Fig. 6.1A). To isolate the effect of the helper lipid, the other three 
LNP components were previously validated. As a control to ensure changes in delivery were not 
driven by a specific molar ratio of the four components, we formulated LNPs with four molar ratios 
(Fig. 6.1B, Fig. 6.2). Thus, each of the 18 helper lipids was formulated eight times (Fig. 6.3). In 
our helper lipid array, we varied two traits. First, we varied charge: eight carried a neutral charge, 
seven carried an anionic charge, and three carried a cationic charge. Second, based on the 
hypothesis that helper lipid traits other than charge could affect LNP delivery via distinct 
biophysical mechanisms210,211, we also varied helper lipid tail structure and linker (Fig. 6.2). After 
formulating the 144 LNPs, we investigated whether helper lipid composition influenced LNP 
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hydrodynamic diameter and polydispersity, as measured by dynamic light scattering (DLS). We 
observed a relationship between helper lipid charge and the resulting LNP diameter; LNPs with 
anionic helper lipids formed smaller particles than LNPs formed with cationic helper lipids (Fig. 
6.1C). We then quantified LNP hydrodynamic diameter as a function of the 18 helper lipids (Fig. 
6.1D, Fig. 6.3) and found no statistical relationship between individual helper lipids and diameter 
(Fig. 6.1E). Finally, we found that LNP hydrodynamic diameter does not change with the molar 
ratio of helper lipid added to the LNP (Fig. 6.1F). 
 
6.2.2 LNP containing cationic helper lipids preferentially deliver to lung cell types compared to 
neutral and anionic libraries 
We then investigated whether helper lipid structure influenced LNP-mediated mRNA 
delivery in vivo. Given the impracticality of injecting, sacrificing, and performing fluorescent 
activated cell sorting (FACS) analysis to quantify cell-level delivery in several hundred mice, we 
utilized a DNA barcoding system that quantifies functional mRNA delivery (i.e., mRNA translated 
into functional protein) mediated by many LNPs in a single animal at the cellular level13-15 (Fig. 
6.4A). In this system, LNP-1, with chemical structure 1, is formulated to carry Cre mRNA and 
DNA barcode 1; LNP-N, with chemical structure N, is formulated to carry Cre mRNA and DNA 
barcode N. LNPs with a hydrodynamic diameter less than 200 nm and a single peak on the DLS 
spectrum are pooled and administered to Ai14 mice19. Ai14 cells contain a Lox-Stop-Lox-
tdTomato reporter driven by a CAG promoter; cells in which Cre mRNA has been translated into 
functional protein that excises the Lox-Stop construct from the genome become tdTomato+. 
tdTomato+ cells are sorted with FACS, and then sequenced to identify barcodes in functionally 
transfected cells. Thus, functional mRNA delivery is quantified as the percentage of tdTomato+ 
cells and the relative rank of each individual LNP is calculated as “normalized delivery”, which is 
analogous to counts per million in RNA-sequencing experiments. 
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To avoid LNPs with opposite charges mixing after pooling, we performed three separate 
experiments, creating one library for each lipid charge. Of the 24 cationic LNPs we formulated, 23 
met our 200 nm and single DLS peak selection criteria. These LNPs were pooled and injected into 
four mice at a total dose of 1.0 mg / kg nucleic acid (i.e., 0.043 mg / kg / LNP, on average). We 
similarly formulated 64 LNPs with a neutral helper lipid; 59 met pooling criteria and were 
administered to four separate mice at a total dose of 1.0 mg / kg nucleic acid. Finally, we formulated 
56 LNPs with an anionic helper lipid, of which 55 met pooling criteria, and were administered to 
four separate mice at a total dose of 1.0 mg / kg nucleic acid. Three days later, we sacrificed mice 
and quantified the percentage of tdTomato+ cells for 20 cell types (Fig. 6.5). We evaluated the 
following two controls. Firstly, we included a DNA barcode that was not encapsulated in an LNP 
as a negative control. Since DNA does not readily enter cells, this barcode should be delivered less 
efficiently into cells than DNA barcodes carried in LNPs, and thus should have a low normalized 
delivery, which was consistent with our observations (Fig. 6.4B, Fig. 6.6). Second, we quantified 
mouse weights post-LNP administration. Relative to PBS-treated mice, those treated with barcodes 
did not lose weight (Fig. 6.7). 
We then quantified mRNA delivery as a function of helper lipid charge in five lung cell 
types, six liver cell types, four splenic cell types, two heart cell types, and two kidney cell types 
(Fig. 2D-H). In all five cell types, LNPs formulated with a cationic helper lipid delivered mRNA 
to the lung, whereas LNPs formulated with neutral or anionic LNPs did not (Fig. 6.4C). When 
cationic helper lipid LNPs were administered, the highest tdTomato+ percentage, over 50%, was 
measured in endothelial cells, which may be explained by the physical accessibility of these cells 
when LNPs are administered intravenously. Between 10% and 25% of lung dendritic cells, T cells, 
B cells, and monocytes were also transfected. These data suggest that immune cells which are less 
accessible than endothelial cells, may still be transfected by systemically administered LNPs. 
Interestingly, we observed a distinct trend in the liver. Neutral and anionic helper lipid LNPs led to 
significantly higher mRNA delivery than cationic helper lipid LNPs (Fig. 6.4D). Notably, the 
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percentage of tdTomato+ lung cells was higher than the percentage of tdTomato+ liver cells when 
the cationic LNP helper lipids were injected. We observed that spleen delivery did not significantly 
vary as a function of LNP helper lipid (Fig. 6.4E). When we examined delivery in the kidney and 
heart, we identified low but statistically significantly increases in mRNA delivery were measured 
with cationic and neutral helper lipid LNPs, compared with anionic helper lipid LNPs (Fig. 6.4F-
G).  
We then used NGS to determine how all 138 LNPs delivered nucleic acids in vivo. First, 
we investigated whether normalized delivery changed as a function of LNP hydrodynamic diameter 
and found no relationship between LNP size and delivery within the tested range (Fig. 6.4H), which 
is consistent with our previous results13. Next, we used the normalized delivery to calculate the 
fold change enrichment of each helper lipid in the lung, liver, and spleen. Enrichment analysis 
determines how often a specific property appears in particles that performed in the top 10% and 
bottom 10%. Fold enrichment change is calculated by subtracting enrichment in the bottom 10% 
from enrichment in the top 10% (Fig. 6.8A). In the cationic library, we found that 18:0 DDAB was 
the most enriched helper lipid in all cell types (Fig. 6.8B-D). Next, we studied the enrichment 
profile of the neutral helper lipids. We did not observe a single helper lipid enrich in all liver or 
spleen cell types (Fig. 6.9A-C). Using the neutral library enrichment data, we investigated the 
effect of tail structure on delivery by comparing the enrichment of three neutral lipids with the same 
head group and linker, but different tail structure. We found that the sterate was the most enriched 
tail structure in both the liver and spleen (Fig. 6.9D-F). We then investigated the effect of head 
group on delivery within the neutral library by comparing the enrichment of four neutral lipids with 
the same tail group and linker, but different head group. We found that ammonium and 
methylamine enriched positively while dimethylamine and trimethylamine negatively enriched 
(Fig. 6.9G-I). Finally, we examine the enrichment profile in the anionic library; we found that 18:1 
PA enrich the most in all liver and spleen cell types (Fig. 6.10A-C). Interestingly, similar to the 
neutral library, we found that smaller, less complex head groups enriched more than larger, more 
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complex head groups in the liver and spleen (Fig. 6.10D-E). These enrichment analyses lead us to 
believe there i(s a relationship between tail and head structures and nanoparticle delivery. 
 
6.2.3 Top LNPs from each screen mimicked the screening results 
Based on the screening data, we selected the top LNP from each library and quantified 
whether it delivered mRNA as predicted by the screen. Each LNP was formulated to carry cre 
mRNA and injected into Ai14 mice at 1.3 mg / kg. Three days later, we quantified the percentage 
of tdTomato+ cells in the lungs, liver, spleen, kidney, and heart by whole tissues imaging and flow 
cytometry. Specifically, we formulated a stable, small cationic LNP with cationic helper lipid 18:0 
DABB which is referred to as ‘Cationic LNP’ (Fig. 6.11A). We found that the cationic LNP 
preferentially targeted lung cell types more than liver cell types (Fig. 6.11B). Specifically, the 
Cationic LNP delivered to lung endothelial cells, as predicted by the screen. Additionally, less 
significant delivery was observed in kidney immune cells and heart endothelial cells (Fig. 6.11C, 
Fig. 6.12A). Next, a small, stable neutral LNP was formulated with neutral helper lipid DSPC 
(referred to as ‘Neutral LNP’) (Fig. 6.11D). Similar to the screen, the neutral LNP preferentially 
delivered to liver cell types (Fig. 6.11E), most significantly, endothelial and Kupffer cells (Fig. 
6.11F). Significant delivery was also observed in spleen DCs (Fig. 6.12B). Finally, an anionic LNP 
formed small, stable particles with anionic helper lipid 18:1 PA which is referred to as ‘Anionic 
LNP’ (Fig. 6.11G). Once again, we observed preferential delivery to liver cells types (Fig. 6.11H, 
Fig. 6.12C) with the highest delivery to endothelial cells (Fig. 6.11I). In all cases, we observed no 
significant weight loss in the mice (Fig. 6.13). 
 
6.2.4 Cationic LNPs can be used to efficiently in genome editing 
Based on these findings, we decided to focus on the relationship between cationic lipids 
and lung endothelial delivery. We first evaluated the ability of the cationic LNP to deliver 
therapeutically relevant payloads intravenously. Gene editing technologies, such as CRISPR–Cas 
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systems, can be a valuable therapeutic to treat diseases. Gene editing facilitated by LNPs outside 
the liver would be valuable to the field. Moreover, certain diseases may benefit from intravenous 
administration of gene modulators. We formulated the Cationic LNP to carry spCas9 mRNA and 
sgRNA. We intravenously injected WT mice with two doses of sgControl or sgRNA targeting 
ICAM-2. Five days later, lung and liver cells were isolated; ICAM-2 protein expression and indels 
were quantified (Fig. 6.14A, Fig. 6.15). Compared to the sgControl, we observed a 50% reduction 
of ICAM-2 expression in lung endothelial cells and no significant reduction in liver endothelial 
cells (Fig. 6.14B). As a confirmation, we observed significant indels in lung endothelial cells when 
compared to mice treated with the control (Fig. 6.14C) using Tracking of Indels by Decomposition 
212; no off-target effects were observed in the liver (Fig. 6.14D). These data suggest that cationic 
LNPs can be used to delivery gene editing tools in vivo. 
 
6.3 Discussion 
Systemically administered RNA drugs have been safely delivered to the liver in patients, 
underscoring the potential value of LNPs with tropism to other tissues. To test the hypothesis that 
a single LNP trait can increase the ratio of non-liver delivery to liver delivery, we quantified how 
137 chemically distinct LNPs delivered mRNA to 19 cell types across the liver, spleen, kidney, 
heart, and lung in vivo using functional DNA barcoding. These studies revealed that helper lipid 
composition alters tissue- and cell-level tropism and identified three novel LNPs with tunable in 
vivo tropism, without the use of targeting ligands. One of these LNPs, named LNP-Lung1, co-
delivered Cas9 mRNA and sgRNA, leading to pulmonary gene editing in adult mice. These data 
support the hypothesis that one LNP component can increase non-liver tropism and suggest that 





6.4 Materials and Methods 
Cre mRNA Synthesis. mRNA was synthesized as described previously21. Briefly, the anchored 
nano-luciferase sequence was ordered as a DNA gBlock from IDT containing a 5’ UTR with Kozak 
sequence, a 3’ UTR derived from the mouse alpha globin sequence, and extensions to allow for 
Gibson assembly. The sequence was human codon optimized using the IDT website. The sequences 
of the GPI anchor and nano-luciferase has been previously stated21. The gBlock was then cloned 
into a PCR amplified pMA7 vector through Gibson assembly using NEB Builder with 3 molar 
excess of insert. All reaction transcripts were 0.8% agarose gel purified prior to assembly reaction. 
Subsequent plasmids from each colony were Sanger sequenced to ensure desired sequence fidelity. 
Plasmids were linearized with NotI-HF (New England BioLabs) overnight at 37 °C. Linearized 
templates were purified by ammonium acetate (Thermo Fisher Scientific) precipitation before 
being rehydrated with nuclease free water. IVT was performed overnight at 37 °C using the 
HiScribe T7 kit (NEB) following the manufacturer’s instructions (N1-methyl-pseudouridine 
modified). RNA product was treated with DNase I (Aldevron) for 30 min to remove template and 
purified using lithium chloride precipitation (Thermo Fisher Scientific). RNA was heat denatured 
at 65 °C for 10 min before being capped with a Cap1 structure using guanylyl transferase 
(Aldevron) and 2’-O-methyltransferase (Aldevron). Transcripts were then polyadenylated 
enzymatically (Aldevron). mRNA was then purified by lithium chloride precipitation, treated with 
alkaline phosphatase (NEB), and purified again. Concentrations were measured using a Nanodrop. 
mRNA stock concentrations were 3–5 mg/mL. Purified RNA products were analyzed by gel 
electrophoresis to ensure purity. 
 
Nanoparticle Formulation. Nanoparticles were formulated using a microfluidic device as 
previously described. cKK-E12 was purchased from Organix. Cre mRNA and DNA barcodes were 
diluted in 10mM citrate buffer (Teknova). DNA Barcodes were purchases from IDT. All PEGs, 
cholesterols, and helper lipids were diluted in 100% ethanol and purchased from Avanti Lipids. 
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Citrate and ethanol phases were combined in a microfluidic device by syringes (Hamilton 
Company) at a flow rate of 3:1.  
 
Nanoparticle Characterization. The diameter and polydispersity of the LNPs were measured using 
DLS (DynaPro Plate Reader II, Wyatt). LNPs were diluted in sterile 1X PBS and analyzed. To 
avoid using unstable LNPs, and to enable sterile purification using a 0.22 μm filter, LNPs were 
included only if they met 3 criteria: diameter >20 nm, diameter <200 nm, and correlation function 
with 1 inflection point. For screens, particles that met these criteria were pooled into respective 
groups. Particles were dialyzed in a 20 kD dialysis cassettes (Thermo Scientific). The nanoparticle 
concentration was determined using NanoDrop (Thermo Scientific).  
 
Animal Experiments. All animal experiments were performed in accordance with the Georgia 
Institute of Technology’s IACUC. All animals were housed in the Georgia Institute of Technology 
Animal Facility. Ai14s were breed at the Georgia Institute of Technology Animal. C57BL/6J 
(B6/000664) were purchased from Jackson Laboratories. In all experiments, we used N = 3-4 mice 
/ group.  
 
Cell Isolation & Staining. Cells were isolated 24 or 72 hours after injection with LNPs unless 
otherwise noted. Mice were perfused with 20 mL of 1X PBS through the right atrium. Tissues were 
finely cut, andt hen placed in a digestive enzyme solution with Collagenase Type I (Sigma Aldrich), 
Collagenase XI(Sigma Aldrich) and Hyaluronidase (Sigma Aldrich) at 37 ºC at 550 rpm for 45 
minutes. The digestive enzyme for heart and spleen included Collagenase IV. Cell suspension was 
filtered through 70μmmesh and red blood cells were lysed. Cells were stained to identify specific 
cell populations and sorted using the BD FacsFusion cell sorters in the Georgia Institute of 
TechnologyCellular Analysis Core. The antibody clones used were: anti-CD31 (390, BioLegend), 
anti-CD45.2 (104,5BioLegend), anti-CD68 (FA11, Biolengend), anti-CD11b (M1/70, Biolegend), 
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anti-CD11c (FC, BioLegend), CD3 (17A2, BioLegend), CD19 (6D5, BioLegend), LIVE/DEAD™ 
Fixable Far-Red Dead Cell Stain (Invitrogen), PE anti-mCD47 (miap301, BioLegend). 
Representative flow gates are located in Supplementary Fig. 6.16. PBS-injected Ai14 mice were 
used to gate tdTomato populations for intravenous administration. 
 
PCR Amplification. All samples were amplified and prepared for sequencing using a one-step PCR 
protocol as previously described.. More specifically, 1 μL of primers (5 uM for Final Reverse / 
Forward, 0.5 uM for Base Forward) were added to 5 μL of Kapa HiFi 2X master mix, and 4 μL 
template DNA/water. When the PCR reaction did not produce clear bands, the primer 
concentrations, DNA template input, PCR temperature, and number of cycles were optimized for 
individual samples. 
 
Deep Sequencing. Illumina deep sequencing were performed on an Illumina MiniseqTM. Primers 
were designed based on Nextera XT adapter sequences. 
 
Data Normalization. Counts for each particle, per tissue, were normalized to the barcoded LNP 
mixture we injected into the mouse. This ‘input’ DNA provided the DNA counts and was used to 
normalize DNA counts from the cells and tissues. 
 
Tissue Immunostaining. Mice were treated with 1 mg / kg of cre mRNA encapsulated in LNPs. 
Cells were treated with 200 µg of cre mRNA encapsulated in LNPs. Four hours later, tissues or 
cells were fixed in 1mL of 4% PFA for 24 hours. Cells were washed with 1X PBS. Tissues were 
cryoprotected in 30% sucrose for 48 hours at 4C. In tissue base molds, tissues were embedded in 
optimal cutting temperature compound (Tissue-Tek) and frozen. Blocks were stored at -80C. 




Microscopy. Images for cell type staining were acquired using a Zeiss Plan-Apo 20x 1.3 NA oil 
objective on an UltraVIEW Spinning Disk Confocal Microscope equipped with a Hamamatsu Flash 
4.0v2 CMOS camera. Images for biodistribution analysis were acquired using a Zeiss Plan-Apo 
20x 0.8 NA air objective. Images were captured and processed using Volocity software 
(PerkinElmer). 
 
Data Analysis & Statistics. Sequencing results were processed using a custom python-based tool 
to extract raw barcode counts for each tissue. These raw counts were then normalized with an R 
script prior for further analysis. Statistical analysis was done using GraphPad Prism 8. Data is 





Figure 6.1 (A,B) 144 chemically distinct LNPs were created by varying the helper lipid content as 
well as the molar ratios of the four components added to the LNP. (C) Hydrodynamic diameter of 
all individual LNPs (gray) as well as the pool of LNPs that were mixed together (purple). The 
diameter of the pool was within the range of the LNPs comprising that pool. (D,E) Helper lipid as 



























Figure 6.4 (A) LNPs were formulated to carry a DNA barcode and Cre mRNA. 137 LNPs were 
pooled into their respective library and were then administered to Ai14 mice. After 3 days, 
tdTomato signal was quantified and tdTomato+ cells were isolated. NGS identified LNPs that 
functionally transfect cells in vivo. (B) Normalized delivery of all LNPs across all cell types in 
each library. The control, unencapsulated barcoded delivered less efficiently than barcodes  
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delivered  by  LNPs. (C) tdTomato+ signal in multiple lung, (D) liver, (E) spleen, (F) heart, and 
(G) kidney. These data show a preferential delivery to lung cell types by the cationic LNPs; in 
contrast, no delivery was observed by the neutral and anionic LNP pools to lung cell types. (H) We 










Figure 6.6 Normalized delivery of all LNPs for various cell types. The negative control, free DNA 
barcode, delivery was lower than barcodes delivered by LNPs in the (A) cationic, (B) neutral, and 





Figure 6.7 (A) Mouse weights measured 24, 48, and 96 hours after administration of PBS or 










Figure 6.8 (A) Enrichment (fold) difference is calculated through the shown formula. Fold 







Figure 6.9 (A,B) Fold enrichment was calculated for neutral LNPs delivered to liver cells, and (C) spleen 
cells. (D,E) Fold enrichment was calculated for all three tail structures in the liver and (F) spleen. (G,H) Fold 









Figure 6.10 (A,B) Fold enrichment was calculated for anionic LNPs delivered to liver cells, and 
(C) spleen cells. (D) Fold enrichment was calculated for sevem different head groups in the liver 





Figure 6.11 (A) The top LNP from the cationic screen (labeled Cationic LNP) was formulated with 
cre mRNA and administered to Ai14 mice at a dose of 1.3 mg / kg. We observed delivery to (B,C) 
lungs cells types more than liver cell types. (D) The top LNP from the neutral screen (labeled 
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Neutral LNP) was formulated with cre mRNA and administered to Ai14 mice at a dose of 1.3 mg 
/ kg. We observed delivery to (E,F) liver cells types more than lung cell types. (G) The top LNP 
from the anionic screen (labeled Anionic LNP) was formulated with cre mRNA and administered 
to Ai14 mice at a dose of 1.3 mg / kg. We observed delivery to (H,I) liver cells types more than 






Figure 6.12 (A) Delivery to the spleen and kidney by the Cationic LNP, (B) Neutral LNP, and (C) 






Figure 6.13 (A) Mouse weights measured 24, 48, 72, and 96 hours after administration of PBS or 





Figure 6.14 (A) The Cationic LNP was formulated carrying Cas9 mRNA and sgRNA targeting 
ICAM-2 (sgICAM-2) or a control (sgRNA targeting GFP, sgCtrl). Two doses of 1 mg / kg were 
administered two days apart. Five days later, ICAM-2 protein expression and indels were 
quantified. (B) Normalized ICAM-2 expression in lung and liver endothelial cells after exposure 
to the Cationic LNP with sgControl or sgICAM-2. (C) Indel analysis at ICAM-2 in lung endothelial 

















Figure 16.16 (A,B) Representative gating strategies for FACS for cells types in the lung, (C,D) liver, 
(E,F) spleen, (G,H) heart, and (I,J) kidney. 
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CHAPTER 7. PERSPECTIVES AND FUTURE WORK 
 
Oligonucleotides, and in particular RNA-based therapies, can be used to modulate the 
expression of any gene, making them a promising way to treat or manage disease. Currently, there 
are ten oligonucleotides that have been approved by the FDA213. One of the advantages of RNA-
based therapies are their ability to target or produce any protein. RNAi therapies such as siRNAs 
can modulate RNA translation and suppress the translation of any gene transcript. mRNA therapies 
can transiently produce any protein and do not require genome integration. As discussed in this 
work, LNPs have become an attractive way to deliver nucleic acid therapies to target cell types. 
The first LNP-based RNAi drug was approved by the FDA in 2018. Today, LNPs carrying mRNA 
have been approved as vaccines for SARS-CoV-2. These advances demonstrate that LNPs and 
nucleic acid drugs can be an integral part of world health and disease treatment.  
While RNA therapies continue to enter the clinic, there is still a need for safe and efficient 
drugs. Systemic delivery to non-liver cell types will require further examination, innovation, and 
improvement. Additionally, one challenge with mRNA therapeutics is their capability to be 
effectively delivered to target cell types. While new chemical methods allow for the rapid 
development of novel lipid-based components, it can be laborious and expensive to test hundreds 
to thousands of novels LNPs. One solution is the use of high-throughput screening systems, which 
have proven to be valuable in the field of drug delivery and nanomedicine. DNA barcoding–based 
screening systems in particular have been used to identify new particles that efficiently deliver 
mRNA76,159,160,214 and siRNA45,135,159,187 in vivo. In the last four years, DNA barcoding has allowed 
for over 5,000 lipid nanoparticles to be screened in vivo, in published and unpublished work, by 
the lab of Dr. James Dahlman. But while screening platforms can increase the likelihood that RNA 
therapies will be clinically approved, we can make significant efforts to improve the field of drug 
delivery. 
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 First, we can improve the way drug delivery vehicles are discovered. Traditionally, 
nanoparticles are tested and characterized in vitro. While successful nucleic acid drugs must 
overcome complex in vivo barriers, nanoparticles are often screened in cell culture conditions. Even 
though in vitro and in vivo delivery involves different physiological obstacles, nanoparticle 
performance is first evaluated in vitro and only then are some LNPs tested in vivo. We have shown 
that in vivo LNP delivery is not predicted by in vitro delivery using cell culture conditions33. 
However, it is impractical, expensive, and time consuming to individually test each nanoparticle in 
vivo. Thus, high-throughput screening systems are among the most practical ways to measure the 
delivery of multiple particles in vivo. The data generated by these screens will only continue to 
grow, and the incorporation of artificial intelligence and computer modeling will be one way to 
process and innovate with these large data sets. 
 The current screening systems described in this work allow us to test thousands of particles, 
simultaneously, in a single mouse. However, the systems described are dependent on i) specialized 
rodent models (i.e. Ai14 mice or GFP-expressing mice) or ii) the knockdown of genes expressed 
only in specific cell types. These factors can greatly restrict the hypotheses posed by researchers. 
Thus, a more accessible screening platform is needed that is free from these constraints. An ideal 
platform would be compatible with i) various species, ii) genetic knockout models, and iii) disease 
models. The payload would need to either target a universally expressed gene (e.g., siRNA or 
sgRNA payload) or deliver an exogenous reporter (mRNA payload). Novel screening platforms 
would allow for a better understanding of the biology involved in delivery. 
Second, we need to better understand the genes that influence potent drug delivery in vivo. 
For example, scientists have found that some LNP-mediated delivery is dependent on the presence 
of serum ApoE; the interactions between ApoE and the LDLR cell surface receptor are critical for 
nanoparticle uptake. Additionally, disease states can create atypical cell states or tissue structures. 
These abnormal states can dramatically affect the potency of a drug uptake and function. In this 
work, we discuss the role of inflammation on drug delivery. We found that TLR4 activation can 
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inhibit mRNA delivery by LNPs; TLR4 activation has been shown in various disease states. Drug 
delivery systems may improve as we better understand the cells involved in uptake and the genes 
required for functional delivery. One way to explore the regulatory genes of drug delivery is the 
use of transcriptomics and RNA-sequencing technologies. Transcriptomic profiles post-delivery 
can provide insight regarding the genes involved in uptake and translation of nucleic acid drugs. 
Transcriptomics-based studies have been used to understand the effects of biomaterials and  gene 
expression; scientist anticipate that omics-like dataset applied to nanomedicines will answer 
important questions about the biology of drug delivery215. 
Third, we need to explore the tolerability and potency of drug delivery vehicles across 
various animal models. Studies show that delivery vehicles behave differently in different animal 
models. For example, scientists found AAVs that delivered payloads across the blood–brain 
barrier56 in one species of mouse but not another216,217. These studies demonstrate the necessity of 
understanding how nanomedicines behave in various animal models. Importantly, as drugs are 
scaled into larger animal models such as NHPs, therapeutic efficiency decreases. This is in part due 
to a more severe immune response in larger animals compared to smaller rodents such as mice218,219.  
Thus, delivery vehicles studied in mice might behave differently in NHPs or humans. It is therefore 
important to study how drugs deliver in larger animal models to identify drugs that work efficiently 
in these models. This will allow for a greater number of drugs to translate into the clinic. 
Nevertheless, the development of nucleic acid drugs provides a bright future for patients. 
siRNA-based therapies interact with their target molecules through complementary Watson–Crick 
base pairing. mRNA-based therapies will produce any protein encoded in the mRNA sequence. 
Because of this, RNA therapies are relatively straightforward to design, are generated to be highly 
specific, and can be designed to knock down or replace any protein. Furthermore, delivery systems 
such as LNPs that deliver one RNA therapy can be exploited to deliver other RNAs of similar size. 
By contrast, small-molecule drugs require laborious screening efforts, and they can only treat a 
small portion of the protein coding genome1. 
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In 2020, the COVID-19 pandemic caused by SARS-CoV-2 affected 220 countries and 
resulted in more than 1.4 million deaths220. In late 2020, two vaccines were approved for clinical 
use against COVID-19; they will be the first messenger RNA-based vaccines approved for clinical 
use. Additionally, these mRNA vaccines would be delivered in LNP vehicles to target cells. The 
rapid development and efficient translation of these vaccines highlight an important achievement 
for RNA-based drugs and LNP delivery systems. RNA therapies can be rapidly produced, 
customized for specific disease, and safely administered to patients, demonstrating their 
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